











Department of Biological Sciences 





Being grateful to Al-Mighty God (Allah) is my first concern for only He has been my first 
support in completing this thesis.  
My gratitude should also be to the School of Life Sciences including Emma Revill and the 
University of Essex, for their support. Sincere warm thanks go also to Iraqi Cultural 
Attaché/ Embassy of the Republic of Iraq and the Ministry of Higher Education of Iraq, 
also Univrsity of Kirkuk and Kirkuk Health Department for their generosity and support. 
Whatever I say, it will not be enough to express respect and sincere gratefulness to 
Professor Glyn Stanway and Dr. Sinan Battah for their kind supervision, judicious advice, 
rigorous efforts, unlimited support and valuable guidance during my study. I guess that 
something would be missing if Dr. Brandon Reeder’s brilliant notice and feedback were 
not there in my work. As such, I hereby thank him for that and for offering me to use his 
HPLC. Special thanks go to Hannah Adams and Elizabeth Welbourn for always being 
around to help. 
I would also like to express my thanks to lab colleagues Dr. Ali Khrid, Dr. Marina Ioannou, 
Dr. Ashjan Shami and Dr. Cheryl Eno-Ibanga for showing me the excitement and joy of 
lab work. I wish also to expand my deepest thanks to Dr. Muslim Mohsin for generously 
providing the cells I needed for the project. 
 Now, my chance for dedicating something comes. I really feel proud to dedicate my 
success to those who prayed for my success. I would proudly dedicate this thesis to my 
actual and spiritual parents, the most loving people in my life for their support, they 
encouraged and inspired me before and during my study, my wife for her love and patience, 
my brothers for their help, my sister for her wishes and my children who understand my 




Many Picornaviridae family members infect humans. Enterovirus (EV), the largest genus, 
causes diseases ranging from the common cold to fatal heart disease and paralysis. Human 
parechoviruses (HPeV) are at least as prevalent as EVs. Currently, no antipicornavirus 
drugs are used clinically and the large number of viruses precludes vaccination. New drugs 
are therefore required. Picornavirus infection exploits viral and host proteins, lipids and 
cellular systems, all potentially targetable by inhibitors. In addition to compounds with a 
known target, natural products are potential sources of new drugs. Plant material such as 
berries are cheap, and some extracts have proven antiviral activity. The aim of this project 
was to repurpose known drugs, approved and used for several years for various medical 
indications, as well as identify new compounds from natural sources. Coxsackievirus A9 
(CAV9) was used as a typical enterovirus and a plaque reduction assay was used to assess 
antivirus activity. Both approaches gave promising agents. Fluoxetine and dibucaine 
caused a complete CAV9 inhibition at low concentrations. All drug resistant mutants 
(DRM) against these compounds had a protein 2C I227V mutation, suggesting this protein 
is targeted, in accord with previous work on coxsackievirus B3. The identification of DRMs 
with a single mutation suggests that drug resistance could be problematical if dibucaine 
and fluoxetine are used clinically. A previously observed interaction between lipid droplets 
(LDs) and CAV9 and HPeV1 led to studies of LD targeting agents. DGAT inhibitors 
A922500 and betulinic acid were the most active compounds, in addition to promising 
results from aspirin and metformin. Redcurrant extract showed antiviral activity, in 
addition to antioxidant and photodynamic activity. Some microalgae extracts also showed 
antiviral effects. Although much works remains to be done to fully develop these novel 
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1.1 Introduction to viruses 
1.1.1 Importance of viruses 
Many virus families contain human pathogens and these cause mild diseases such as the 
common cold, cold sores and chickenpox (Vleck et al., 2011), as well as fatal diseases like 
Ebola, severe acute respiratory syndrome (SARS), AIDS and pandemic influenza (Han et 
al., 2003; Abdul-Quader & Collins, 2011; Mukherjee et al., 2012; Narayanan et al., 2014). 
It is calculated that 15% to 20% of all cancers may be related to viruses, including hepatitis 
B viruses, hepatitis C viruses (HCV) and papilloma viruses (McLaughlin-Drubin & 
Munger, 2008). Some chronic diseases have also been linked with viral infections (Tang & 
Holmes, 2017), and there is possible link with neurological diseases such as chronic fatigue 
syndrome, multiple sclerosis (Voumvourakis et al., 2010) and psychiatric disease (Crow, 
1978). 
The increasing concentration of human populations into cities increases the opportunity for 
viruses to spread quickly and this has probably contributed to epidemics of emerging and 
re-emerging viruses. These can also be introduced rapidly to other countries due to 
increased travel. Human activity such as clearing of forests for farming may also displace 
animals, bats and insects and increase human exposure and this is the probable cause of 
some diseases such as Ebola and SARS. Therefore, there is steady increase in the number 
of known viruses around the world and an increase in outbreaks of infection. For example, 
between 2008 and 2012, enteroviruses (EVs) caused 7 million infections leading to 2457 
deaths in China. Moreover, some viruses and RNA viruses in particular have high mutation 
rates due to errors during RNA replication which may result in more virulent viruses 
(Huang & Shih, 2015). For most virus infection there is no effective vaccine or drug. When 
drugs are available, resistance to these drugs occur early, especially if the drugs target 
specific virus proteins (de Chassey et al., 2014). 
1.1.2 History of virus classification 
Virus taxonomy has been described as “a polarizing subject, based on the opinionated use 
of data” (Fauquet & Said, 2005). Evidence for the existence of viruses and their scientific 
study started to receive attention around the end of the 19th century (Van Der Want & 
Dijkstra, 2006; Arzt et al., 2011). Virus classification has evolved with the continuous 
development of technologies used to study them. The background of virus classification is 
along the lines of the general classification of organisms, such as the Linnean and the 
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Adansonian systems. The Linnean system is a monothetic system proposed by Linnaeus, 
while the Adansonian classification is a polythetic system applied by Adanson (Wayne, 
1967; Vasilyeva & Stephenson, 2008).  
Virus classification was first attempted in 1927 (by Johnson, a plant virologist). Before 
1940, virus classification depended on ecological and biological features, particularly the 
symptoms of infection, host and mode of transmission. For instance, all viruses that cause 
hepatitis (Hepatitis A, B, C, yellow fever and Rift Valley fever viruses) were classified as 
the hepatitis viruses, although these have been shown subsequently to belong to distinct 
virus families. In 1939, around 90 plant viruses were classified according to their host 
reaction and named by a binomial or trinomial system according to their host plants. 
Between 1940 and 1970, virus classification started to include virion properties depending 
on electron microscopy, centrifugation and biochemical studies that gave new information 
on virus shape, structure and size; biology (e.g. serology); and physicochemical properties 
(acid stability, sedimentation, density, the type of nucleic acid, the number and size of 
genome segments and proteins). Groups such as Herpes virus and Poxvirus were identified 
(Fauquet, 1994). 
In 1966, the International Congress for Microbiology was held in Moscow and established 
the ICNV (the International Committee on Nomenclature of Virus) to generate a world-
wide unique taxonomic and nomenclature system for all viruses. After 1970, virus genome 
structure (the sequence of the genome and the encoded proteins), as well as the replication 
cycle, started to be understood much more clearly. At this stage most virologists agreed to 
group all viruses at the family and genus levels, except plant virologists who still used 
groups for virus classification. Before 1990, the family level was the highest hierarchical 
classification. In 1977, ICNV was changed to ICTV (the International Committee on 
Taxonomy of Viruses) which is active today (Lefkowitz et al., 2018). In 1991, a higher 
taxonomic level, the order, was introduced, starting with Mononegavirales. This order 
contained non-segmented ssRNA negative sense viruses, which comprised families 
Filoviridae, Paramyxoviridae and Rhabdoviridae (Afonso et al., 2016). Despite its 
fundamental importance in virus classification, it was only in this year that the concept of 
virus species was uniformly applied (Van Regenmortel & Mahy, 2004).  In 1993 the second 
order Caudovirales was added. Taxonomic levels higher than order, for instance, kingdom, 
class and subclass have not been used by ICTV yet. In 1993, the ICTV finally proposed a 
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united system for all virus types (animals, human and plants) then including 2 orders, 50 
families, 9 subfamilies, 126 genera and 2644 virus species (Fauquet, 1994).  
Classification of a virus within a genus or family is usually easier than assigning to a 
particular species. Usually a few morphology and chemical characteristics are enough to 
classify a virus into a family. For example, all members of the family Picornaviridae are 
non-enveloped with a small icosahedral particle and single-stranded positive-sense RNA 
of around 7000-9000 bases. However, these general features, cannot distinguish between 
viruses that potentially belong to different species or even genera as these will all share 
these basic properties. More discriminating properties are needed, which initially included 
genome sequence, physicochemical and antigenic properties, host range, tissue tropism, 
cytopathology, pathogenicity and mode of transmission (Van Regenmortel & Mahy, 2004; 
Buchen-Osmond, 2007).  
The introduction of sequencing, and more recently metagenomics, have substantially 
increased the amount of virus information available for taxonomy. This includes genome 
expression, genome replication, genome organization, the presence or absence of 
characteristic motifs and evolutionary relationships. As well as better identifying species, 
using this information will expand taxonomy to a great extent and help to assign viruses to 
orders, and define higher rank taxa (Simmonds et al., 2017).        
1.1.3 The ICTV Nomenclature of virus taxa 
According to ICTV taxonomic rules, the species and genus names end in -virus, the 
subfamily ends in -virinae, the family ends in -viridae and the order names end with -
virales. The names of the specific virus order, family, subfamily, genus, and species should 
be printed in italics and the first letter is capitalized. The taxon name comes always before 
the taxonomic unit. Lower taxonomic levels such as serotypes, pathotypes and isolates have 
not been proposed by ICTV (Van Regenmortel & Mahy, 2004). As an example of up to 
down classification, coxsackievirus A9 (CAV9) belongs to Picornavirales, 
Picornaviridae, Enterovirus, Enterovirus B, CAV9 (type/serotype), and so on 
(isolate/strain).  
Very recently, the introduction of new taxonomic ranks by the ICTV has considerably 
changed classification at the higher end. Realm is now the highest rank in the approved 
ICTV taxonomy, followed by subrealm, kingdom, subkingdom, phylum, subphylum, class, 
subclass, order, suborder, family, subfamily, genus, subgenus and species. Names of these 
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ranks end with the suffixes “-viria”, “-vira”, “-virae”, “-virites”, “-viricota”, “viricotina”, 
“-viricetes”, “-viricetidae”, “-virales”, “-virineae”, “-viridae”, “-virinae”, “-virus" and “-
virus” (Gorbalenya et al., 2017; Walker et al., 2019). RNA viruses are assigned to the realm 
Riboviria, which is likely monophyletic and contains RNA viruses of both positive and 
negative strands, in addition to double stranded RNA viruses, as these all use a related 
RNA-directed RNA polymerase to replicate. 
1.2 Picornaviridae 
1.2.1 Picornaviridae classification 
Picornaviridae family members infect humans and many animal hosts (e.g. foot and mouth 
disease virus [FMDV], which infects cows, sheep and pigs) and form one of the largest 
virus families with over 300 virus types, classified in 47 genera and 110 species, in addition 
to new 16 proposed genera and new 37 proposed species (Picornavirus Home Page, 2019). 
1.2.2 Significance of picornaviruses 
Although most picornavirus infections are asymptomatic, specific diseases are associated 
with particular groups of picornaviruses. Eight genera of the Picornaviridae family include 
pathogens infecting humans. They are Enterovirus (250 serotypes), Parechovirus, 
Hepatovirus, Cardiovirus, Kobuvirus, Cosavirus, Salivirus, Rosavirus (Zell et al., 2018). 
Enterovirus (EV), the largest picornavirus genus, includes viruses that can cause a range of 
diseases such as mild respiratory and gastrointestinal infections and skin rashes 
(Chansaenroj et al., 2017), or potentially fatal diseases involving the CNS (paralysis, 
encephalitis, meningitis) and heart (myocarditis) as well as pancreatitis and chronic 
inflammatory myopathy. Some cases of disease may be caused by persistent infections and 
these infections may also contribute to spread (Rhoades et al., 2011). There is also great 
evidence of the relationship between coxsackievirus B (CBV) and diabetes (Alidjinou et 
al., 2015). In addition, pre-existing clinical manifestation are sometimes aggravated by 
picornaviral infection. For instance, rhinovirus infection has been shown to exacerbate 
asthma and chronic obstructive pulmonary diseases (Hershenson, 2013). Though usually on 
the less severe side, the common cold, which is mainly caused by rhinovirus, leads to loss 
of working days and visits to doctors costing up to $40 billion annually in the USA (van der 




1.2.3 Examples of clinically important picornaviruses 
1.2.3.1 Poliovirus               
Poliovirus (PV) is the best-known member of the enteroviruses and has been studied 
extensively. It is responsible for paralytic poliomyelitis. It is grouped into 3 distinct 
antigenic types, 1, 2, and 3, depending on neutralisation tests and this means that a second 
or third infection could occur caused by a different serotype (Mehndiratta et al., 2014). 
Currently, there are 2 vaccine types against these 3 serotypes, the live attenuated oral 
poliovirus vaccine (OPV) and inactivated poliovirus vaccine (IPV) (Blake et al., 2018). IPV 
use has replaced OPV use in many countries as part of the Global Poliovirus Eradication 
Initiative and because the live vaccine strains can revert to virulent forms.  
The oldest evidence of PV dates back to 1580-1350 BCE and is a picture of an Egyptian 
man with a flaccid leg and holding a crutch (Nathanson & Kew, 2010). However, PV was 
only firstly isolated in 1909 and the sequence published in 1981 (Racaniello et al., 1981; 
Baicus, 2012). The usual transmission mode of PV is the hand-to-hand-to-mouth route after 
excretion in feces and pharyngeal secretions. After ingesting the virus, it passes through the 
stomach and the principle replication site is the gastrointestinal tract. Viremia may result 
and, in this stage, the infection is often either asymptomatic or causing minor symptoms 
such as fever, headache and sore throat. However, in a low proportion of infections (less 
than 1%), the virus enters the CNS and replicates in motor neurons causing a clinically 
unique flaccid paralysis of legs and/or arms without a permanent sensory loss. More rarely, 
involuntary muscles responsible for breathing can be affected leading to respiratory arrest 
and death. Poliovirus is a strictly human pathogen and there is no known extra human 
reservoir to infect. (Melnick, 1996; Fine & Carneiro, 1999; Howard, 2005; Nathanson & 
Kew, 2010; Mehndiratta et al., 2014). In 1988, the Global Polio Eradication Initiative was 
established by WHO in order to eradicate PV worldwide and this has decreased the global 
rate of the disease by more than 99% (from 350,000 cases per year to less than 2000 cases 
per year). However, there are 3 countries still endemic with PV type 1 and 3, Nigeria, 
Pakistan and Afghanistan (Thompson et al., 2008, GPEI, 2020).  
1.2.3.2 Coxsackievirus    
Coxsackievirus (CV) is a relatively large and genetically diverse group within the 
Enterovirus genus. CVs affect different human age groups causing various clinical 
manifestation. The first CV was isolated in the New York State Department of Health in 
1948-1949 (Afrose, 2017). In most cases the infection is symptomless, while sometimes it 
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gives a non-specific illness with fever and often upper respiratory tract symptoms, sore 
throat and occasionally a runny nose. Skin rash often appears at the end of the illness (Xiang 
et al., 2012; Huang et al., 2013; Afrose, 2017). During pregnancy, CV infection can cause 
early abortion, fetal myocarditis and delayed neurological development in new-born babies 
(Ornoy & Tenenbaum, 2006). Neonate and immunocompromised individuals are always at 
higher risk (Shin et al., 2010; Weber et al., 2016), and are prone to developing meningitis, 
encephalitis and myocarditis, as CNS and heart are main targets of infection. In adults, CV 
myocarditis is a leading cause of dilated cardiomyopathy which leads to 50% of heart 
transplants, in addition to demyelinating diseases including acute disseminated 
encephalomyelitis and acute transverse myelitis, delayed neuropathology including 
schizophrenia, encephalitis lethargica and amyotrophic lateral sclerosis (Kearney, 2001; 
Feuer et al., 2009). CVs also replicate in bone marrow and affect hematopoietic progenitor 
cells (Althof & Whitton, 2013). The usual transmission routes include respiratory droplets, 
stool exposure, blister fluids, fomites and maternal secretion exposure during delivery.       
Epidemiological studies in different areas throughout the world showed considerable 
prevalence of CV. For example, antibodies against certain CV strains were detected in 60-
80% of French-Canadian population in Montreal. In China, one serotype of CV showed a 
prevalence as high as 50%, and in different areas of Greece, the seroprevalence of some 
CVs were between 6.7 and 21.6%. (Khelifa et al., 1999; Sin et al., 2015). Coxsackievirus 
is divided into 2 subgroups A (CAV) and B (CBV) depending historically on histopathology 
and clinical signs detected in new-born mice. There are 23 serotypes of subgroup A and 6 
serotypes of subgroup B (Kuan, 1997; Harvala et al., 2002). In terms of tropism which may 
reflect clinical findings, CAV infects mainly striated muscles (skeletal and heart muscles) 
and CBV replicates in addition to the striated muscles, in the CNS, pancreas, liver and 
brown fat. As a result, CAV can cause flaccid paralysis. Some CAV serotypes are also 
frequent causes of hand-foot-and-mouth disease (HFMD) and herpangina in different 
human age groups. CBV causes spastic paralysis and has been associated with autoimmune 
and chronic diseases including diabetes mellitus, chronic myocarditis and chronic 
inflammatory myopathy. Severe hepatitis often with a high mortality rate is commonly seen 
in neonates. However, it is much less common in adults (Talsma et al., 1984; Hyypiä et al., 
1993; Hyypiä et al., 1997; Harvala et al., 2002). Diseases reportedly caused by some CV 




Table 1. Selected Coxsackievirus members and related diseases. 
CV group Related disease(s) References 
CAV4 HFMD. (Li et al., 2015). 
CAV5 HFMD. (Andreoni & Colton, 2017). 
CAV6 HFMD and onychomadesis. (Zeng et al., 2015; Puenpa et al., 
2016). 
CAV9 HFMD and aseptic 
meningitis. 
(Harvala et al., 2002; Moreau et 
al., 2011). 
CAV10 HFMD and onychomadesis. (Mirand et al., 2012). 
CAV16 HFMD and onychomadesis. (Shin et al., 2014; Gan & Zhang, 
2017). 
CAV21 Respiratory tract infection. (Xiang et al., 2012). 
CAV24 Acute haemorrhagic 
conjunctivitis. 
(Oh et al., 2003; Medina et al., 
2016). 
CBV1 HFMD and onychomadesis. (Cabrerizo et al., 2010). 
CBV3 Chronic inflammation and 
immunology and diabetes 
mellitus. 
(Drescher et al., 2004; Feuer et 
al., 2009). 
CBV4 Meningoencephalitis and 
diabetes mellitus. 
(Dotta et al., 2007). 
CBV5  Schizophrenia and 
onychomadesis. 
(Suvisaari et al., 2003; Andreoni 
& Colton, 2017). 
CBV2 Myocarditis. (Mehta et al., 2018). 
 
1.2.3.3 Enterovirus 71 
Enterovirus 71 (EV71, or EVA71) is a serotype showing great genetic diversity and is 
classified into the human EVA species of the Enterovirus genus (Fernandez-Garcia et al., 
2018; Mandary & Poh, 2018). EV71 infection is a potentially life-threatening and 
communicable disease and is one of the most common causes of the worldwide hand-foot-
and-mouth disease (HFMD) and herpangina. These are also caused by other viruses, such 
as CAV16, however EV71 is often associated with more severe symptoms and higher 
incidence of severe complications (Lee, 2016). EV71 infection exhibits a wide spectrum of 
symptoms. It could be asymptomatic or show symptoms ranging from skin eruption and 
flu-like symptoms to visceral manifestation. EV71 can also be a highly neurotropic virus 
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affecting most commonly the brainstem and sometimes causing with polio-like myelitis, 
aseptic meningitis and death (McMinn, 2002; Linsuwanon et al., 2014; Chang et al., 2018).  
EV71 was firstly detected and then isolated from a child with encephalitis in California in 
USA in 1969 (Schmidt et al., 1974). However, retrospective studies in the Netherland and 
evolutionary analysis indicated EV71 emergence as early as 1941 (Tee et al., 2010). 
Although EV71 epidemics have been reported since 1970s in different regions including 
America, Europe and Australia, it is particularly prevalent in the Asia-Pacific region with 
a high incidence rate during summer months and mortality rate of 0.5% to 19% (Cardosa 
et al., 2003; Linsuwanon et al., 2014; Lin et al., 2018a). EV71 has shown a rapid 
evolutionary change and has diverged into different genetic lineages with differences in 
pathogenicity and morbidity between countries (Chang et al., 2016). Most EV71 infections 
occur in 5-year-old children or younger with more cases of viremia and sepsis reported in 
the under 2-year-olds and higher rates in boys than girls (Chang et al., 2016, 2018; Lin et 
al., 2018b). 
Because of the significant mortality and morbidity rates, especially in younger children, 
there have been remarkable efforts to develop effective vaccines for EV71 and inactivated 
vaccines were approved in China in 2015 and give a protection rate of up to 90% against 
EV71-related HFMD and up to 80% against other diseases related to EV71 (Liang et al., 
2014; Chang et al., 2018; Lin et al., 2018a).   
1.2.3.4 Enterovirus 70  
Enterovirus 70 (EV70 or EVD70), a member of the EVD species, is a causative of acute 
haemorrhagic conjunctivitis (AHC) and was the first identified AHC virus. It has also been 
associated with neurologic poliomyelitis-like illness, although in a lower proportion of 
cases than poliovirus. It was identified in 1971 by two independent groups in Japan and 
India. Subsequently, EV70 was detected in different parts of India during 1975, 1981, 1986 
and 1991 (Wadia et al., 1983; Maitreyi et al., 1999). In addition, during the early 1980s 
there was a large pandemic spread of EV70 in different parts of the world, including the 
USA (Mirkovic et al., 1973; Takeda et al., 1994). EV70 infection usually starts by direct 
entry into the eye, rather than an initial enteric infection leading to viremia and spreading 
to other organs (Langford et al., 1986; Kim & Racaniello, 2007). Paralysis occurs in around 
0.01% of symptomatic EV70 infections (Wright et al., 1992), and it is usually transient but 
more permanent flaccid paralysis of the lower limbs and cranial nerve paralysis can occur. 
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However, the understanding of EV70 pathogenesis is sketchy as it has not been studied 
thoroughly and there is no suitable animal model (Kim & Racaniello, 2007). 
1.2.3.5 Enterovirus 68  
Enterovirus 68 (EV68 or EVD68) is another member of the EVD species within the 
Enterovirus genus. It shows some biological characteristics more usually associated with 
rhinoviruses, including acid sensitivity. Indeed, it was realised that EV68 and rhinovirus 
87 are actually the same virus (Blomqvist et al., 2002). EV68 (and EV69) infects both 
upper (the principle entry route) and lower respiratory tract via virus-containing respiratory 
secretions (Esposito et al., 2015). Infection does not require prior enteric infection as EV68 
is acid labile so cannot survive passing through the stomach (Oberste et al., 2004). As well 
as respiratory infections, rare CNS neuro-complications have been reported and several 
recent reports have highlighted acute flaccid myelitis cases (Oermann et al., 2015; Pfeiffer 
et al., 2015; Lau et al., 2016a). Although most cases of respiratory EV68 infections are 
asymptomatic or mild (similar to influenza-like illness), a few cases are severe enough to 
require intensive care (Oermann et al., 2015).  
The first report of EV68 was published in 1967, 5 years after virus recovery from 4 children 
with bronchitis and pneumonia in California. Subsequently, sporadic respiratory cases were 
reported in the Philippines, Japan, Netherlands and USA in 2008-2010. Thereafter, 
increasing outbreaks started to appear in other places such as the UK, France, Italy, China, 
Thailand, New Zealand and Africa and the majority of cases in all areas were from children 
(Esposito et al., 2015; Oermann et al., 2015; Lau et al., 2016a). However, the largest and 
the most widespread outbreak of EV68 was reported in USA in 2014 with higher morbidity 
and mortality rates. It has been suggested that recombination has been the reason for the 
increase in prevalence and virulence of EV68 in recent years. For instance, 26 cases were 
detected in USA between 1970 and 2005 and up to 1000 cases since 2014 with 14 fatal 
cases (Khetsuriani et al., 2006; Midgley et al., 2014; Oermann et al., 2015). Phylogenetic 
analysis of VP1, 2C and 3D showed 4 clades of EV68, A1, A2, B1 and B3 (Lau et al., 
2016a), while other authors describe 3 distinct genetic groups, clade A to C (Tokarz et al., 
2012).  
1.2.3.6 Rhinoviruses  
Rhinoviruses (RV) include about 160 serotypes divided into 3 species within the 
Enterovirus genus, RV-A, RV-B and RV-C (Lee et al., 2012; Palmenberg & Gern, 2015; 
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Fawkner-Corbett et al., 2016). RV infections occur throughout the world and these viruses 
have been extensively studied (Arakawa et al., 2012; Lu et al., 2014; L’Huillier et al., 2015; 
Launes et al., 2015; Tsatsral et al., 2015; Wildenbeest et al., 2016; Leotte et al., 2017). In 
humans, RV infection is the most common cause of common colds and acute respiratory 
infections (responsible for one half to two thirds of cases), particularly in childhood, but 
also in adulthood, which are the most frequent cause of lost work days in the USA. RV 
infections are generally confined to the upper respiratory tract, but recent investigations 
have strongly implicated RV in complications such as bronchitis and pneumonia, as well 
as the making worse symptoms of chronic respiratory diseases like asthma, chronic 
obstructive pulmonary disease and cystic fibrosis (Kennedy et al., 2012; Cox et al., 2013; 
Cathcart et al., 2015; Annamalay et al., 2016; Klaiber, 2018). RV, particularly RV-C, are 
also frequently reported viruses in cases that have to be admitted to paediatric intensive 
care units, the rate being equal to or even exceeding that of respiratory syncytial virus 
(RSV). RV may also be more significant in allergic sensitizations and recurrent wheezing 
than RSV (Sun et al., 2016a; Cox et al., 2018). RV infection predisposes to secondary 
bacterial infection, including Haemophilus influenzae and Streptococcus pneumoniae, that 
sometimes lead to otitis media and sinusitis (Jacobs et al., 2013). Unlike other EVs, RVs 
are acid and temperature labile (the optimum temperature growth is 33 ºC and they are 
inactivated at pH 3.0) (Jacobs et al., 2013; Tapparel et al., 2013). Humans (and 
chimpanzees) are the only known reservoir for RV and nasal secretion is the usual way of 
viral spread (nose to hand to hand to nose) rather than respiratory droplets and aerosols 
(Blaas & Fuchs, 2016). 
1.2.3.7 Parechoviruses  
Human parechovirus (HPeV) belongs to the Parechovirus A species of the Parechovirus 
genus and contains 19 genotypes (Picornavirus Home Page, 2019). When the first two 
HPeVs were isolated in 1956 they were classified as echovirus 22 and 23 in the Enterovirus 
genus due to shared cell-culture features and infection symptoms with enteroviruses (Nix 
et al., 2008; Faria et al., 2009). Later analysis showed that HPeVs are genetically distinct 
from enteroviruses and other genera (Stanway et al., 1994; Stanway and Hyypiä, 1999) and 
they are now classified in a separate genus, Parechovirus (Zell et al., 2017).  
The prevalence of HPeVs has been underestimated until recently and they seem to be at 
least as prevalent as EVs according to several recent data. HPeVs are estimated as the 
second most important cause of viral sepsis-like illness and meningitis in infants (van der 
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Linden et al., 2015). In areas where HPeV infections have been studied most thoroughly 
(Europe, USA, Japan and Australia), genotypes HPeV1 to HPeV6 are isolated most 
frequently, with HPeV1 usually being the most common (de Crom et al., 2016; Britton et 
al., 2018a; Olijve et al., 2018).  In fact, based on the presence of antibodies against HPeV1 
which indicate an infection at some point in life, a very high proportion of people in some 
countries have been infected with HPeV1 (Westerhuis et al., 2013). Infections by HPeV1 
commonly take place during the first years of life (Wildenbeest, 2014; de Crom et al., 2016). 
It usually causes relatively mild symptoms, including fever, rash and otitis media (Benschop 
et al., 2006; Tauriainen et al., 2008).  
HPeV1, and also HPeV4, have been associated with some more serious conditions such as 
sepsis-like illness, meningitis, paralysis and myocarditis (de Crom et al., 2016; 
Kolehmainen et al., 2014; Kolehmainen et al., 2017). However, it is HPeV3 which is most 
frequently associated with serious disease, particularly in neonates and young infants 
(Harvala et al., 2009; Britton et al., 2018a; Olijve et al., 2018; Aizawa et al., 2017; Nelson 
et al., 2017). HPeV3 is associated with severe sepsis-like disease and is the HPeV most 
likely to be recovered from the CNS in cases of meningitis and encephalitis, as well as being 
reported as the cause of serious myalgia. Most severe HPeV3 infections occur in children 
under 3 months old and can be fatal. It is also possible that some children who recover from 
an HPeV3 infection subsequently show developmental difficulties (Britton et al., 2018b).  
1.2.3.8 Hepatitis A virus 
Hepatitis A virus (HAV) is classified in the Hepatovirus A species of the Hepatovirus genus 
and all isolates belong to a single serotype (Nainan et al., 2014). Other viruses which infect 
the liver belong to different families, for instance, hepatitis B virus is a small DNA virus 
from the Hepadnaviridae family, and hepatitis C virus is an RNA virus from the genus 
Hepacivirus of Flaviridae (Liang, 2009; Bukh, 2016; Smith et al., 2017). Human, 
chimpanzees and some small non-human primates are natural hosts for HAV, and liver is 
the primary replication site. The infection by itself causes little hepatocellular injury 
although it is usually accompanied by elevated ALT (Kwo et al., 2017; Malakouti et al., 
2017). 
HAV is transmitted by the fecal-oral route, mainly by ingestion of contaminated food or 
water. Transmission is facilitated by this route as HAV has stability towards freezing, 
moderate heating and low pH (Sattar et al., 2000). Acute infection is accompanied initially 
by hepatic necro-inflammation which cures spontaneously in ≥ 99% of cases. There are 
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many infrequent complications including rash, pancreatitis, myocarditis, arthritis, aplastic 
anaemia and fulminant hepatitis (0.015-0.5%). In addition, there are some reported 
prolonged symptoms such as fatigue, weight loss, fat intolerance, bilirubinaemia, 
cholestasis and emotional instability (Glikson et al., 1992; Lemon et al., 2018). In terms of 
severity of clinical outcomes, there is an increased incidence of infection and its 
complications with an increase of age. For example, only 10% of under “6 years of age” 
children with HAV develop jaundice compared to 70% of older children and adults. In 
addition, co-infection of HAV with other viruses like HBV, HCV, HEV, HIV, and dengue 
virus leads to increase rate of hepatic failure (Lemon et al., 2018).  
According to WHO estimates acute HAV hepatitis cases increased from 117 million to 126 
million between 1990 and 2005, with an increase in HAV-related deaths from 30,283 to 
35,245 (WHO, 2012). HAV is a preventable disease. Good personal hygiene is an effective 
way to protect against the disease. In addition, the availability of a vaccine has reduced 
infection rates. For example, in Israel after high levels of vaccination coverage (one dose 
90%, two doses 85%) HAV incidence dropped from 33-70/100,000 between 1992-1998 to 
2.5/100,000 cases in 2002 (Dagan et al., 2005). 
1.2.3.9 Foot-and-Mouth Disease Virus 
Foot-and-mouth disease virus (FMDV), from the genus Aphthovirus, causes foot-and-
mouth disease (FMD) in cloven-hoofed farm animals including cattle, sheep, goats, and 
pigs, as well as wild animals such as antelope, bison and deer. Infection gives vesicles 
spread around the mouth, feet and mammary glands, which is not fatal but causes loss of 
productivity and is therefore economically important (Verma et al., 2012; Pal, 2018; Paton 
et al., 2018). Chronic infection drops milk production by 80% and impairs growth and 
increases the mortality rate of young livestock (Knight-Jones & Rushton, 2013; Truong et 
al., 2018). Losses are concentrated in dairies and intensive pig farms, which are the main 
protein sources particularly in poor countries (James & Rushton, 2002).  
Beside a great loss in livestock and its products, FMD infection control is expensive, and 
is needed not only in endemic countries but also their neighbours and even FMD-free 
countries. These costs include outbreak control, culling, vaccination, import control, early 
detection, restrictions on the livestock sector and research. For instance, worldwide 
vaccinations against FMDV cost 1-7 billion dollars annually and up to 21 billion dollars in 
some years (Sutmoller et al., 2003; Forman et al., 2009). In the UK, the 2001 outbreak cost 
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respectively with £4-5 billion in lost tourism alone, while the 2001 outbreak in Uraguay 
cost $700 million (Knight-Jones & Rushton, 2013).  
There are 7 known serotypes of FMDV, O, A, C, Asia 1, SAT-1, SAT-2 and SAT-3 with 
different distribution patterns through the affected areas. For instance, there are 6 serotypes 
of FMDV (O, A, C, SAT-1, SAT-2, SAT-3) in Africa, 4 serotypes in Asia (O, A, C, Asia-
1) and 3 in South America (O, A, C). In addition, a high mutation rate and quasi-species 
dynamic has led to several subtypes (OIE, 2009; Ludi et al., 2013, 2014; Eldaghayes et al., 
2017; Paton et al., 2018). FMD spreads mainly in Africa and Asia and there have been a 
periodic outbreak of types SAT-1 and SAT-2 from Africa in the Middle East (Rweyemamu 
et al., 2008; Ludi et al., 2013, 2014). Several outbreaks of FMD in some FMD-free 
countries including the UK in 2007 and Korea and Japan in 2010 have occurred (Verma et 
al., 2012).   
The virus transmits by respiratory aerosols, secretions (milk and semen), shedding from 
burst blisters, ingestion and abrasion. Virus-contaminated equipment and vehicles can also 
spread infections. Pigs transmit a high level of air-borne virus compared with cattle or 
sheep but are less sensitive to infection by this route. The virus can survive from days to 
months in the environment and in animal products including meat and can be spread by 
wind across long distances as occurred in 1981 when virus from a pig farm on the coast in 
North France infected animals on the  Isle of Wight (Donaldson & Alexandersen, 2002; 
Cottam et al., 2008; Paton et al., 2018). FMDV is also transmissible to humans causing 
conjunctivitis, skin vesicles and mild influenza-like symptoms. Because symptoms in 
human are usually very mild and self-limiting, they are often unnoticed (Hyslop St., 1973). 
1.2.3.10 Aichi virus  
The Kobuvirus genus consists of 3 species Aichi virus A (AiV-A), Aichi virus B (AiV-B) 
and Aichi virus C (AiV-C). The prototype strain, Aichi virus (strain A846/8) was first 
detected in humans in the Aichi prefecture, Japan in 1989 (Reuter et al., 2011; Cathcart et 
al., 2015). Aichi virus A comprises of 4 types, Aichi virus 1 (AiV-1, which includes the 
prototype Aichi virus), canine kobuvirus 1, feline kobuvirus 1 and murine kobuvirus 1. 
Aichi virus 1 is distributed worldwide and causes a low incidence of gastroenteritis in 
humans. The usual infection route is fecal-oral transmission and good hygiene and avoiding 
raw food is important to prevent the disease (Kitajima & Gerba, 2015). The prevalence of 
Aichi virus seemed to rise with age. For instance, 30% of young adults are seropositive to 
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the virus and 80% are positive by middle age. Globally, AiV-1 infection has been 
responsible for several outbreaks of acute gastroenteritis in Asia (Japan, China, Vietnam, 
Thailand and Bangladesh) and its prevalence has been reported in European countries 
including Germany, France, Sweden, Finland and Hungary, as well as Brazil and Tunisia. 
Reports of other Aichi virus A members have also been published such as canine kobuvirus 
in domestic dogs and murine kobuvirus in wild rodents (Khamrin et al., 2014; Kitajima & 
Gerba, 2015; Lu et al., 2018).  
AiV-B was firstly found in Japan and then isolated from stool sample of cattle in Brazil, 
Italy, Belgium, Korea (where the virus is particularly prevalent) and Thailand. The 
prevalence varied between 1 and 34.5% using RT-PRC. Samples from domestic sheep in 
Hungary and black goat in Korea were also seropositive to the AiV-B (Khamrin et al., 
2014b; Kitajima & Gerba, 2015).  
AiV-C infection is common in pigs and the virus has been detected in countries throughout 
the world with reported prevalence rates of 3.9-100%. Infection can be bloodborne and can 
also occur through suckling and from contaminated food (Reuter et al., 2011, 2013).    
1.2.3.11 Other picornaviruses   
Cosavirus (HCoSV) contains five species  from Cosavirus A to F, excluding the candidate 
species “Cosavirus C”, which is not yet officially recognised. The first cosaviruses were 
found in Pakistan and Afghanistan in stool samples of healthy and non-polio acute flaccid 
paralysis (NPAFP) patients. Other cosaviruses were identified in several countries from 
samples of different origin, such as diarrhoea, stools of NPAFP patients, sewage, river 
water and pig stools (Khamrin & Maneekarn, 2014a; Okitsu et al., 2016).  
The Cardiovirus genus consists of 3 species, Cardiovirus A (formerly called 
Encephalomyocarditis virus), Cardiovirus B (formerly called Theilovirus) and Cardiovirus 
C (ICTV, 2019; Drexler et al., 2008). Cardiovirus B contains Saffold virus (SAFV), a virus 
which has recently been found to be highly prevalent in the human population, as well as 
Vilyuisk human encephalomyelitis virus. The role of SAFV in human disease is not yet 
understood, but it is found in respiratory and gastrointestinal samples (Zoll et al., 2009; 
Drexler et al., 2011; Himeda & Ohara, 2012; Tan et al., 2017). SAFV has been identified 
in stool samples from children having gastroenteritis in in the USA, Brazil, Germany, 
Denmark, Thailand, China, South Asian and Malaysia, and in the respiratory specimens 
from children with influenza-like disease in China, Japan and Canada. More recently, 
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SAFV has been detected in the blood, the CSF, and myocardium of a child who experienced 
a sudden death (Zhang et al., 2015). 
Viruses of the genus Salivirus with a single species, Salivirus A, were originally identified 
in 2009 in the stool of children with gastroenteritis in the USA and Australia and called 
klasseviruses, and in children with NPAFP in Nigeria (called salivirus). Later, several 
molecular and seroepidemiology studies associated salivirus with acute gastroenteritis and 
paediatric diarrhoea and it has been subsequently reported worldwide (Yu et al., 2015; Itta 
et al., 2016).  
1.2.4 Picornavirus particle and replication 
The picornavirus particle consists of a protein capsid containing the genome, which is a 
single strand of positive-stranded RNA varying in length between 6700–8800 nucleotides 
between members of different genera (Zell et al., 2017). Picornavirus capsids contain 60 
copies of each capsid protein (Figure 1.1). In EVs, as in the majority of picornaviruses, 
there are 4 capsid proteins VP1, VP2, VP3 and VP4. VP4 and VP2 are released from a 
precursor VP0 and some picornaviruses, such as parechoviruses, have only 3 capsid 
proteins, VP0, VP1 and VP3, because VP0 is not cleaved. VP2 (or VP0), VP3 and VP1 are 
similar in size and are structurally related as they share a common 8-stranded β-barrel fold. 
These pack together into a triangular protomer and 5 protomers assemble into a pentamer 
with VP1 closest to the 5-fold axis and VP2 (or VP0) and VP3 alternating further away 







Figure 1-1. The picornavirus capsid. 
a. The X-ray crystal structure of a typical EV, poliovirus. The image is colour-coded to 
show the highest parts of the structure in yellow and the deepest in dark blue. The deep 
region surrounding the 5-fold axis is the canyon which is used for receptor attachment 
in many picornaviruses. b. Schematic of the icosahedral arrangement of the 60 copies of 
the capsid proteins VP1, VP2 and VP3. VP4 is an internal protein so not visible. The 
axes of symmetry of the icosahedron (5-fold, 3-fold and 2-fold) are also shown. c. The 
8-stranded beta barrel structure seen in VP1, VP2 and VP3. Images from Zell et al., 2017 









The genome encodes one open reading frame (ORF) and this is preceded by a long 5`-
untranslated region (5`UTR) and followed by a 3`UTR and a poly-(A) tail. The 5`UTR 
contains an internal ribosome entry site (IRES) required for translation of the RNA. A 
small viral protein, VPg, is covalently linked to the 5`end of the viral genome (Norder et 
al., 2011; Kempf et al., 2013). (Figure 1.2). A single polyprotein is encoded, and this is 
processed by virus proteases to give precursors and the final proteins, 1A-1D, 2A-2C and 
3A-3D.  
Picornaviruses differ between genera in the details of virus replication and Enterovirus 
(EV) replication will be described as these are the best studied picornaviruses (Figure 1-3). 
EV infection starts with binding to a specific receptor on the cell surface. Sometimes more 
than one receptor is needed and there may be an initial binding to a less specific molecule 
such as heparan sulfate (Figure 1.3). The virus then enters the cell by endocytosis. Several 
mechanisms have been seen e.g. clathrin-mediated endocytosis. This triggers uncoating of 
the virus RNA and its release into the cytoplasm. VPg is separated away from the viral 
RNA, which is then translated to give a polyprotein. Proteins released from the polyprotein 
include structural (capsid) proteins that will form the new virus particles, as well as those 
involved in RNA replication and altering the host cell, for instance by shutting-off of 
cellular cap-dependent translation and stimulation of viral IRES-mediated translation.  
Replication of the genomic RNA occurs inside the cytoplasm, within newly-made double-
membrane vesicles derived mainly from the ER, and the new RNAs are either used for 
translation or packaged into preassembled procapsids. The assembled particles undergo a 

















Figure 1-2. A and B, picornavirus genome and cleavage of polyprotein by viral 
proteases. 
(A) The 5`UTR contains the IRES (internal ribosome entry site) which is needed for 
translation. The genome encodes a single polyprotein (cylinder) which is cleaved into the 
precursors P1 (green), P2 (yellow) and P3 (blue) and then into the final proteins (boundaries 
marked on the cylinder). (B) Viral proteases namely 2Apro and 3Cpro (and its precursors) 
cleave the single polyprotein into some stable precursors (e.g. 2BC and 3CD) and the final 
viral proteins. VP0 cleavage to VP4 and VP2 occurs by an apparently autocatalytic process. 




















Figure 1-3. Replication cycle of EVs 
First, the bind to a receptor and is internalized into the cell, The virus is usually 
taken into the cell in a vesicle (not shown). Then the viral RNA is released from 
the virion and translated into a single polyprotein. After that, viral proteases split 
this polyprotein into capsid proteins non-structural proteins, which copy the 
genome RNA in a two-stage process, where negative sense molecules are produced 
and then copied to give further positive sense ones. Almost all these events occur 
in the replication complex that is created by virus induced membrane 
rearrangement. The new positive-stranded RNA molecules are then either 
translated, used for further RNA replication or packaged to form infectious viruses 
which become released by cell lysis. (Image from van der Linden et al., 2015). 
37 
 
1.3 The importance of receptors in picornavirus infection 
1.3.1 Receptors in infection and disease 
Cells employ multiple barriers against virus infection. Some of these are physical such as 
the plasma membrane, which protects individual cells, or epithelia which protect the whole 
body or specific tissues. Others are restriction factors, usually triggered by interferon 
(Drummond et al., 2017; Ingle et al., 2018). Viruses use general common tactics to 
overcome these barriers. In the case of the plasma membrane, the virus interacts with a cell 
surface molecule, its receptor to allow entry into the cell. Sometimes multiple receptors, 
which are usually proteins, carbohydrates or glycolipids are involved (Domingo et al., 
2012; Kato & Ishiwa, 2015). Cellular receptors are exploited as these can allow the virus 
to be efficiently delivered to specific locations in the cell by endocytosis, as well as possibly 
activating distinct signalling pathways that facilitate entry, induce conformational changes 
or enhance infection (Grove & Marsh, 2011). The presence or absence of specific receptors 
on a given cell type contributes to virus cell tropism, as only cells with the appropriate 
receptor can be infected. Variations in the sequence and structure of a receptor between 
different organisms may also limit host range or determine the nature of disease caused 
(Domingo et al., 2012). For instance, normally mice are not infected by poliovirus. 
However, they become liable to poliovirus infection when they are manipulated to express 
the human poliovirus receptor (PVR) and show similar neurological diseases to those seen 
in humans (Ren & Racaniello, 1992; Khan et al., 2014). However, viral productivity and 
cell permissiveness is not defined only by receptor recognition but also by other host 
components. For example, substitution of amino acids in non-structural viral proteins 
which interact with intracellular factors can also modify cell tropism or host range (Harris 
& Racaniello, 2005; Pan et al., 2011). In addition, tissue susceptibility and tropism are not 
always determined by involvement of receptors and in many cases the tissue distribution 
of a receptor is wider than the tropism would suggest. For example, PVR is distributed in 
many tissues including neurons, small intestine, heart, liver, spleen, pancreas, kidney and 
lung. However, heart, liver, kidney and lung have not been identified as efficient sites for 





1.3.2 The main receptor types of picornaviruses 
Like other viruses, different picornavirus species, or even serotypes within a species, 
recognise distinctly different receptors. Many of these are proteins and have an intracellular 
domain, a transmembrane domain that anchors the protein into the cell membrane, and a 
usually larger extracellular domain, part of which is recognised by the virus to allow 
attachment followed by internalisation.  
The coxsackie and adenovirus receptor (CAR) is a receptor coxsackie B viruses (CBV). 
This molecule is part of a tight junction complex between cells involved in an early 
embryonic cardiac development and is expressed on human islets, which may explain the 
possible link between these viruses and heart disease and type 1 diabetes (Dorner, 2005; 
Hodik et al., 2016). Intercellular adhesion molecule 1 (ICAM1), involved in cell adhesion 
and the immune response, is a receptor for the major group human rhinovirus (HRVs) 
(Winther et al., 2002; Shukla et al., 2017), as well as some CBV and CAV types. Both 
these molecules, as well as PVR (CD155, nectin-like molecule-5) belong to the Ig-like 
superfamily of receptors which have an extracellular domain made of varying numbers of 
70–110 amino acid Ig-like domains (Schneider-Schaulies, 2000; Tu et al., 2009).   
Decay accelerating factor (DAF or CD55) functions to decrease cell lysis caused by the 
complement system and it is a receptor for several echoviruses, some CBVs and EV71 
(Bergelson et al., 1994). In at least some of these viruses DAF is only a primary receptor 
and internalisation/uncoating requires a second, often Ig-like, receptor.   
Integrins are dimeric molecules made up of one α and one β chain. There are several 
different α and β chains and these combine to give 24 different integrins (Campbell & 
Humphries, 2011). Several of these recognise the Arg-Gly-Asp (RGD) tripeptide and a few 
picornaviruses, including FMDV, some parechoviruses, CAV9 and echovirus 9 contain 
this motif in the capsid protein VP1 and bind to an RGD-recognising integrin (e.g. αvβ6, 
αvβ3, αvβ1, αvβ8) during entry (Shakeel et al., 2013; Merilahti et al., 2016; Kotecha et al., 
2017). Echovirus 1 binds to integrin α1β2 in a non-RGD-dependent manner (Smyth & 
Martin, 2002; Xing et al., 2004) Like DAF, at least for some picornaviruses, binding to 
integrins is not sufficient for infectious entry and other cell molecules are required. In 
addition, compared with HPeV1, which is absolutely integrin dependent, CAV9 can infect 
cells even after RGD deletion (Boonyakiat et al., 2001). 
Low density lipoprotein receptor (LDLR), LDLR-related protein, and very LDL receptor 
(VLDLR) have been recognized as receptors for minor group HRV. LDLR binds at the 
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virus 5-fold axis and does not induce structural alteration to the virus, but as HRVs are 
acid-labile their particles are destabilised in the acidic environment of endosomes leading 
to uncoating (Reithmayer et al., 2002; Blaas, 2016). The scavenger receptor B2 (SCARB2) 
and P-selectin glycoprotein ligand-1 (PSGL-1) have been identified as receptors for EV71 
and other members of the species EVA (Yamayoshi et al., 2014). Heparan sulphate is found 
to support FMDV and echovirus adherence to cellular membranes (Schneider-Schaulies, 
2000). 
1.3.3 The role of canyon in some viral infection 
In the major HRV receptor group (but not minor group), coxsackie A and B viruses and 
poliovirus (PV) the receptor binding sites are amino acids within a deep and narrow 
depression which runs around 5-fold axis to form a moat-like canyon (Newcombe et al., 
2003; Shingler et al., 2015). The amino acids making up the binding site are highly 
conserved within the groups and cannot be contacted by neutralizing antibodies as these 
are too large to penetrate the canyon (Shingler et al., 2015; Dong et al., 2017).  
In the viruses containing a canyon, receptors also function in the triggering of the 
conformational changes required for subsequent virus entry/uncoating (Rossmann et al., 
2002). In non-canyon viruses like FMDV, or viruses where the canyon is not the site of 
binding like minor receptor group HRVs, other triggering factors like endosomal 
acidification are crucial for virus entry (Smyth & Martin, 2002). In CAV9, which is acid 
stable, it is expected that interaction with a canyon-binding molecule is needed to 
destabilise the particle after RGD/integrin interaction, which does not take place in the 
canyon. GRP78 and/or MHC1 have been found to be involved in CAV9 entry/uncoating 
and could function in this way (Triantafilou et al., 2002). 
1.3.4 Virus movement and entry across the host cell membrane 
The first interaction between a virus and a molecule/molecules on the cell surface can often 
be non-specific and just allow an initial, often weak, attachment. This is often mediated by 
charged proteins such as heparan sulphate, gangliosides and sialic acid (Mothes et al., 
2010; Boulant et al., 2015).  
Following attachment, and depending on the mobility of the receptor, some viruses remain 
where they are attached before endocytosis in a passive or signal induced manner, while 
others migrate around the surface until recognised by a specific receptor that mediates virus 
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uptake (Yamauchi & Helenius, 2013). Some viruses apparently use one type of receptor 
molecule, such as CDI55 for PV and LDLR for minor receptor group HRVs. Some others 
can infect cells, sometimes different types of cells, using one of two or more efficient 
receptors such as PSGL-1or SCARB2 for EV71. Others, such as CAV9 probably use two 
or more molecules with different roles.  Different viruses use distinct strategies as some 
receptors allow multivalent binding which increases avidity, leads to irreversible binding, 
stimulates signalling and mediates membrane curvature to facilitate endocytosis. On the 
other hand, multivalent attachment can reduce mobility and interactions with further 
molecules needed for entry as well as engaging a preformed endocytic structure (Smith & 
Helenius, 2004; Burckhardt & Greber, 2009; Yamauchi & Helenius, 2013).  
Enteroviruses have a lipid “pocket factor” contained within a hydrophobic pocket, made 
up of amino acids in VP1 and located under the canyon (Smyth & Martin, 2002). The 
pocket factor stabilises the capsid and its removal by receptor attachment is essential for 
uncoating (Figure 1.4).  Binding of cellular receptor(s) also destabilizes the N-terminus 
region of VP1 and VP4 and causes them to be externalised from inside the capsid, so that 
the myristoyl group at the N-terminus of VP4 can help the hydrophobic N terminus of VP1 
to attach to the cell membrane. Six to 10 copies of myristoylated protein, together with the 
associated VP1 make a channel with 5 amphipathic helixes. An irreversible expansion of 
the particle then causes the RNA genome to exit through the hole made near the 2-fold axis 





Figure 1-4. The enterovirus pocket factor.  
The pocket factor (PF) is a small lipid-like molecule that fits into a hydrophobic pocket 
underneath the canyon. The initial binding of the receptor into the canyon leads to the loss 
of the PF, and the space now vacant allows a deeper interaction of the receptor with the 
canyon (activated binding state) which is needed for uncoating. Drugs such as pleconaril 
can replace the PF and bind irreversibly into the pocket. Receptor binding does not remove 












1.3.5 Endocytosis, the principle pathway of entry 
Most picornaviruses use a specific cellular endocytic vesicle, which either already exists 
or is made after virus-induced signalling, to pass through the cell membrane and be 
internalized into an endosome, before releasing their genetic material into the cytoplasm. 
Viruses which depend on low pH for uncoating are absolutely endosome-dependent, while 
those which uncoat at neutral pH may release their RNA directly through the plasma 
membrane or use an endocytic mechanism (Jha et al., 2011). Using an endocytosis pathway 
enables the virus to penetrate the cell membrane, avoid the immune system and move 
through the cytoplasm to the desired location (Marsh & Helenius, 2006). Vesicles include 
several dynamic types such as recycling, early and late endosomes and lysosomes. Some 
of these endosomes can return the virus to the cell surface and so cell infection would not 
occur, while others expose it to harsh environment of very low pH, proteases or nucleases. 
To avoid that, many viruses uncoat and penetrate the endosome membrane at the mild 
acidic pH (around pH6) found in the early endosome. Others can time their penetration 
precisely with the changing environment inside the endosome (Grove & Marsh, 2011; 
Huotari & Helenius, 2011).  
Several endocytosis pathways are used by viruses. The best identified one is clathrin-
mediated endocytosis. A ligand (or virus particle) binds to the receptor which is located in 
a pit with a clathrin coat. The curvature of the pit changes to form a sphere surrounding the 
receptor and this sphere is sealed and detached from the cell membrane by dynamin. The 
clathrin-coated vesicle is then uncoated and fuses with an endosome (Vidricaire & 
Tremblay, 2007; Kim et al., 2017). Caveolae are another type of coated pits found on the 
cell surface. They occur in regions of the cell surface, called lipid rafts, which are enriched 
for specific lipids and caveolae are coated with caveolin proteins. Receptors and ligands 
are internalised in caveolae in a similar dynamin-dependent process to clathrin-mediated 
endocytosis and the caveolae fuse with endosomes. There are also several 
clathrin/caveolin-independent mechanisms, such as micropinocytosis and routes dependent 
on flotillin and Arf6 but these all tend to also lead to fusion with endosomes (Mercer et al., 
2010). In general, the route of virus entry is usually determined by the receptor type. For 
example, integrin αv-dependent picornaviruses usually use clathrin-mediated endocytosis, 
while integrin α2β1-dependent EV uses caveolin-mediated endocytosis. Nevertheless, in a 
few cases viruses which bind to similar receptors may have different entry routes (Merilahti 
et al., 2012).  
43 
 
1.4 Virus replication within the host cell 
Synthesis of viral protein from the released RNA is the next step in replication. 
Approximately, 2 hours after infection, the virus genome is uncoated and translated (van 
Kuppeveld et al., 1995). This uses a cap-independent IRES element in the 5´UTR of the 
genome to recruit both standard initiation factors and IRES-specific trans-acting factors 
(ITAFs), to allow ribosome binding and translation initiation (Pilipenko et al., 2000; Tan et 
al., 2014). The viral genome is translated to give viral proteins, initially synthesized as a 
large polypeptide that is cleaved into individual structural, and non-structural proteins. In 
enteroviruses cleavage is done by the virus-encoded proteases 2Apro and 3Cpro (Garmaroudi 
et al., 2015). The proteins include the virus polymerase 3Dpol which adds U residues to VPg 
to give the uridylylated state of VPg (VPg-pUpU), which is the primer for the synthesis of 
new RNA. 3Dpol uses the positive sense viral RNA as a template to synthesize the negative 
strand, which then acts as the template to synthesize new positive strands (Yang et al., 2002; 
Sun et al., 2012; Kempf & Barton, 2016). RNA synthesis occurs on intracellular, tubule-
vesicular membranes, the replication complex (RCo), which are only present in virus-
infected cells and which originate from different organelles such as the endoplasmic 
reticulum or Golgi (Strating et al., 2015). These modified membranes provide the platform 
needed to assemble host and virus components needed for RNA replication. RCos also hide 
viral RNA and proteins from the innate immune system, so host defence mechanisms can 
be avoided (Martín-Acebes et al., 2013). In addition, as RCo formation diverts components 
of the cellular protein secretion system, such as endoplasmic reticulum, it plays an important 
role in viral pathology and also prevents MHC-mediated presentation of virus peptides 
which again limits the host response to infection (Tan et al., 2014; Murat & Tellam, 2015). 
The newly-synthesized positive-strand RNA genomes and structural proteins are 
assembled to make the complete virus particle. The uncleaved precursor of VP4 and VP2, 
VP0, together with VP1 and VP3 come together to form a protomer initially. After that, 
five protomers aggregate together to bring about a pentamer. The virus particle is then 
formed by accumulation of twelve pentamers that surround the RNA genome. There is then 
a maturation step when VP0 is cleaved to give VP4 and VP2 (Stanway, 2013).  
The final step of the life cycle is the release of the mature viruses so they can infect other 
cells, which occurs by cell lysis (Garmaroudi et al., 2015; Kirkegaard, 2017). However, 
non-lytic spread of PV in the central nervous system (the spinal cords of Bonnet monkeys) 
has been observed (Ponnuraj et al., 1998). According to more recent investigations, PV 
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particles, as well as other enteroviruses, can be released non-lytically from cells within 
phosphatidylserine-lipid-enriched autophagosome-like vesicles which are more infectious 
than single viral particles (Garmaroudi et al., 2015; Bird and Kirkegaard, 2015; Kirkegaard, 
2017).  
1.5 Functions and interactions of untranslated regions 
1.5.1 5´-untranslated region (5´-UTR) 
Conserved structures and sequences within the 5´ and 3´ ends of the picornaviral RNA play 
important roles in viral replication (Figure 1.5). The 5´-untranslated region (5´-UTR) is 
involved in the initiation of translation and RNA replication, and also contains determinants 
of virulence of viruses including PV and EV71 (Kloc et al., 2018).  
The picornavirus genome functions like a cellular mRNA, but unlike cellular mRNA the 
5´ end is not capped. The 5´ UTR is exceptionally long compared to cellular mRNAs but 
variable in length (between 415 nts for passerivirus and 1451 nts for cardiovirus) (Duke et 
al., 1992; Woo et al., 2010).  
The 5´UTR has extensive secondary structure, with several stem-loops, some forming 
complex domains. Taking enteroviruses as an example, the 5´-UTR consists mainly of 2 
distinct elements, the cloverleaf (CL) and the internal ribosome entry site (IRES). Other 
structures seen in some 5´-UTRs include pseudoknots (PK), poly (C) and poly-pyrimidine 
tracts (Liu et al., 2009).  Some antiviral classes have been identified to target the 5̀´ UTR, 
including phosphonodiamidite morpholino oligomers (PMOs) used in single-stranded 


















Figure 1-5. Picornavirus untranslated (non-coding) regions. 
 The structure of the 5´ and 3´-UTRs differ between picornaviruses and the EV structures 
are given as an example. VPg (black oval) is linked to the 5´end of the genome. There is a 
5´- end clover leaf structure (I) made up of a stem (a) and three stem-loops, b, c and d. The 
loops of b and d bind cell and virus proteins. Much of the rest of the 5´ UTR consists of the 
IRES, internal ribosome entry site, needed for translation of the virus RNA. This involves 
structures II-VI which contain binding sites for proteins needed for translation and a critical 
GNRA motif. Structure VI contains a polypyrimidine region (heavy line and an AUG motif 
(black dot), which is the site of ribosome binding. The ribosome then scans along the 
genome and protein synthesis is initiated at the AUG at the start of the open-reading frame. 
The open reading frame is shown as a green box. The EV 3´-UTR folds into either two 
(e.g. EVC, Y, X) or three (e.g. EVB, Z, Y, X) stem-loops. The loops of X and Y are 
complementary in sequence and form a tertiary “kissing” interaction (purple lines). This is 
needed for RNA replication (Lin et al., 2009; Mirmomeni et al., 1997).  
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1.5.1.1 The cloverleaf structure  
The cloverleaf (CL) structure is at the 5´ terminus of the enterovirus RNA. Many other 
picornaviruses have a single stem-loop at this position but have been less well-studied and 
the function of this structure is largely unknown. The CL is highly conserved in 
enteroviruses and involved in different parts of genome replication (Sharma et al., 2009). 
In PV, the CL functions to enhance VPg uridylation and the initiation of negative-strand 
synthesis (Lyons et al., 2001). The CL gets its name because it has the same shape as a 
cloverleaf, with a stem (domain a) topped by three stem-loops (b, c and d) (Rieder et al., 
2003). Binding of the cell protein PCBP2 (poly C binding protein) to stem-loop b enhances 
binding of the virus protein 3CD to stem-loop d which inhibits translation initiation (Lloyd, 
2015). The loop in domain b is the most stable one and a C-rich sequence has been found 
to be essential for PCBP binding (Toyoda et al., 2007). Cleavage of 3CD releases the active 
3Dpol allowing RNA replication (Headey et al., 2007). This mechanism prevents 
ribosomes from attaching to the RNA, so they do not interfere with RNA replication, as 
well as allowing RNA replication to start.  
1.5.1.2 The internal ribosome entry site  
The internal ribosome entry site (IRES) is an RNA sequence element that occupies much 
of the entrovirus 5´ UTR extending from stem loop II to stem loop VI, about 450 nts 
(Martinez-Salas & Fernandez-Miragall, 2018). Using a cap-independent mechanism and 
recruiting necessary host translation machinery including canonical (initiation factors 
[eIFs]) and non-canonical (ITAFs) factors the IRES directs host ribosomes to initiate an 
internal initiation of translation of the viral genome (Pickering et al., 2003; Walsh et al., 
2013). This mechanism is different from the cap-dependent mechanism used to translate 
most cell mRNAs and so can still occur when the virus shuts of host cell protein synthesis, 
e.g. by cleaving some proteins needed for cap-dependent translation.  
The IRES contains domains that bind specifically to eIFs or directly to ribosomes, as well 
as to ITAFs such as La and PTB and these domains are required for IRES function. For 
example, it was found that in PV stem-loop V binds to eIF4B and eIF4G, as well as PTB 
and this binding is weaker in the attenuated vaccine strains, which contain a critical 
mutation in this stem-loop (Ochs et al., 2003). IRES mediated functions are modulated by 
many stimulatory and inhibitory factors, for instance the 3´-UTR and poly (A) tail 
sequences strongly stimulate IRES activity while some ITAFs are found to inhibit IRES 
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function after they are cleaved like La autoantigen and PTB (Back et al., 2002; Dobrikova 
et al., 2006). In addition, some IRES sub-domains can make long range RNA-RNA 
interactions. For instance, an interaction between part of domain III and the cre may block 
IRES activity and stimulate switching from translation (protein synthesis) to RNA 
replication (Romero-López et al., 2012).  
1.5.2 The role of the 3´-untranslated region in virus replication 
There is still little information of the precise role of 3´-UTR in virus translation and/or 
replication. However, the extensive sequence and structural conservation between related 
viruses of this relatively short length region (e.g. around 40-120 nt in EV) (Duque & 
Palmenberg, 2001) indicate its importance. The 3´-UTR is thought to have signals to 
initiate negative strand RNA synthesis and to play a role in regulating polymerase activity 
(Iwakawa et al., 2007; Lodeiro et al., 2009; Gebhard et al., 2011). Interestingly, the poly 
(A) of picornavirus is genetically encoded. However, there is a special mechanism which 
regulates its length and part of the 3´-UTR (oriR) has a key position in this mechanism.  
The predicted secondary structures of all EV (except rhinovirus) 3´-UTRs show 2 stem-
loop structures, the loops of which interact in a tertiary “kissing” interaction. Members of 
EVA and EVB also show a third stem-loop (Mirmomeni et al., 1997). The kissing 
interaction has been called oriR and implicated in RNA replication as well as regulating 
the length of the poly A tail (van Ooij et al., 2006a).  
1.5.2.1 The importance of poly (A) tail in viral replication 
Poly (A) is a stretch of adenine nucleotides found at the 3´end of cell mRNAs, following 
polyadenylation by poly A polymerase which recognises a polyadenylation sequence near 
to the end of the immature mRNA. In picornaviruses, poly (A) is instead genetically 
encoded by complementary transcription in the minus strand from poly (U) (Steil et al., 
2010; Kempf et al., 2013). The poly (A) tail has important functions in viability, RNA 
stability, genome translation and viral replication (Barr & Fearns, 2010; Steil et al., 2010). 
Reporter mRNA translation mediated by the picornaviral IRES is greatly stimulated by 
poly (A) (Bergamini et al., 2000; Michel et al., 2001). In addition, the PABP-poly (A) 
complex may enhance the interaction between elF4G and IRES which is very important 
for translation initiation (Svitkin et al., 2001). The template for negative strand synthesis 
most likely adopts a circular conformation, where the 5´ and 3´ ends are close together due 
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to an interaction between PABP (poly A binding protein) and PCBP2. PABP binds to the 
3´ poly A tail, while PCBP2 binds to the CL near to the 5´end of the genome (Andino et 
al., 1993; Parsley et al., 1997; Herold et al., 2001; Svitkin et al., 2007). Poly (A) is variable 
in length between different picornaviruses and for normal functions there is a minimum 
length (Silvestri et al., 2006). In case of PV, it has average length between 50 and 90 
nucleotides with a minimum length for virus viability of 12 nucleotides, shown by the non-
ability to recover viruses from complete cDNA copies of the virus genome with poly A 
lengths of to less than 12 nucleotides (Yogo & Wimmer, 1972; Kempf et al., 2013).  
1.5.3 Cis-acting replication element (cre)  
The cre is a stem-loop structure found at different locations within the genome of different 
picornaviruses, but most often within the coding region. In EVs except rhinoviruses, the 
cre locates within the 2C-encoding region, while in RV-A, RV-B and RV-C it is located in 
the regions encoding 2A, VP1 and VP2 respectively (Goodfellow et al., 2000; van Ooij et 
al., 2006b). However, it can be found the 5´UTR in FMDV (Mason et al., 2002). The 
diversity of genomic location does not affect its function significantly. Based on 
biochemical, computational and nuclear magnetic resonance spectroscopy analysis, cres 
have a similar hairpin shape with a terminal loop (usually 14 nt in EVs), although the size 
is variable in different picornaviral species (Cordey et al., 2008). The main function of the 
cre is to template the uridylylation of VPg to VPgpU/VPgpUpU by 3Dpol (Rieder et al., 
2003; Goodfellow et al., 2003). A single A (adenosine) residue in the cre loop acts as the 
template. Poly (A) is also a potential template for 3Dpol-catalysed VPg uridylylation 
besides the cre, with the exception of FMDV, in which poly (A) is not used as a template 
(Herold et al., 2001; Paul & Wimmer, 2016). Interestingly, the cre-mediated VPgpUpU 
seems only to prime positive-strand RNA initiation (Murray & Barton, 2003). The presence 
of the cre structure in the positive-strand RNA may enable the replication complex to 
distinguish the viral and host mRNA poly (A) tails to avoid competition with virus RNA 
replication (Barton et al., 2001). 
1.6   Protein roles during viral infection  
Picornavirus proteins have critical contributions to make during the virus life cycle. They 
are either structural (also called capsid proteins) that form the virus particle, protect the 
genome, mediate cellular entry and allow release of the genome into the cell cytoplasm of 
the host cell, or non-structural, which act only intracellularly (e.g. facilitate viral 
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translation, polyprotein processing and RNA replication) (Ross et al., 2017), and are never 
packaged in the virion (Ogawa et al., 2009).  
1.6.1    Capsid proteins (Structural proteins)   
The picornavirus virion become complete and infectious only after the capsid is assembled 
around the genome (Lucas & Knipe, 2010).  
 Capsid proteins may also interact with non-structural proteins, such as VP3 which interacts 
with 2C and plays a role in assembly of the particle, or with cell proteins, for example VP2 
of CBV3, binds to proapoptotic protein Siva, leading to apoptosis, viral spread, and tissue 
damage (Lin et al., 2009).  
1.6.2    Non-structural proteins  
The non-structural proteins (2A, 2B, 2C, 3A, 3B, 3Cpro, 3Dpol and in some picornaviruses L 
protein) are involved in translation and replication, as well as interfering with defence 
mechanisms and generating the RCo needed for RNA replication. Figure 1-6 shows the 
sizes and conserved structures in picornavirus non-structural proteins. 
1.6.2.1   2A protein    
2A gets its name from its position in the viral polyprotein, but it is important to understand 
that this protein can be a completely different type of protein, with different function, size 
etc, between picornaviruses in different genera (Hughes & Stanway, 2000). This is in 
contrast to other viral proteins (except L) that are homologous in all picornaviruses. For 
instance, 2Apro of EVs (Figure 1-6) acts as a trypsin-like protease. However, in 
aphthoviruses and many other picornaviruses, 2A is very short, around 18 amino acids, and 
is involved in an unusual function at the 2A-2B junction, where during translation no 
peptide bond is formed between the third and fourth amino acids of an NPGP motif at the 
2A/2B boundary. Translation then continues, so that the polyprotein is made in two pieces 
(Donnelly et al., 2001).  Several picornaviruses, including parechoviruses, have a 2A with 
H box and NC motifs, but the function of these has not been identified.  (Hughes & Stanway, 
2000). A number of picornaviruses have multiple copies of 2A (Picornavirus Home Page, 
2019).  
During EV translation, 2Apro cleaves at its own N-terminus, separating capsid proteins in 
the P1 region from non-capsid proteins in the P2-3 region (Teterina et al., 2010). In addition, 
EV 2Apro functions also include dealing with shutoff of cellular processes by cleaving of a 
number of cellular proteins. 2Apro cleaves the initiation factor eIF4GI and/or PABP to 
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prevent cap-dependent translation and selectively facilitate viral RNAs translation. In 
addition, 2Apro cleaves several other cell proteins involved in cap-dependent translation, 
transcription, splicing and nucleocytoplasmic shuttling (Castello et al., 2011). For example, 
under experimental condition, transient increase of 2Apro expression results in increase of 
nuclear permeability and translocation of its proteins in to the cytoplasm (Belov et al., 
2004). A recent study showed that this protease inhibits stress granule formation, so 
blocking their antiviral effect, and stimulate atypical stress granule formation which 
enhances viral translation (Yang et al., 2018).   
1.6.2.2 Leader protein  
Leader protein (L protein) is encoded before the capsid-encoding region in some, but not 
all, picornaviruses and has different structures and functions among L protein-encoding 
genera. In aphthoviruses, Lpro is a papain-like protease responsible for releasing itself from 
the P1 region of the polyprotein and also cleavage of eIF4G (Liu et al., 2015), a process 
which is done by 2Apro in EVs, and this contributes to shut down of cellular cap-dependent 
translation (Watters & Palmenberg, 2011; Su et al., 2018).  
In cardioviruses such as EMCV and Theiler’s murine encephalomyelitis virus (TMEV), L 
protein has no enzymatic activity. Instead, it stimulates kinases to hyper phosphorylate 
nuclear pore protein FG-repeat domains and so interferes with nucleocytoplasmic 
trafficking (Porter & Palmenberg, 2009; Ciomperlik et al., 2016). Treatment of cells with 
staurosporine, a protein kinase inhibitor, reverses the inhibitory effect of L protein on 
nuclear import/export process. In addition, EMCV’s L protein binds directly to RAN-
GTPase giving an additional way to disrupt nucleocytoplasmic trafficking (Porter et al., 
2006; Porter & Palmenberg, 2009; Flather & Semler, 2015). 
The Aichi virus L protein has a distinct sequence from that of aphthovirus and cardiovirus 
and different functions including morphogenesis and viral replication. For instance, 
mutation of this protein caused a significant decrease of mature virus but not the empty 
capsid although its importance for RNA encapsidation has been already identified. In 
addition, deletion of its C-terminal region resulted in a severe reduction in virus yield 
(Sasaki et al., 2003; Jiang et al., 2014).  
1.6.2.3 2BC and 2B proteins 
2BC protein is a relatively stable precursor which in some picornaviruses induces 
accumulation of vesicles, derived from the secretory pathway, that will form replication 
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complexes (RCo) (Bienz et al., 1987). In addition, 2BC, but not either 2B or 2C separately, 
has the ability to induce autolysosome accumulation in cells infected with PV and EV71 
(Taylor & Kirkegaard, 2007; Klein & Jackson, 2011; Lai et al., 2017).  
2B protein is a small hydrophobic membrane protein (Figure 1-6) which is usually localized 
closer to ER and Golgi complex membranes in infected cells. In EVs, 2B is functional as a 
part of 2BC and as a mature protein (Bienz et al., 1987; Schlegel et al., 1996; de Jong et 
al., 2008). In some picornaviruses, including EVs, 2B acts as a viroporin and permeabilizes 
membranes, probably by forming homomultimers to build up pores through these 
membranes, and this increases the levels of cytosolic Ca+2 and decrease ER-Golgi complex 
Ca+2 concentration. 2B also disrupts Golgi-protein trafficking and localises to ER surfaces 
in EVs. Mutations that disrupt coxsackievirus 2B viroporin activity change 2B localization 
and prevent its effect on host secretory pathways, as well as inhibiting viral replication (de 
Jong et al., 2004). 
However, in other picornaviruses that are not closely related to EV, such as HAV, FMDV 
and ECMV, 2B shows a different localization pattern and has very little effect on Ca+2 
homeostasis (Van Kuppeveld et al., 1997a, 1997b; Jecht et al., 1998; de Jong et al., 2008).  
In Aichi virus (AiV), 2B seems to act with other proteins like 2BC, 2C, 3A and 3AB to 
bind acyl-coenzyme A binding domain containing 3 protein (ACBD3), which binds and 
forms a complex with PI4KB to synthesize PI4P for RNA replication (Ishikawa-Sasaki et 
al., 2014a). 2B also interacts with oxysterol binding protein (OSBP) which is then recruited 
to AiV-induced RCos. OSBP was also found to interact with 2BC but little with 2C, 3A, 
3AB and ACBD3 (Aldabe et al., 1996; Ishikawa-Sasaki et al., 2018).  
1.6.2.4 2C protein 
Although 2C vial protein is essential for picornavirus replication, highly conserved, 
multifunctional, the location of mutations that give resistance to many potential anti-
picornavirus drugs and has been extensively studied, it is still little understood (Norder et 
al., 2011).The explanation of its structure (Figure 1-6), functions and interactions often 
depends on assumptions from 2C sequence motifs, and it is predicted to have an RNA 
binding motif, an N-terminal membrane-binding motif (an amphipathic helix) and an 
ATPase domain seen in RNA SF3 helicases of the AAA+ ATPase superfamily (Pfister et 
al., 2000). RNA helicase activity has recently been demonstrated for the EV71 2C (Xia et 
al., 2015). The recently described EV71 2C structure should be very useful as a basis for 
52 
 
understanding this protein more clearly (Guan et al., 2017). 2C is likely to form a 
hexameric ring structure held together by interactions between a C-terminal amphipathic 
helix and a hydrophobic pocket in an adjacent 2C molecule. The structure also emphasizes 
the importance of a cysteine-rich region in zinc binding (Guan et al., 2017). 
In general, 2C and its precursor 2BC protein localise to the EV RCo and are probably 
needed for their formation (Teterina et al., 1997; Norder et al., 2011). Viral proteins 2B, 
2C, 2BC and 3A are hydrophobic, interact with membranes and modify these membranes. 
2B or 2BC proteins interact with Golgi and cause its disassembly and also alter the 
permeability of the plasma membrane which causes cell lysis (Norder et al., 2011). 
Producing RCo from components of the protein secretion system prevents presentation of 
virus peptides on the surface of the infected cell, so 2C/2BC, and in some viruses 3A, help 
to hide virus infection from the immune system. Another event of the virus lifecycle in 
which 2C protein has been shown to be essential is encapsidation of RNA to give the virus 
particle.  An interaction between 2C and VP3 is essential for this process (Liu et al., 2010).  
1.6.2.5 3AB and 3A 
3AB is a small basic protein that is involved in several functions in replication. For 
example, the hydrophobic 3A domain of 3AB binds cellular membranes and interacts with 
their vesicles anchoring induced RCos to vesicles. The 3B domain interacts strongly with 
3Dpol stimulating its elongation activity (Lama et al., 1994; Plotch & Palant, 1995; Xiang 
et al., 1998a; Cameron et al., 2010). 3AB itself is a nonspecific RNA binding protein. 
However, in PV after interacting with 3CD, 3AB has the tendency to specifically bind the 
5´-clover leaf and 3´-UTR, stimulating 3CD proteolytic activity, and probably also 
anchoring 3Dpol protein to the replication complex and strongly stimulating its 
polymerization activity. In addition, 3AB is an identified substrate for 3D itself during VPg 
uridylylation (Plotch & Palant, 1995; Xiang et al., 1995; Richards et al., 2006). 3AB was 
also found to have a helix destabilization activity in PV, indicating a nucleic acid chaperon 
action which can destabilise secondary structures to make replication of complementary 
RNA more efficient (DeStefano & Titilope, 2006). In vitro, 3AB has the ability to 
multimerize through both the N-terminal region and the hydrophobic domain of 3A to form 
higher oligomers in solution (Xiang et al., 1998b; Strauss et al., 2003). This may be related 
to possible viroporin action through forming multimeric ion channels in membranes. 
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When proteolytically cleaved, 3AB gives 3A and 3B. In addition to functioning as a domain 
within 3AB, 3A (Figure 1-6) has some individual functions. Some mutations in 3A have 
been found to affect positive strand RNA synthesis, but not negative strand. In some 
picornaviruses, 3A inhabits ER-Golgi traffic of membrane and secretory proteins and 
facilitates translocation of some ADP-ribosylation factors into the membrane (Doedens et 
al., 1997; Belov et al., 2005). Recently, it was found that the experimental expression of 3A 
protein in CBV3 and PV recruits phosphoinositol-4 kinase (PI4K) IIIβ to membranes and 
this enzyme is known to be important for viral replication by increasing PI4P levels at 
replication complexes. Recently, oxysterol-binding protein (OSBP) was found to be 
important for regulating lipid homeostasis between the ER and the Golgi complex. It traffics 
cholesterol and PI4P between these membranes and stabilises ER-Golgi membrane contact 
sites. It is also involved in recruiting cholesterol to RCos, due to accumulation again 
stimulated by 3A (Strating et al., 2015; van der Linden et al., 2015). In vitro, 3A is also 
found to bind GBF1 protein and prevent its binding to COP-1 which is needed to generate 
vesicles needed for the protein secretion system. This recruits these vesicles for RCo 
formation as well as inhibiting proteins secretion (Belov et al., 2007).  
1.6.2.6 Viral genome-linked protein (VPg) 
The first step of viral RNA synthesis is the production of uridylylated VPg (3B) made by 
the 3D polymerase (3Dpol) to give VPgpU and VPg-pUpU. The uridylylated VPg (Figure 
1-6) primes both positive- and negative-strand RNA transcriptional synthesis (Lin et al., 
2009). VPg is therefore attached covalently to the 5´end of both negative and positive 
(genome) sense RNA (through a phosphodiester bond) because it was the primer. Unlike 
some other positive sense RNA viruses, VPg is not necessary for translation and is actually 
removed by a cellular enzyme after entry into the cell and before translation. It may be that 
whether VPg is removed from or kept by the newly made positive sense RNA controls 
whether these are used for transcription or packaging into new virus particles (Lin et al., 
2009). 
1.6.2.7 3Cpro  
3Cpro a chymotrypsin-like member of the trypsin proteases in all picornaviruses. Unlike 
most members of this protease family, 3Cpro (Figure 1-6) has an active site cysteine rather 
than a serine. Two other amino acids, a glutamic or aspartic acid and a histidine are located 
close to the cysteine in the folded protein and form a catalytic triad (Birtley et al., 2005). 
3Cpro and its precursor 3CDpro do several inhibitory duties by cleaving cell proteins, as well 
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as their primary function of performing most cleavages in the viral polyprotein. These 
events results in shutting off transcription, impairing host RNA processing and 
polyadenylation by cleavage of the cellular CstF-64 protein (Weng et al., 2009), inhibition 
of protein synthesis, blocking nucleocytoplasmic shuttling and which eventually induce cell 
death (Sun et al., 2016b), by triggering apoptosis mediated by the caspase pathway (Li et 
al., 2002). When the virus shuts off host cell protein synthesis by inactivating cap-
dependent translation, its own translation can continue as this is initiated by a different 
mechanism which is IRES-mediated initiation (Martinez-Salas & Fernandez-Miragall, 
2018). 
1.6.2.8 3Dpol 
3D polymerase (3Dpol) is an RNA-dependent RNA polymerase (RdRP) which is found 
exclusively in RNA viruses and is one of template-directed nucleic acid polymerase 
superfamily characterised by “a cupped right-hand structure” including fingers, palms and 
thumb domains (Peersen, 2017). The crystal structure of 3Dpol has been described for 
several EVs (Figure 1-6) including CBV3, PV, EV71, FMDV and some HRVs (Ferrer-
Orta et al., 2004; Wu et al., 2010; Gong et al., 2013). 3Dpol has a central catalytic role in 
the viral lifecycle including both priming and elongation activities as it forms, together with 
VPg, 3Cpro, and probably the 3CD precursor, the VPg uridylylation complex that organizes 
the uridylylation of VPg in vivo at the cre element (Ferrer-Orta et al., 2004, 2015; Pathak 
et al., 2007; Paul & Wimmer, 2016). The first initiation step in this process is to uridylylate 
the very conserved (position 3 in all picornavirus VPgs) tyrosine of VPg by 3Dpol which 
catalyzes covalent addition of 2 UMP molecules to its hydroxyl group using an A in loop 
of the cre element as a template (in some other viruses like caliciviruses the nucleo-adding 
step is template-independent) (Paul et al., 2003; Paul & Wimmer, 2016). Then 3Dpol uses 
the uridylylated form (VPg-pUpU) as a primer to start replication of negative and positive 
RNA strands (Paul et al., 2003; Steil & Barton, 2009). The fingers, palm and thumb 
domains within 3Dpol contain conserved residues that were found to stabilize VPg in the 
binding cavity and mutation of 3Dpol-conserved residue that interact with VPg resulted in 
an extreme defect in the uridylylation of VPg (Richards et al., 2006). In addition to primer 
formation, 3Dpol also copies the viral RNA genome to make new copies. 3Dpro is less 
accurate than cellular replication polymerases as it lacks proof-reading and (wrong 
sequence) excision activities, and this means that high mutation frequencies are observed 
during the picornavirus replication, as is the case for other RNA viruses. This corelates 
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with the high rate of addition of nucleotides in RNA viruses, i.e. the faster polymerases are 
lower in accuracy (Campagnola et al., 2015). The mutation rate allows a prompt adaptation 


















Figure 1-6. Diagram of the non-structural proteins of an enterovirus, showing some 
of the conserved features known to be important for function.  
In enteroviruses 2A is a chymotrypsin-like protease with a catalytic triad made up of 
conserved histidine (H), aspartic acid (D) and a cysteine (C) within the sequence GXCG, 
where X is any amino acid. 3C, the protease which performs most cleavages of the virus 
polyprotein, is a similar type of protein with a catalytic triad containing a glutamic acid (E) 
instead of aspartic acid. 2B and 3A are small proteins which interact with membranes using 
hydrophobic regions (hr) and also an amphipathic helix (ah) in the case of 2B. 2C is a 
helicase with three domains (A, B and C) which are found in ATPase enzymes. It also has 
a cysteine-rich sequence which binds zinc ions (Zn). An N-terminal ah binds to membranes, 
while a C-terminal ah is involved in protein-protein interactions that bring 6 2C molecules 
together to give a hexamer. 3B is VPg. All picornavirus VPgs have a tyrosine (Y) at 
position 3 and the –OH of the tyrosine is used by 3D to urylyldate VPg to form the primer 
for RNA replication, VPgpUpU. 3D is the virus polymerase and contains several motifs 
seen in all picornavirus 3Ds (KDELR, GGXPSG, YGDD, FLKR. The sequence GDD is 





1.7 Lipids as important host factors mediating infection 
Lipids are involved in replication of both enveloped and non-enveloped viruses (van der 
Schaar et al., 2016; Guo et al., 2017). They are involved in early events including 
endocytosis, as well as the formation of the viral replication complexes (RCo) by 
manipulation of organelles, including mitochondria, peroxisomes, endosomes, Golgi and 
the ER, as well as assembly of some viruses (Ogawa et al., 2009).  
Some viruses require cholesterol-enriched microdomains (lipid rafts) in the cell membrane 
for entry (Strating et al., 2015). Lipid rafts use cholesterol to accumulate proteins which 
can be used as receptors for viruses (Simons & Ehehalt, 2002). Following entry and 
translation, picornavirus non-structural proteins stimulate formation of protrusions within 
the host membranes in which lipids are integral to giving the curvature of the membranes 
to form RCo (Reid et al., 2015). In addition, it is also found that picornaviruses use different 
unexpected mechanisms to increase the pool of cholesterol available for RCo formation. 
For example, CBV3 and PV have been demonstrated to use clathrin-mediated endocytosis 
to transfer cholesterol from extra cellular compartment (Ilnytska et al., 2013). The 3A-
mediated accumulation of OSBP and PI4KIIIβ to RCo described above also increases the 
available cholesterol pool and PI4KIIIβ knock down caused a serious decrease in EV RNA 
synthesis.  
During infection by many viruses an important enzyme needed for fatty acid production, 
fatty acid synthase, is recruited to the viral RCo by specific interaction with virus proteins 
and its level has been found to increase in some virus infected tissues (Heaton et al., 2010a). 
Similarly, inhibition of enzymes known to catalyse cholesterol synthesis reduces viral RNA 
synthesis. One example is HMG-CoA reductase which has been found to be relocalized to 
viral RCo in West Nile Virus (Mackenzie et al., 2007). 
Added to that, the rearrangement of lipid metabolism during infection can lead to the 
increased synthesis of ATP to provide the required energy for replication (Corsetto et al., 
2017; Duncan et al., 2017). Apart from damaging cells by relocalization or activity changes 
to host proteins, changed lipid composition may also lead to host complications. For 
instance, elevated liver lipid content during viral infection, may result in liver diseases 
(Zhang et al., 2012), and also causes down-regulation of the interferon-stimulated antiviral 
signalling response to infection (Martín-Acebes et al., 2013).  
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Finally, in the later stage of infection, cholesterol and lipid raft microdomains have an 
essential role in the assembly of a variety of viruses. For instance, HCV assembly occurs 
on the surface of lipid droplets (Martín-Acebes et al., 2013).   
1.8 Lipid droplets 
Lipid droplets (LDs), also called lipid bodies, oil bodies or adiposomes are dynamic and 
mobile cellular components whose structure and size (usually 0.4–100 μm) differ 
considerably in different cells and in response to different situations (Thiam et al., 2013).  
They are vitally involved in various physiological activities and human pathologies. 
Recently, LDs were also detected in nuclei where they were found to regulate aspects of 
nuclear homeostasis (Sołtysik et al., 2019).  
LDs consist of a hydrophobic core of neutral lipids (NLs), usually triacylglycerols (TAGs) 
and/or cholesterol esters (CEs), inside a phospholipid monolayer which is usually 
decorated by some specific proteins (Vanni, 2017). However, the relative amount of the 
NLs and the types of LD surface proteins vary according to cell type. For instance, 
adipocyte LDs are composed mainly of TAGs and macrophage foam cells LDs are 
primarily CEs. LDs of yeast are a mixture of both lipids possibly arranged in layers 
(Buhman et al., 2001; Czabany et al., 2008). In addition, some other lipids can also be 
found within LDs such as retinyl esters in the hepatic stellate and the retina cells (Blaner et 
al., 2009; Orban et al., 2011), and wax ester and ether lipids form 10-20% of some 
mammalian neutral lipids (Yamamoto et al., 2010). Ribosome-like structures can be seen 
inside some LDs using electron microscopy (Fujimoto & Parton, 2011). The dynamic 
nature of LDs can be seen in that there can be a threefold increase in LD diameter within 
hours and a tenfold increase in the surface area (Walther & Farese, 2012). 
Isolating the hydrophobic neutral lipid from the hydrophilic cytoplasmic medium, 
phospholipids covering the monolayer surface layer are polar and amphipathic. In 
mammals these are mostly phosphatidylcholine (PC) which accounts for 60% of 
phospholipid mainly as lyso-PC and is important for LD emulsification and coating to 
avoid adhesion, followed by phosphatidylethanolamine (PE) as lyso-PE and 
phosphatidylinositol (PI) and small amounts of phosphatidylserine, phosphatidic acid and 




LDs associate with a specific and characteristic set of proteins, both transiently and 
permanently, LD-associated proteins including membrane trafficking proteins, signalling 
proteins, intracellular organelles-associated proteins and chaperone proteins (Onal et al., 
2017). The Parkinson’s disease–related protein, α-synuclein and chromatin-associated 
histones (in Drosophila embryo) are transiently recruited to LDs (Colebc et al., 2002; 
Cermelli et al., 2006). Some proteins stimulate LD fusion such as FSP27, a fat-specific 
protein that enhances triglyceride storage, or a cell death-inducing DFF45-like effector C 
which are also transiently recruited to LDs (Nishino et al., 2008). There are proteins that 
have amphipathic properties like viperin (HCV endogenous inhibitor) which can 
distinguish the phospholipid monolayer surface of the LD from that of other cellular 
membranes (Hinson & Cresswell, 2009). PAT (which refers to perilipin, adipocyte 
differentiation-related protein, and TIP47, a tail-interacting protein of 47 kDa, two of the 
members) is the main known family of LD-related proteins.  Perilipin3/Tip47 is localized 
to the ER along with DAG (diacylglycerol) and organizes DAG functions, along with other 
LD proteins for LD formation (Bulankina et al., 2009; Skinner et al., 2009). A small 
GTPase, Rab18, integrates with LDs using lipid-like modifications of certain amino acids 
to anchor it and this facilitates ER-LD interaction (Ozeki et al., 2005). It is known that the 
unique composition of the LD phospholipid membrane affects the biogenesis, size, 
expansion and degradation of LDs (Ferré et al., 2009; Zanghellini et al., 2010; Singh & 
Cuervo, 2012) and is regulated by LD proteins. For instance, long chain FA CoA ligase 
(which is also important for lipid metabolism), squalene epoxidase and lanosterol synthase 
are important for lipid biosynthesis and patatin-like phospholipase domain containing 
protein 2 (CGI-58) for lipid degradation (Hodges & Wu, 2009).      
LDs have multiple interactions with other intracellular organelles particularly the ER, but 
also including mitochondria, endosomes and peroxisomes. In mammals, ER membrane 
partially covers the LD forming an egg-cup shape (Robenek et al., 2006). Rab18, 
perilipin2/ADRP and caveolin are possibly involved in LD-ER interactions as may be 
OSBP and related proteins, as these are ER resident and involved in lipid trafficking 
(Hynynen et al., 2009). LDs can recruit proteins such as HMG-CoA reductase when the 
ER is degraded, suggesting there is a close   LD-ER connection (Olzmann & Kopito, 2011).  
Synthesis of LDs is thought to occur within the ER even though LDs and ER have different 
membrane structures (Tauchi-Sato et al., 2002). When LDs become large enough, they are 
released from the ER, but the mechanism is not clear. The simplest model is that they bud 
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from the ER with an outer bilayer membrane. Excision of LDs as a bicelle has also been 
reported (Walther & Farese, 2009; Pol et al., 2014).  
LDs seem to associate with other organelles, in addition to ER. In skeletal muscle, during 
exercise and training activities, LDs number and mitochondrial contacts increase. Along 
with peroxisomes, this interaction may allow a pathway for lipids stored in LDs to be 
degraded by lipases to fatty acids which can then be oxidised in mitochondria (Binns et al., 
2006; Tarnopolsky et al., 2006).  Endosomes have been also found to coil round the LDs, 
transporting them to lysosomes through macrophageal autophagy. Rab5 may have a role in 
the early LDs-endosomes interaction as it was found in purified LDs (Liu et al., 2007; 
Ouimet et al., 2011).  
LDs are largest in adipocyte cells, which specialise in lipid storage. In white adipocytes, 
there is one very large LD in the cytoplasm, mainly made up of triglycerides as an energy 
store, cholesterol esters and fat-soluble vitamins. Leptin, the primary adipocyte-associated 
hormone is the principle regulator of the long-term energy stability. Mammalian adipocyte 
brown cells degrade lipids within mitochondria to produce heat. LDs are also abundant in 
these cells but are much smaller than the single LD of white adipocytes. The liver is the 
second main reservoir of LDs after adipose tissue, but LDs are also present extensively in 
skeletal muscle, intestine, lactating mammary glands, adrenal cortex and macrophages 
(Walther & Farese, 2012; Nishimoto & Tamori, 2017).  
There are two main ways for LDs break down, lipolysis and autophagy. Lipolysis is usually 
triggered by changing energy levels in the cell and involves three main lipolytic enzymes, 
ATGL, HSL and MGL which eventually liberate energy from the disintegrated TAGs. 
Autophagy is activated by cellular starvation, pathogenic infection and ER stress and takes 
unwanted cellular structures to degradation centres (Zhang et al., 2017).      
Apart from lipid and cholesterol storage, metabolism and breakdown, LDs have other 
important roles in the cell. These include membrane trafficking and providing building 
blocks for new membranes as well as, more unexpectedly, cell signalling, autophagy, 
immunity and clearance of inclusion bodies (Farese & Walther, 2009; Moldavski et al., 
2015; Molenaar et al., 2017). Some hydrophobic drugs and fat-soluble vitamins are also 
recruited to LDs core (Thiam et al., 2013). In addition, LDs also harbour and protect some 
specific unfolded and hydrophobic proteins which otherwise causes adverse effects by 
interactions with intracellular compounds such as histones and α-synuclein and they also 
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store certain amphipathic proteins. These can be are exploited by viruses during   assembly 
and are targeted by other pathogens such as bacteria, fungus and parasite (Cermelli et al., 
2006; Bozza et al., 2017; Vallochi et al., 2018). In some flaviviruses, including HCV and 
Dengue Virus, LDs are known to function as a place for the processing of viral protein and 
RNA production, (Samsa et al., 2009; Lindenbach, 2013; Martins et al., 2018). Hydrolysis 
of cholesterol esters derived from LDs was shown to be important in human rhinovirus 
A16 replication (Ilnytska et al., 2013). LDs have also been identified as a store of fatty 
acids for specific phosphatidylcholine and phospholipid synthesis for building PV RCos 
(Viktorova et al., 2018). 
Although LDs are normally important in cellular homeostasis and cellular functions, they 
are a significant source of cellular dysfunction and metabolic diseases where excessive 
lipid aggregation within LDs exceeds the capacity of cells to buffer or detoxify. Abnormal 
LD accumulation within the liver gives hepatic steatosis which may end with chronic 
fibrosis, cirrhosis, hepatic resection or transplantation (Tevar et al., 2010). Other 
complications that directly related to excessive LDs accumulation are obesity, diabetes 
mellites and heart diseases including atherosclerosis (Onal et al., 2017). LDs are also 
upregulated in most cancer cells, possibly due to an increase in the rate of FA synthesis for 
rapidly proliferating membranes or a decrease in FA oxidation (Tirinato et al., 2017). LD 
deficiency that results in lipodystrophy is a rare genetic mutation encoding for generalized 
lipodystrophy that results from mutation of caveolin (coxsackie A1), seipin (BCSL2) and 
an acylglycerol-phosphate acyltransferase (AGPAT2), or for partial lipodystrophy by 
mutations including peroxisome proliferator-activated receptor-γ (PPARG), lamin A/C 
(LMNA), protein kinase B (AKT2) and endo-protease Face-1 (ZMPSTE24). Some of 
these are associated with white adipose tissue insufficiency and others cause leptin 
deficiency leading to kind of diseases like massive hepatic steatosis, abnormal lipid 
deposition in non-adipose tissue and insulin resistance (Wideman et al., 2009; Walther & 
Farese, 2012).   
1.9 Antiviral agents with their therapeutic targets 
Although all virus families have a generally similar life cycle including attachment, 
uncoating, genome replication, assembly, maturation and release, they differ considerably 
in the detailed mechanisms and requirements of each stage of the life cycle. This partially 
explains the challenge to find wide spectrum antivirus drugs. However, for some specific 
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viruses a range of drugs have developed. HIV-1 is the clearest example of a virus where a 
number of drugs are available, that each target one of the steps of replication listed above.  
HIV-1 is an enveloped, single-stranded RNA virus, that uses reverse transcriptase (RT) to 
copy the RNA genome to DNA, which is then integrated into the chromosomal DNA of 
the infected cell. CD4 is the primary HIV-1 receptor and there is a requirement for a second 
co-receptor molecule, CCR5 or CXCR4, for entry (Martínez-A. et al., 2002; Wei et al., 
2019). The drug Maraviroc binds to CCR5 and prevents the HIV-1 gp120 protein from 
binding, thus blocking infection. Due to the evolution of HIV-1 to use of CXCR4 in later 
stages of infection, this drug is useful only in patients at an early stage of infection.  
Following binding of gp120 to CCR5/CXCR4, a fusion domain on the virus protein gp41 
causes fusion of the virus envelope with the cell membrane which is needed for entry. The 
peptide drug enfuvirtide binds to gp41 and prevents this fusion. The experimental peptide 
drug VIR-576 is based on a molecule found in human blood, VIRIP, which is a naturally-
occurring anti-HIV-1 peptide. VIR-576 also inhibits fusion (Raja et al., 2003; Falkenhagen 
& Joshi, 2018).  
 Drugs which inhibit reverse transcription of viral RNA into cDNA by viral RT were the 
first class of anti-HIV-1 molecules to be developed. They include substrate-binding site 
molecules, called nucleoside RT inhibitors (NRTI, e.g. lamivudine, tenofovir and 
zidovudine), which are incorporated into the DNA chain being made and prevent it being 
extended. Non-nucleoside RT inhibitors (NNRTI, e.g. delavirdine, efavirenz, nevirapine 
and travertine) are allosteric, non-substrate-binding site molecules, which bind to RT and 
prevent its enzyme activity (Pau & George, 2014). Drugs which inhibit HIV-1 integrases 
prevent integration of viral cDNA into the cellular genome. Both integrase binding 
inhibitors (INBI) and integrase strand-transfer inhibitors (INSTI) have been developed, but 
only INSTI such as raltegravir elvitegravir and dolutegravir have been used for the 
treatment of patients successfully (Thierry et al., 2017).  
HIV-1 RNA is translated to give a polyprotein which is cleaved by the viral protease. The 
development of drugs which inhibit this protease was very important in advances in HIV-
1 therapy. Drug resistance is a major problem in HIV-1 therapy, but having drugs with 
different targets e.g. NRTI, NNRTI, protease, meant that combination therapy (or highly 
active anti-retrovirus therapy [HAART]), using two or three drugs, could be used and this 
reduces the risk of drug resistance. Protease inhibitors include nelfinavir, ritonavir, 
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saquinavir and amprenavir and these are peptide-like molecules which irreversibly bind to 
the protease active site work (Borrajo et al., 2017).  
Influenza virus is another virus where several antivirus drugs have been developed. The 
most useful (e.g. oseltamivir and peramivir) decrease viral maturation and infectivity by 
inhibiting viral surface neuraminidase to prevent viral release. Amantadine and 
rimantadine block the influenza M2 protein, which is needed to allow pH-dependent 
breakdown of the virus particle and release of the virus genomic content during release 
from an endosome in the entry process. However, they inhibit only influenza A, and do not 
affect influenza B which has another substitute protein named NB that is not affected by 
these drugs (Stiver, 2003). 
Drugs against herpesviruses (double-stranded, DNA genomes) include nucleoside and 
nucleotide analogue compounds (acyclovir, famciclovir, ganciclovir, penciclovir, 
valacyclovir and cidofovir) which selectively inhibit viral thymidine kinase (TK)  (Piret & 
Boivin, 2011; Said & Abdelwahab, 2013). Hepatitis B virus (double-stranded DNA virus 
which uses RT during replication) can be inhibited by different synthetic thymidine 
nucleoside analogues such as telbivudine, tenofovir and entecavir which block RT activity 
and have showed better antiviral activity than both lamivudine and adefovir, which also 
inhibit HIV-1 RT (Clercq et al., 2010). These examples explain the complexity of and 
diversity of antiviral agents and their targets.  
Most of the antivirals developed so far against picornaviruses target the virus capsid itself, 
to prevent early stages of infection, or the proteases to prevent polyprotein processing and 
later steps in replication. However, despite several drug strategies that look promising in 
clinical trials, there are no anti-picornavirus drugs in use (Norder et al., 2011). For instance, 
pleconaril (capsid binder) and rupintrivir (a protease inhibitor), were in clinical trials but 
pleconaril was not accepted by the FDA due to side-effects and rupintrivir was stopped 
because it proved to be ineffective in a clinical context. However, pleconaril is again being 
assessed for treating high-risk patients with chronic respiratory diseases (Wildenbeest et 
al., 2012).  
As picornaviruses need many cell structures and machinery e.g. Golgi apparatus, 
endoplasmic reticulum and stress granules, as well as several cell proteins such as PI4KIII 
and OSBP for their successful replication, these structures and proteins could be used as 
potential targets for antiviral drugs. In addition, several natural products and herbal 
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medicines seem to be able to inhibit picornaviral infections. Furthermore, incorporating 
nanotechnology, photodynamic and sonodynamic approaches may even improve drug 
effects toward viruses, and/or decrease their side effects. 
The first step of picornavirus infection is entry. Kappa carrageenan, a sulphated 
polysaccharide from seaweed, has shown potential antiviral activity by targeting viral 
attachment and entry. Lactoferrin also exhibited antiviral effects in vitro and in vivo 
through interfering with viral attachment to the cell surface (Wakabayashi et al., 2014). 
Uncoating blockers, also called pocket binders, which include pleconaril, have been 
extensively studied in many picornaviruses. The reason behind the efficacy of the pocket 
binder is the ability to fit into a hydrophobic pocket underneath the canyon, the site of 
receptor binding, causing capsid structure stabilization which means that uncoating of the 
RNA cannot occur (refer to figure?).  However, and despite this promising and highly-
specific mechanism some EVs readily generate drug resistant mutants. Another problem is 
that they do not inhibit all EVs (van der Linden et al., 2015). In addition to pleconaril, 
another group of capsid binders, pyridazinyl oxime ethers, chemically derived from 
pirodavir, such as BTA39 and BTA188, inhibited EV71 infection to a significant degree 
(Tan et al., 2014). 
Amantadine, a tricyclic amine developed to treat influenza A infections, interferes with EV 
IRES-mediated translation (Wakabayashi et al., 2014). Translation inhibition was also 
observed with a flavonoid, kaempferol, due to its ability to inhibit ITAF e(complex or make 
it plural? Because it not just one) binding to the IRES (Wakabayashi et al., 2014). Regarding 
viral polyprotein processing, as already discussed, rupintrivir, which is a peptidomimetic 
protease inhibitor, has been tested for the treatment of rhinovirus infections. It has also 
shown to be effective against other picornaviruses as well as members of other virus 
families such as coronaviruses and caliciviruses (Rocha-Pereira et al., 2014). 
Many drugs against other viruses target the virus polymerase and so inhibition of the 
picornavirus polymerase 3Dpol could be a successful antiviral approach. Two types of 
polymerase inhibitors are being explored. Some nucleoside analogues lack the 3´OH needed 
for the addition of the next nucleotide during RNA replication and so incorporation by 3Dpol 
causes chain termination. Others are incorporated into the RNA and result in mutations. 
(van der Linden et al., 2015). One example of the second type is ribavirin, a synthetic purine 
analogue, which leads to a high level of mutations which is lethal. Another class of 
polymerase inhibitor includes non-nucleoside inhibitors. Amiloride inhibits EV replication 
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possibly by increasing the error rate of 3Dpol, although this may be due to its effect on 
intracellular Mg2+ concentration as it blocks ion channels, and inhibition of VPg 
uridylylation make be more important (Ogram et al., 2014). In addition, several antiviral 
compounds have been shown to target 2C including guanidine hydrochloride and 
fluoxetine, but their mechanisms of action are not clear yet (van der Linden et al., 2015).  
Currently, Hsp90 inhibitors have been tested and shown to have antiviral activity toward 
some picornaviruses including poliovirus, coxsackieviruses and rhinovirus (Geller et al., 
2012), as well as a wide spectrum of enveloped and non-enveloped, RNA and DNA viruses. 
A potentially important finding is that these compounds do not seem to lead to drug 
resistant viruses. This was found for poliovirus which did not show any resistance after 
extensive repeated passaging of the virus in cells containing Hsp90 inhibitors. This is 
important as poliovirus becomes resistant to all other antivirals studied, regardless of their 
mechanisms (against viral or host factors) (Geller et al., 2012). 
1.10 G-protein-coupled receptors Inhibitors 
G-protein coupled receptors (GPCRs) are part of the seven-transmembrane receptor 
superfamily that can modulate gene expression by transmitting signals from outside the 
cell to intracellular pathways. They form a very large superfamily with hundreds of 
members, and it is estimated that 35% of approved drugs target GPCRs. Several GPCRs 
are encoded by some larger DNA viruses such as herpesviruses and poxviruses (Beisser & 
Verzijl, 2005). It has been reported that some viruses enter the cell using a specific GPCR 
complex, the best-known one being HIV which uses one of two GPCRs chemokine 
receptors CCR5 or CXCR4. The HIV drug maraviroc blocks the CCR5 pathway and other 
inhibitors of these receptors may be useful as antiviral compounds (Wilen et al., 2012). 
Some in vivo studies showed that GPCRs are very important for viral replication as well as 
virus-induced cellular pathogenesis (Paulsen et al., 2005). GPCR antagonists have been 
reported to inhibit both Ebola virus and Marburg virus either by interfering with viral entry, 
such as trimipramine maleate and promethazine hydrochloride, and/or antagonising the 
replication of infectious viruses as with benzatropine mesylate (Cheng et al., 2015). It has 
been also found that fluoxetine (a distinct class of GPCR antagonist), is an effective 




1.11 Lipids, lipid droplets and lipoproteins targeting agents   
Lipids play a critical role in many parts of virus life cycle and several strategies have been 
tried to exploit lipids as antivirus targets. To begin with, interference with the biosynthesis 
of cholesterol by inhibiting 3-hydroxy-3-methyl-glutaryl-CoA reductase (3-HMG-CoA 
reductase) is one approach and statins have some antivirus activity (Chang & Jo, 2011; 
Peng et al., 2011). Apart from suppression of the 3-HMG-CoA reductase pathway, statins 
also inhibit the binding of leukocyte function-associated antigen-1 (LFA-1) to the 
intercellular adhesion molecule (ICAM-1) which affects the immune system and can 
enhance the response against several viruses (Weitz-Schmidt et al., 2001). 
Another potential antiviral approach with wide activity spectrum is the use of C75, (4-
methylene-2-octyl-5-oxotetra-hydrofuran-3-carboxylic acid). It targets lipid droplets (LD) 
by acting on FASN and inhibiting one of the prominent pathways of fatty acid biosynthesis 
(Tan et al., 2015). It has been reported to suppress the replication of CBV3 and PV (Martín-
Acebes et al., 2015). Similar results had been previously obtained for many enveloped 
viruses (Munger et al., 2008; Yang et al., 2008; Heaton et al., 2010b; Targett-Adams et al., 
2010; Martín-Acebes et al., 2011). 
Itraconazole (ITZ), which was developed as an antifungal drug and has also been found to 
have anticancer properties, has recently been found to be active against EVs and 
cardioviruses, as well as HCV (Strating et al., 2015). The host protein OSBP was identified 
as the target of ITZ antiviral effect. ITZ binds OSBP and blocks cholesterol and PI4P-
transport activities of OSBP. This leads to a decrease in cholesterol levels on RCos in 
infected cells (Strating et al., 2015). 
For viruses to replicate successfully, they have to use phospholipid in multiple steps. PI4P 
a specific phospholipid component has been found to be important for replication of most 
EVs (Albulescu et al., 2015; Berryman et al., 2016). PI4P is produced by the enzymes 
PI4KIIIα and β and these lipid kinases have become more attractive targets for drug design. 
A drug which targets 3A (Chen et al., 2008b), enviroxime, which is a benzimidazole 
derivative, and two related molecules T-00127-HEV1 and GW5074, act by inhibiting lipid 
kinase activity (Martín-Acebes et al., 2015). Finally, being part of lipid rafts and involved 
in different steps of viral replication, cycle sphingolipids are expected to be potential targets 
for antivirals for many viruses (Martín-Acebes et al., 2016). They also modulate the host 
cell immune system, which could be another important feature as antivirus agents (Olivera 
& Rivera, 2005). 
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1.12 Some aspects of using antiviral compounds 
It is important to mention that drug resistant viruses commonly emerge with drugs that 
target viral proteins. This is due to the fact that the virus polymerase does not have proof-
reading activity and makes many errors during replication. Random errors in proteins 
targeted by drugs can lead to drug resistance and these mutants will be rapidly selected. In 
contrast, the target site for drugs against cell proteins is unlikely to change (Van Der Schaar 
et al., 2012). Blocking important cell metabolism pathways may cause more side effects 
than blocking viral proteins. However, most drugs apart from antibiotics work on important 
cellular functions without major side effects, so targeting host components may not cause 
problems. For example, inhibiting cellular protein cyclophilin A, which is needed for HCV 
replication, and which makes up 0.1%–0.4% of the total cellular protein, gives few side 
effects (van der Linden et al., 2015). Many of the drugs mentioned, including statins and 
ITZ, in addition of drugs from different classes such as amantadine and ribavirin have been 
used clinically for several years for other conditions and are considered safe so their use as 
antivirals should not cause problems (Tan et al., 2014). 
EVs and HPeVs are usually considered to be the most important picornaviruses from the 
point of view of human health. Therefore, it would be useful to have a drug(s) which inhibit 
both. This is feasible as they belong to the same virus family and so share many structural 
and mechanistic similarities. However, there are many differences between them as they 
are genetically distinct and belong to different picornavirus supergroups and this may result 
in difference effects of drugs (Picornavirus Home Page, 2019). Known differences include: 
VP0 cleavage or not, N-terminal myristoylation of VP0 (VP4) or not, presence/absence of 
a canyon and hydrophobic pocket, IRES type, 2A protein type. Pleconaril, a capsid binder 
which showed a good response towards EVs, has no effects against HPeVs as these viruses 
have no hydrophobic pocket for pleconaril binding (Kalynych et al., 2016). Other 
successful capsid binders of EVs may be inactive against HPeVs and vice versa. The fact 
that VP0 is not cleaved to VP2 and VP4 in HPeVs, despite this being an essential step in 
EV assembly and maturation, may mean that the viruses have completely different 
assembly pathways, and this may mean that any assembly inhibitors would not have broad 
specificity (Stanway et al., 1994; Alho et al., 2003). 
The well-known EV 3Cpro inhibitor, rupintrivir has no activity regarding HPeV 3Cpro but it 
is not clear why not as the HPeV 3Cpro structure is not known. HPeV and EV 2As are 
completely different types of protein so EV drugs which target 2A will not work against 
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HPeVs (Hughes and Stanway, 2000). Compounds like guanidine HCl and HBB (2-(α-
hydroxybenzyl)-benzimidazole) inhibit all tested EV 2Cs but are ineffective agains HPeV. 
Other 2C protein inhibitors may also be inactive on HPeVs. The activity of fluoxetine and 
TBZE-029 was proposed to require the presence of a certain amino acid motif (AGSINA) 
in the EV 2C. This is absent in HPeV 2C and these drugs do not seem to be effective 
inhibitors for HPeVs (van der Linden et al., 2015). 
In summary, it may be possible but difficult to identify or design compounds active against 
EVs and HPeVs.  
1.13 Naturally occurring antiviral agents 
Natural products including herbal medicines are an indispensable source for novel antiviral 
approaches. Many effective drugs for non-infectious diseases were introduced from nature, 
such as aspirin, digitoxin, morphine, ephedrine, atropine and reserpine, and most chemicals 
developed as drugs (respectively 60% and 75% in the field of cancer and infectious 
diseases) between 1981 and 2002 were also derived from natural products. General 
speaking, natural medicines are relatively cheap, easily obtained and have a good long-
term safety profile (Kurokawa et al., 2010). 
Some herbs and natural products are active against lots of picornaviruses. For instance, 
extracts of the herb Ocimum basillicum inhibit replication of both EV71 and CBV1 
effectively and extracted molecules such as linalool, apigenin, and ursolic acid are 
effective. A previously tested inhibitor of CBV1, raoulic acid, again blocks EV71 infection. 
In addition, epigallocatechin gallate from green tea inhibits EVs by modulating the cellular 
redox environment (Lin et al., 2014). 
Regarding viruses other than Picornaviridae, Houttuynia cordata extracts have been found 
to inhibit coronaviruses by targeting both 3CL protease and RNA-dependent RNA 
polymerase activity. Moreover, Xiao Chai Hu Tang, a Chinese herb has antioxidant, 
antiproliferative and immunomodulating properties. It promotes synthesis of antibodies 
and interferon in chronic hepatitis patients and inhibits reverse transcriptase in HIV and 
murine leukemia virus (Zheng et al., 2013). Pelargonium sidoides roots extracts inhibit 
influenza A by blocking entry (Lin et al., 2014). According to Zandi et al, the flavone 
baicalein was a potent inhibitor all stages of the Dengue virus replication cycle including 
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adsorption and intracellular replication (Zandi et al., 2012). Investigation of different plants 
could identify large numbers of useful drugs.  
1.14 Berries 
Berries are small, fleshy fruit with no stones, and many are known to be rich in bioactive 
compounds (BAC). They are produced by many plant families including Rosaceae 
(strawberry, raspberry, blackberry), and Ericaceae (blueberry, cranberry) and species such 
as Ribes nigrum (blackcurrant), Ribes rubrum (redcurrant) but also contain species with 
only low to medium BAC content such as elderberries (Sambucus spp.), bilberries 
(Vaccinuim myrtillus), gooseberies (Ribes uva-crispa), cape gooseberies (Physalis 
peruviana), honeyberies (Lonicera caeulea), chokecheries (Prunus virginiana), 
marionberries (Rubus spp.), saskatoon berries (Amelanchier alnifolia), arctic brambles 
(Rubus articus), cloudberries (Rubus chamaemorus), crowberries (Empetrum nigrum), 
lingonberries (Vaccinium vitis-idaea), loganberies (Rubus loganobaccus), Rowan berries 
(Sorbus spp.), and sea buckthorn (Hippophae rhamnoides) (Beattie et al., 2005; Suvetha & 
Shankar, 2014; Skrovankova et al., 2015). 
Broadly, berries contain some sugars such as glucose and fructose and small amounts of 
fat. They are also rich in fibre such as cellulose, hemicellulose and pectin; organic acids 
including citric, tartaric, malic, oxalic, ellagic and fumaric acid; vitamins like ascorbic acid 
and folic acid; trace amounts of minerals and more importantly in terms of antimicrobial 
and anticancer activities, the bioactive phytochemicals including phenolics which is in turn 
involve flavonols such as quercetin, kaempferol, myricetin, flavonoids, such as 
anthocyanins and flavanols such as catechins and epicatechin. These may be partly the 
basis of antioxidant properties and other reported health benefits of berries, including 
effects on oxidative stress, blood pressure, platelet aggregation, detoxification enzymes, 
the immune system inflammatory processes and cancer (Cosmulescu et al., 2015; 
Skrovankova et al., 2015; Paunović et al., 2017). 
In addition, berries are considered to be a potential source of antiviral and antibacterial 
pathogens of different classes. Cranberries which contain high levels of polyphenols have 
been demonstrated to prevent some bacterial infections such as Helicobacter pylori, and 
infection by viruses from different families including reoviruses, rotaviruses, and 7 (Ikuta 
et al., 2013). Anti-influenza effect has been also seen with flavonoids from elderberry fruit 
extracts (Tiralongo et al., 2016). Blackcurrant extracts inhibit herpes simplex virus type I, 
influenza virus type A and B and respiratory syncytial virus. Anthocyanins from 
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blackcurrant block both influenza virus adsorption and release from infected cells (Weiss 
et al., 2005, Ikuta et al., 2013).  
1.15 Microalgae  
The recently growing importance of microalgae comes from many features they have. 
Firstly, they can accommodate stressful growing conditions including cold, heat, salinity, 
drought, anaerobiosis, osmotic pressure, UV exposure and photo-oxidation. This makes 
them easy to grow and also increase the range of biological products as the microalgae 
adapt to different conditions. Microalgae resemble higher plants in efficient photosynthesis 
and simple nutritional requirements and at the same time, they are generally similar to 
microorganisms regarding the fast rates of growth and production of many primary and 
secondary metabolites (Guedes et al., 2011). They are flexible metabolically and a variety 
of metabolites can be easily obtained by just changing their nutritional state e.g. removing 
a nitrogen source (Amaro et al., 2011). 
Microalgae include at least 30,000 species and so there is a very great potential for the 
identification of novel drugs (Guiry, 2012). They produce many types of compounds like 
polysaccharides, vitamins, fatty acids, chlorophyll, acetogenins, xanthophylls, halogenated 
compounds and amino acids. The products are widely used commercially e.g. in food 
stuffs, cosmetics and for pharmaceuticals. For instance, 9% of all compounds isolated from 
marine organisms are from algae (Ahmadi et al., 2015). Microalgae also contain many 
different antibacterial, antifungal, antiplasmodial and antiprotozoal materials (Amaro et al., 
2011).  Algae contain several compounds with reported antiviral activities, and they are 
rich in polysaccharides. Carrageenans, sulfated polysaccharides, are produced by red algae 
and inhibit many viruses at the entry stage, including papilloma viruses that can lead to 
cervical cancer and genital warts. Another type of polysaccharide, alginates are found in 
the cell wall of brown algae and have been shown to inhibit hepatitis B virus and HIV. 
Fucans are high molecular weight sulphated polysaccharides with several reported 
biological activities. They are diverse in structure among species raising the possibility that 
they may include several potential drugs (Ahmadi et al., 2015). Recent research has also 
found many further applications of microalgae metabolites as diagnostic tool, including 
fluorescent agents which can be used additionally for photodynamic therapy (Schuurmans 
et al., 2015).  
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1.16 Oxidative stress and its relationship to viral replication 
Oxidative stress (OS) occurs when the production of reactive oxygen species (ROS) 
exceeds the capacity of antioxidant (AO) defences (Costantini et al., 2010). Normally, ROS 
are involved in useful physiological functions including mitochondrial electron transport 
and signal transmission (Sena & Chandel, 2012). However, in some conditions such as 
infection, stress and other pathological conditions, the level of ROS overwhelms AO 
capacity and causes oxidative changes, leading to dysfunction of proteins, lipids, 
carbohydrates and nucleic acids (Bargagli et al., 2009). The altered proteins are more 
susceptible to photolytic activity and loss of function. Membrane phospholipids are 
oxidised by ROS resulting in lipid peroxidation. Oxidative DNA deletion and gene 
mutation caused by OS often cause cell death, but cancerous changes could also occur, 
while OS in the immune system cells can reduce protective immunity and response to 
vaccination (Valle et al., 2013). OS may be induced by virus infection and could enhance 
viral replication. On the other hand, an increase of ROS enhances the activity of some 
cellular transcription factors activity and increases cytokine secretion and inflammatory 
response (Narayanan et al., 2014). Long term elevation of ROS caused by viral infection 
can increase AO consumption and lead to serious damage of major cell components, as 
seen in Newcastle Disease Virus infection in chicken (Venkata et al., 2013). In addition, it 
was found that acute HCV infection was associated with a significant increase in ROS 
levels and a decrease in AO levels. In contrast, the chronic phase in infected cells was 
associated with a low ROS production and elevated GSH level that could serve viral 
persistence. It was also found that pro-oxidant treatment of the chronically infected cells 
caused an increase in the titre of HCV-RNA (Anticoli et al., 2019). 
AOs are one of most important defence mechanisms against OS. AOs can be classified as 
enzymatic such as superoxide dismutase (SOD), catalase (CA), peroxidase and other 
enzymes, and non-enzymatic (Sharma et al., 2012; Power et al., 2013). The most important 
non-enzymic AOs are scavengers, including hundreds of agents such as carotenoids, 
flavonoids, tocopherols, ascorbic acid, amino acids, phospholipids, and sterols which are 
mostly derived from food, with some sources like berries being rich in AOs (Choe & Min, 
2009). Mammalian cells can synthesize some types of AOs such as glutathione (GSH) and 
nicotinamide adenine dinucleotide phosphate (Eriksson et al., 2015; Moreira et al., 2015). 
Vitamin E, the major mitochondrial AO, and polyphenols protect against lipid peroxidation 
by scavenging free radicals (Saeidnia & Abdollahi, 2014). 
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Different AOs can inhibit viral replication and different mechanisms have been identified. 
Vitamin C inhibits HIV-1 RT and supresses replication. GSH blocks influenza virus 
infection by inhibition of apoptosis which then decreases the influenza release (Cai et al., 
2003). N-acetyl- L- cysteine that is often used to treat acetaminophen overdose-induced 
OS, increases intracellular GSH, which is depleted by HIV-1 infection, and can reduce 
AIDS symptoms in animal models, while 2, 3 dimercapto-1-propanol blocks HIV-
1replication by inhibiting viral trans-activating protein. AOs have also been investigated 
as possible anti-EV therapeutics. Both N-acetylcysteine (Ho et al., 2008), and gallic acid 
(Choi et al., 2010), are reported to inhibit EV71 infection.  
1.17 Photodynamic therapy and photodynamic antimicrobial 
chemotherapy 
Photodynamic therapy (PDT) refers to using harmless visible light in combination with 
photosensitizers (PS). These are chemical dyes, usually administered either parenterally or 
externally, and after reaching the target tissues are triggered using visible or infrared light 
(Reddy et al., 2009). When the PS is a photo-antimicrobial the process is termed 
photodynamic antimicrobial chemotherapy (PACT). As soon as light is absorbed by a PS, 
it undergoes transition to an excited state at which it can react with molecular oxygen to 
produce either reactive oxygen species (type 1 reaction) or singlet oxygen (1O2) (Figure 
1.7). PDT is both useful and highly selective. This is due to the fact that cells growing 
rapidly specifically up take PS and the effect of the whole process is confined to the area 
of applied light. PACT is applicable for antimicrobial use as microbes are highly 
proliferative cells (Denis & Hamblin, 2011). For PACT treatment to be both effective and 
safe, many factors need to be considered such as light sources, photosensitizer properties, 
dose of photosensitizer, barriers to reaching the target site and patient acceptability 
(Cassidy et al., 2009). 
In terms of safety profiles, human cells such as keratinocytes and fibroblasts can tolerate 
PACT doses that are fatal to microbes. This is probably because of big differences in 
structures and sizes of cells. Human cells are much larger than other microorganisms (they 
are between 25-50 times larger than bacteria cells) and therefore can survive in more 
damaging environments. Photodynamic antimicrobial chemotherapy has many 
applications including infected wounds, nail infection, intranasal complications like 
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maxillary sinusitis, oral candidiasis, periodontal disease, cystic fibrosis and lung infection 
(Cassidy et al., 2009), in addition to warts and psoriasis (Monge-fuentes et al., 2015). 
Increasingly, PDT is applied for a variety of tumour and cancer types of different stages. 
For instance, porfimer sodium (Photofrin) has been licensed for treating non-small cell lung 
cancer and obstructing oesophageal cancer in the UK (Cassidy et al., 2009). In addition, 
PACT was studied extensively for many pathogens including Staphylococcus aureus and 
Pseudomonas aeruginosa. It has been found that multidrug-resistant members are equally 
susceptible to PACT as normal strains. In recent years several types of PS have been tried 
for various types of viruses (Xu et al., 2019). Both enveloped and non- enveloped viruses 
have demonstrated susceptibility in vitro (Cassidy et al., 2009). However, enveloped viruses 
have shown better sensitivity than non-enveloped viruses to photodynamic destruction 
(Costa et al., 2012). 
The natural photosensitizers, psoralens (furanocoumarins) have been used for a long time 
to treat different skin disorders in Asia. Recently, psoralen photomedicine was shown to be 
significantly active for lymphoma. Psoralen therapy has also been investigated for blood 
treatment against both intracellular and non-associated viruses. Perylenequinonoid 
pigments were shown to be possible antiviral candidates, due to their high lipophilicity and 
negative charge along with large pseudoplanar area. It is thought that hypericin has photo-
destruction activity toward HIV-1 by cross linking viral capsid proteins, and also has an 
inhibitory action on protein kinase C, an important target for antiviral drugs. In addition, 
there is possibility PACT could be used for deep and disseminated viral infection by 
exploiting optical fibre technology (Wainwright, 1998). 
There are many drawbacks of antibiotic drugs such as limited spectrum of antimicrobial 
effects, emerging resistant strains, failure to reach areas with limited blood flow, systemic 
adverse effects and lack of patient compliance. PACT may be able to overcome some of 
these drawbacks, since this technique is less invasive, causes least damage to normal cells, 









Figure 1-7. Photodynamic therapy states.  
In the first step light absorption stimulate the photosensitizer (PS) to move up an excited 
singlet state, then it may lose its energy and return back ground singlet state or relax to 
triplet state, at which, it is either falling down ground state or combing molecular oxygen 
to produce reactive oxygen species (ROS) by entering type l reaction or singlet oxygen 











1.18 Aim and Objectives 
At present there are no drugs against picornaviruses in clinical use. The large 
number of medically important viruses in this family, particularly in the 
Enterovirus genus (nearly 300 distinct types), means that vaccine development is 
not feasible in most cases and so effective drugs are required. The aim of the 
project is to identify compounds which can potentially be used to combat these 
important viruses. The works will focus mainly on enteroviruses, but some 
comparisons will be made with parechoviruses, as these are genetically very 
different human pathogens. In this way, broadly active anti-picornavirus 
approaches may be discovered. There are two objectives: 
1. To use compounds present in biological materials as a “library” of 
potential anti-virus agents, which can be identified, studied and 
chemically modified for optimisation. 
To explore existing drugs which may be repurposed for use as anti-picornavirus agents. 
Work published on the anti-enterovirus effect of fluoxetine will be extended to investigate 
the limitations of this compound and if these can be overcome by chemical modification. 
Previous work in the laboratory showed that enterovirus, and particularly parechovirus, 2C 
protein interacts with lipid droplets.  A second approach to repurposing existing drugs is to 
investigate if drugs which inhibit lipid droplet formation are effective against enterovirus 









































2.1 Materials  
The viruses, cells, reagents, chemicals and biological material use are listed in Appendix 
1. 
2.2 Methods 
2.2.1 Methods of cell culture 
2.2.1.1 Splitting of cells   
Cells were observed using a microscope to ensure they were confluent and healthy. The 
old medium was discarded, and cells washed twice with 1X PBS. Then 600 μl of 0.25 % 
trypsin-EDTA or accutase solution was added and the flask was placed on a rocking 
platform until the cells were detached when checked under the microscope. DMEM 
medium (20 ml containing 10% FBS, 1% MEM non-essential amino acid and 1% 
Penicillin-Streptomycin) in the case of GMK cells and A549 cells, or McCoy's 5A medium 
(20 ml containing 10% FBS and 1% Penicillin-Streptomycin) in the case of HT29 cells was 
added to the flask and the cell suspension was divided into 4 new 25 cm2. These were 
incubated in a 5% CO2 incubator at 37 °C. Cells were passaged every 5 days.  
2.2.1.2 Cell line storage 
Old medium of a confluent cell line was discarded, and the cells were washed twice with 
1X PBS. Trypsin-EDTA (600 μl of a 0.25 % solution) or 600 μl of accutase solution was 
added and the flask was placed on a rocking platform until the cells were detached. FBS (1 
ml) was added and mixed. A 1 ml aliquot of the mixture was placed in a cryo tube and 111 
μl of DMSO was added. The tube was placed in an insulated container, to ensure slow 
freezing, for three days at -80 °C, then stored at -80 °C.   
To recover the cells, the tube was thawed, and the cell suspension was transferred to a flask 
containing 4 ml of new medium and 1 ml FBS and incubated in a 5 % CO2 incubator at 37 
o C. The medium was changed next day and the cells observed until they became confluent. 
The cells were then propagated as described in section 2.2.1.1. 
2.2.2 Virology methods 
2.2.2.1 Direct and indirect plaque assays and drug treatment 
To evaluate the antiviral effect of drugs and extracts, plaque assays (Bird & Britton, 1979; 
Cornelis et al., 1982; Hung et al., 2010; Baer & Kehn-Hall, 2014) were performed, mostly 
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in 6 well plates. For the direct plaque assay approach a flask of confluent cells was used 
and detached as described in section 2.2.1.1. The detached cells were re-suspended in 12 
ml medium and 2 ml was added to each well of the 6-well plate. The cells were incubated 
at 37 °C in a humidified incubator with 5 % CO2 for 3 days until they were confluent. The 
old growth medium was aspirated away, and 0.5 ml of new medium was added. Then 
compounds, either the drugs or the natural extracts, were applied at different concentrations 
in growth medium. Two wells had no drug added to give a cell control and a virus control. 
The plate was placed on a rocking platform for 30 min. Diluted virus (370 PFU in 15 µl) 
was added to all wells except the cell control and the plate was held on the rocking platform 
for 45 minutes. CMC medium (2 ml), made up of a 2:1 mixture of growth medium: 2 % 
CMC, was added to each of the 6 well-plate. The plate was incubated at 37 °C for 3 days. 
The growth medium was discarded, and the cells were washed with PBS then stained with 
crystal violet to stain cells and make plaques, areas where cells have been killed and 
detached from the plate, more visible. These plaques were then counted. 
The same initial steps described for the direct plaque assay were applied for indirect plaque 
assay approach, including the preparation of confluent cells, drug treatments and virus 
infection. Subsequently, 2 ml of media (instead of growth medium: CMC) were added and 
the plate was incubated for 48 h instead of 3 days, then frozen and thawed 3 times without 
discarding the growth media. The amount of virus present in the samples was then 
measured using a plaque assay. Confluent cells were prepared and 370 PFU in 15 µl of 
each sample was allocated in plate wells and the plate incubated for 45 minutes on the 
rocking table and added by 2 ml CMC and incubated at 37 °C for 3 days and stained. 
Dilutions of the sample were made and 15 µl of each dilution was applied to a well of a 6 
well plate containing a confluent cell monolayer, overlaid with 0.5 ml of growth medium. 
The plate was incubated for 45 minutes on the rocking table and then 2 ml of growth 
medium: CMC was added. The plate was incubated at 37 °C for 3 days and stained. The 
plaques were counted and the virus concentration was calculated, taking into account the 
dilution factor and volume of the sample. 
2.2.2.2 Selection of drug-resistant mutants  
To evaluate the potential usefulness of a drug, and to gain information on the possible virus 
protein targeted by the drug, a multi-step experiment was conducted to obtain drug-resistant 
mutants (Boucher et al., 1993; Brown et al., 2003). In the first step, 50 μl of a 10x virus 
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dilution was added to confluent cells that were previously treated with the lowest inhibitory 
concentration of drug under investigation. This was incubated at 37 °C and checked daily 
using a microscope to see cytopathic effect which usually appears after 3 days of 
incubation. The infected cells were then frozen and thawed 3 times before they were 
collected in a small tube and labelled as first passage. Each passage was carried out by 
taking a sample volume from the previous passage, diluting it by 10 times and repeating 
the same procedure with 50 μl of the sample, with increased drug concentration each time. 
Plaque assay at a drug concentration found to inhibit the original virus was applied to some 
of the passages during the process, and compared with the original virus, to assess whether 
the passaged virus showed drug resistance.  
2.2.2.3 Direct effect of compound on the virus particle 
In this assay, an effective concentration of the active compound was mixed directly in a 
tube with a virus being tested. An active compound or extract was mixed with growth 
medium in a microcentrifuge tube to give a 990 µl solution of drug at an effective 
concentration. 10 µl of neat virus were added to make 1000 µl of media with virus and 
drug. The mixture was incubated for different times then plaque assay was performed.  
2.2.2.4 Time of addition assay 
 A time-of-addition assay was performed to study the mechanism of drugs and inhibitors 
(Daelemans et al., 2011; Aoki-Utsubo et al., 2018). A six well plate with each well 
containing a cell monolayer and 1 ml of growth medium was used. The drug or inhibitor 
was added to one well (zero time point). After 30 min 100 PFU of virus was added to all 
the wells and the plate were placed on a rocking platform for 45 min. The drugs or inhibitors 
were added at 1, 3, 5 and 8 hours post- infection. The plate was incubated, (36 hours for 
CAV9 and 42 hours for HPeV1) in a 5 % CO2 37 °C incubator. The plate was frozen-then-
thawed three times and a plaque assay was applied on the liquid from each well. 
2.2.2.5 Determination of compound-induced apoptosis by Nicoletti 
assay  
The Nicoletti method is an assay for cell apoptosis detection and quantification. The 
principal purpose of this assay in the current work is to confirm safety and antiviral activity 
of investigated compounds. Cells were treated with or without the investigated compounds 
using certain concentrations to measure the intrinsic toxicity of the compounds. Others 
were incubated with the virus only. In addition, there were cells which were pre-treated 
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with a range of concentrations of each compound for 30 min and then infected with 5 µl of 
neat virus. The plate was incubated for 45 min on a rocking table and each well was covered 
by 2 ml of growth medium. After incubation for 12 h at 37 ˚C, media was discarded, and 
cells we washed with PBS and trypsinized. The detached cells were collected separately in 
tubes and centrifuged at 2000 rpm for 2 min. The cells were washed twice with PBS (250 
µl) and centrifuged again to be fixed with 4% formaldehyde for 10 min at 4 ˚C in the dark 
and then washed with PBS and centrifuged twice. Finally, 0.5 ml of Nicoletti buffer was 
added to each sample and kept cool briefly until analysis using a BD Accuri cytometer® 
(C6). The results were processed using Flowing Software version 2.5.1.   
2.2.2.6 Cell viability assays 
Cell viability assays were conducted according to the colorimetric MTT method 
(Mosmann, 1983; Vistica et al., 1991; Bahuguna et al., 2017). GMK cells were grown 
(until 80 % confluent) in 96-well plates. Some cells were incubated with the compounds or 
extracts, and some with the viruses. Other cells were treated with the compounds or extracts 
plus virus. The incubation period was 3 days at 37 °C. MTT (3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl tetrazolium bromide) was dissolved in media at 1 mg/ml and filtered using a 
0.22 µm sterile filter (Millipore). Media in each well were discarded and 100 µl of MTT in 
medium were applied for 2 h at 37 °C and then carefully aspirated. The resulting blue 
crystals were mixed thoroughly with 100 µl DMSO to dissolve and the absorbance at λ550 
was recorded on a plate reader (infinite M200PRO, TECAN®). The absorbance value given 
by the treated sample as a percentage of that of the cells only sample were calculated as a 
measure of cell viability.  
2.2.2.7 Photodynamic inactivation effect of compounds and 
extracts 
Blue light (BL) and red light (RL) LED sources (Phantom, Shenzhen CIDLY 
Optoelectronic Technology, China), equipped with a fan to eliminate any heat and emit a 
uniform field of low-power, LED (25 pieces x 3 Watt) were used in experiments with 
microalgae and RC extracts in order to stimulate active phototensitive compounds within 
the extracts. Using 96-well plates, several wells containing confluent cells in duplicates 
were designated as controls incubated with/without the photosensitive compounds, other 
wells were cells incubated with the viruses only, or with viruses and photosensitisers. The 
plates were exposed to BL or RL alone to assess the effect of the light on the cells. The 
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plates were exposed to the light for 20 min. In order to assess the effect of light exposure 
on the cells, on the viral infection of the cells, and on the treatment efficacy of the 
photosensitisers, certain plates with the same arrangement were kept in the dark without 
light exposure and wrapped with aluminium foil. Plates were incubated for 3 days at 37 °C 
then cell viability was assessed using the MTT assay.  
2.2.3 Molecular biology methods 
2.2.3.1 Extraction of viral RNA using a QIAamp Viral RNA Mini 
Kit   
Virus RNA was isolated from infected cells which had been freeze-thawed 3 times, using 
a QIAamp viral RNA mini kit (Monleau et al., 2009; Cornelissen et al., 2017; Zhang et al., 
2018). The virus-containing sample (140 µl) was added to a 1.5 ml microcentrifuge tube 
containing 560 µl of AVL buffer and 5.6 µl of RNA-AVE carrier. The tube was vortexed 
for 15 seconds, incubated at room temperature for 10 min and briefly centrifuged. Next, 
560 µl of ethanol (100%) was added, vortexed for 15 seconds and centrifuged briefly. Then, 
560 µl of the solution was added to the QIAamp Mini column and centrifuged at 8000 rpm 
for 1 minute. The column was placed into a clean 2 ml collection tube and once again 560 
µl of the solution was added and the column was recentrifuged. The column then was 
washed with AW1 buffer (500 µl) and centrifuged at 8000 rpm for 1 minute. A second 
wash was done with AW2 buffer (500 µl) followed by centrifugation for 3 minutes at 
14,000 rpm after discarding the flow-through and changing of the collecting tube. The 
column was placed in a clean 1.5 ml microcentrifuge tube and 50 µl of AVE buffer was 
added and centrifuged for 1 min at 8000 rpm to elute the RNA. The purified RNA was 
stored at -80 ˚C.    
2.2.3.2 Reverse transcription-PCR (RT-PCR)   
Purified virus RNA was reverse transcribed, and the cDNA amplified using a 
SuperScript™ III One-Step RT-PCR System with Platinum™ Taq DNA Polymerase 
(Invitrogen). To construct a 50 µl RT-PCR reaction, 25 μl of reaction mix, 1 μl of forward 
and reverse primers (Table 2.1), 1 μl RT/Taq, 5 μl of RNA and 17 μl DNase free water 
were mixed and placed in a PCR machine (GeneAmp PCR System 2400, PERKIN 
ELMER®). The machine was programmed (Figure 2.1) to give an initial RT step of 30 min 
at 50 ˚C. The thermocycling pattern of the PCR reactions consisted of an initial 
denaturation step at 94 ˚C for 2 minutes, followed by 35 cycles of denaturation at 94 ˚C for 
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30 seconds, annealing at 48 ˚C for one minute and extension 68 ˚C for 90 seconds. The 
PCR was completed by a final extension step of 68 ˚C for 5 minutes.   
 
Table 2. Oligonucleotide primers used for the amplification and sequencing of part of 
the 2C protein-encoding region of CAV9. 

















Figure 2-1 Schematic diagram of the PCR amplification component of the RT-PCR 
reaction. 
Following a 50 ˚C incubation for 30 min to allow reverse transcription, the first 
denaturation step at 95 ˚C for 5 minutes is to activate the polymerase enzyme which is 
followed by 35 cycles of denaturation (94 ˚C for one minute), annealing (45 ˚C – 55 ˚C, 
1 min) and extension (72 ˚C for 1 min). The final extension step takes 5 minutes (72 ˚C) 

















2.2.3.3 Agarose gel electrophoresis   
Agarose powder (0.5 g) was added to 50 ml of 1X Tris-EDTA buffer and heated in a 
microwave until it was completely dissolved. After cooling down to around 50 ˚C, Safe 
View (5 μl) was added and the agarose solution was poured into the gel tray. The gel tray 
had a comb to form slots. When the gel had set, it was placed in the electrophoresis tank, 
and enough Tris-EDTA buffer was poured into the tank to cover the gel. The comb was 
removed. 5 μl of the DNA sample for analysis or 50 μl for purification was mixed with 1 
μl or 8 μl respectively of 6x gel loading buffer and each sample was loaded onto the gel. 
The gel was run for 18 minutes at 118V (using CROSSPOWER 1000, ATTA and FHU6 
mini submarine gel, serial number 30025588) and the DNA was viewed using a blue light 
LED transilluminator (SYNGENE®). Subsequently, a clean scalpel was used to isolate and 
purify fragments of interest from the gels for DNA sequencing.   
2.2.3.4 Gel extraction of DNA  
Purification of DNA from agarose gel bands was performed using a QIAquick gel 
extraction kit (Abraham et al., 2017; Shi et al., 2018).  Using a 1.5 ml microcentrifuge tube, 
each slice of agarose gel containing the DNA of interested component was soaked in 300 
µl of QG buffer and incubated at 50 ˚C until it was completely dissolved. The dissolution 
was facilitated by vortexing every 2-3 minutes. Isopropanol (100 µl) was added to the tube, 
mixed and the solution was uploaded to the QIAquick column and centrifuged at 13000 
rpm for one min. The flow-through was discarded and the column set back into the same 
tube. To wash, 750 µl of PE buffer was added and re-centrifuged and the flow-through was 
discarded. The QIAquick column was placed into a clean 1.5 ml microcentrifuge tube and 
50 µl of EB buffer was added. The column was left for up to 4 minutes at room temperature 
and centrifuged at 13000 rpm for one min to elute the DNA. The tube was labelled and 
stored at -80 ˚C.  
2.2.3.5 Sequencing of DNA  
For DNA sequencing, 2 1.5 ml microcentrifuge tubes were prepared, one of them contained 
10 µl of the resultant purified DNA and the other tube contained 3.3 µl of the sequencing 
primer and 96.7 µl of purified water. The products were sequenced by Source BioScience 
LifeSciences Company. All results were analysed using the ExPASY-Translate tool 
(web.expasy.org/translate/), Reverse complement (Reverse-complement.com) and 
Multiple Sequence Alignment-CLUSTALW (www.genome.jp/tools-bin/clustalw).  
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2.2.3.6 Antioxidant activity assay 
The antioxidant activity in this assay utilizes the spectroscopic absorbance spectra of 
myoglobin after its reaction with hydrogen peroxide. This reaction oxidises the ferric ions 
(Fe III) of the myoglobin to ferryl ions (Fe IV) resulting in spectral changes. The highest 
intensity absorbance of the myoglobin with Fe III ions is usually at the wavelength of 409 
nm. Whereas, the highest absorbance of the oxidised myoglobin with Fe IV will be shifted 
to the wavelength 425 nm. Antioxidant compounds have the capacities of reversing the 
above process. The rate of the reaction can be monitored kinetically, and the rate depends 
on the antioxidant power of the compounds (Terashima et al., 2007, 2010, 2012, 2013; An 
et al., 2014; Morikawa et al., 2015). Firstly, the spectrophotometer (8453 UV- 
spectrophotometer) was setup at a wavelength of 350-750 nm for spectra trace of 
myoglobin only (Mb). The kinetics of oxidised myoglobin (ferry-myoglobin) with 
antioxidant (RC) reaction was followed at two wavelengths 409 nm (highest intensity of 
the normal myoglobin (ferric-myoglobin) and 420 nm the oxidised myoglobin (the ferryl-
myoglobin). The kinetics steps started with filling a cuvette with 3 ml PBS as blank for 
background correction. Then, cuvettes prepared for the reactions with (according to the 
number of samples to be tested) were prepared with 3 ml PBS and 30 μl of PBS was taken 
from each one. Working solution of myoglobin (Mb) was prepared by adding of (13.5 μM) 
Mb working solution was added to the PBS at pH 7.2 and the absorbance was recorded at 
wavelength of 409 nm. To create a state of oxidative stress, 10 μl of hydrogen peroxide 
(H202, 140 μM) was added at room temperature. The reaction was terminated after 10 min 
by adding 2 μl of catalase enzyme and the absorbance spectra was recorded again after 2 
min. The samples that contain AO activity were added and the kinetics of oxidised 
myoglobin (ferryl-Mb) was followed after addition of antioxidants (RC) at two 
wavelengths 409 nm and 425. The absorbance of Mb before and after AOs (RC) was 
recorded at 409. The percentage of myoglobin protection ratio (%MPR) was calculated 
according to the following calculation: 
 
 
Where (Abs°) is absorbance of at myoglobin only at (λ409) and Abs
ROS is the absorbance 
with hydrogen peroxide with/without AO samples.  
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2.2.4 Methods of synthesis and structural modifications   
Modification methods were aimed to improve the antiviral activity of some compounds 
that were inactive against virus resistant mutants in spite of their activity on parent viruses. 
2.2.4.1 Modification of hydroxyquinoline 
1- Linker formation 
 
 
(E)-N-(2-bromoethyl)-2hydroxy quinoline-4-carboxamide 2-Hydroxy quinoline-4-
carboxylic acid (QHC) (1 g, 4.2 mmol) dissolved in DMF (10 ml) with Bromo ethyl amino 
hydrobromide (1.1 g, 1.2 eq, 4.9 mmol), DCC (0.93 g, 1.1 eq), HOBT (0.61 g, 1.1 eq), and 
Bmim (0.99 g,1.1 eq.) were mixed and stirred at 0 °C for 1h. DIPEA was added (1.0 ml, 
1.1 eq). The mixture was stirred for 3 h at 0 °C then 18 h at room temperature.  The 
precipitate was filtered off and the solvent was evaporated in vacuum. The residue was 
dissolved in DCM and washed with water (100 ml) five times. The solvent was evaporated, 
and the residue was purified by flash chromatography using ethyl acetate/methanol to 
obtain yellow paste of 987 mg. 
2- Conversion of halide group to amino group/Hydroxy quinolone ethyl 





 (2-Hydroxy)quinolone-4-carboxamide (1.4 g, 4 mmol) was dissolved in toluene, 
potassium phthalimide (0.75 g, 4 mmol) was added and the mixture was refluxed for 24 
hours. The solvent was evaporated under reduced pressure. The residue was dissolved in 
DCM and washed with dilute HCl (0.5 M) and water. The solvent then evaporated to yield 
solid material. 





dissolved in ethanol and hydrazine was added and the mixture was refluxed for one hour. 
The solvent was evaporated, and the mixture was dissolved in DCM and washed with HCl 
(1M) the phthalimide. 




N-(2-aminoethyl)-2-hydroxyquinoline-4-carboxamide (1 g, 3.75 mmol) dissolved in THF 
(10 ml) with chlorambucil (1.37 g, 1.1 eq.), DCC (0.93 g, 1.1 eq, HOBT (0.56 g, 1.1 eq), 
and Bmim (09 g,1.1 eq)), all at once, and the mixture was stirred at 0 °C for 1h. DIPEA 
(0.81 ml, 1.1 eq.) was added. The mixture was stirred for 3 h at 0 °C then 18 h at room 
temperature.  The precipitate was filtered off and the solvent was evaporated in vacuum. 
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The residue was dissolved in DCM and washed with water (100 ml) five times. The solvent 
was evaporated, and the residue was purified by flash chromatography using ethyl 
acetate/methanol to obtain the compound. The fractions were evaporated and dissolved in 
acetone. The m/z of quinoline chlorambucil conjugated molecule was confirmed by GC 
technique to be m/z 530 D. 
2.2.4.2 Modification of fluoxetine  
a- Synthesis of Linker amino-BOC protection: tert-Butyl (2-bromoethyl) 
carbamate 
In order to reduce the steric hindrance between two conjugated bulky moieties small spacer 
was prepared to link between them.   
 
 
The compound (2-bromoethanamine hydrobromide, 5 g, 0.025 mol) dissolved in 
acetonitrile (50 ml) and di-tert-butyl dicarbonate (8.09g, 0.037 mol, 1.5 eq) was added with 
stirring at 0 °C on an ice-bath. DIPEA (5.3 ml, 0.041 mol, 1.2 eq) was added drop-wise 
over 30 min. The mixture was stirred for 2 h on an ice-bath, then 18 h at room temperature. 
The solvents were evaporated under reduced pressure and the residue was dissolved in 
DCM (50 ml) then washed three times with water. The solvent then was evaporated in 
vacuum.  
b- Formation of fluoxetine N-BOC Ethyl linker 
 
 
Fluoxetine (0.2 g, 0.57 mmol) dissolved in acetonitrile (50 ml) under argon. Anhydrous 
potassium carbonate (2 g) and N-BOC ethyl bromide were added to the above solution. 
The mixture was refluxed for 18h. The solvent was then evaporated, and the residue was 
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dissolved in 50 ml of DCM and washed several times with water. The organic layer was 
evaporated to yield the impure linker, which had the appearance of a yellow paste.       
c- Fluoxetine-linker amino group deprotection/BOC Cleavage   
 
 
Fluoxetine-N-BOC ethyl (0.2 g) dissolved in 20 ml of trifluoroacetic acid 
(TFA). The solution was stirred at room temperature for 1 h. The excess of TFA was 
evaporated under reduced pressure to yield a yellow paste. 
d- Formation of fluoxetine-chlorambucil conjugate 
  
 
N-(2-aminoethyl)-fluoxetine (0.15 g, 0.43 mmol) dissolved in THF (10 ml) with 
chlorambucil (0.14 g, 1.1 eq.), DCC (0.13g, 1.1 eq, HOBT (0.16 g, 1.1 eq), and Bmim (0.15 
g,1.1 eq)) were combined and the mixture was stirred at 0 °C for 1 h. DIPEA (0.11 ml, 1.1 
eq was added. The mixture was stirred for 3 h at 0 °C then 18 h at room temperature.  The 
precipitate was filtered off and the solvent was evaporated in vacuum. The residue was 
dissolved in DCM and washed with water (50 ml) five times. The solvent was evaporated, 
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and the residue was purified by flash chromatography using ethyl acetate/methanol to 
obtain a yellow residue. The residue was purified by flash chromatography using DCM and 
methanol as the mobile phase with a gradient over 1 h. The fraction at 12 min gave the 
correct product and this was confirmed to have the correct mass of 651 dalton using 
analytical gas chromatography-mass spectroscopy.   
2.2.5 Redcurrant extracts 
2.2.5.1 Extraction methods  
Initially, crude RC extracts were made using four different methods:  
1- Refluxing: Red currants (RC, 500 g) were placed with 500 ml of ultrapure water in a 
glass round bottom flask connected to a condenser. The mixture was refluxed for 1 h then 
the residue was filtered off through several Whatman® filter papers. The filtrate was 
freeze-dried and yielded 7 g of red, solid gum.  
2- Room temperature direct filtration: The RC (500 g) were soaked in water for 2 h at room 
temperature then blended slightly with an electric blender (monilex blender). The mixture 
was filtered through Whatman® filter papers and the filtrate was frozen dried to yield 4 g 
of red gum.  
3- Sonication: RC was blended with an equivalent amount of water and placed in a 
sonicator (by applying agitated energy to the sample) at room temperature for 30 min and 
solid materials was filtered off. The water was evaporated by freeze-drying to yield 5 g as 
a red gum.  
4- Solid-liquid phase extraction: The residue that was filtered off after reflux and sonication 
(about 300 g of each) were placed separately in the thimble of a Soxhlet apparatus for solid-
liquid phase extraction. Reflux was continued for 3 h using the organic solvents, 
dichloromethane (300 ml) and methanol (200 ml). The organic solvents were evaporated 
under vacuum to yield 2 g of yellowish oily paste of each one.  
The antiviral activity of each of these extracts was examined. Refluxed RC extract showed 
much more antiviral activity and was not toxic on cells. Therefore, all subsequent extraction 
processes were done by reflexing. 
2.2.5.2 Fractionation methods of redcurrant 
The crude RC extract was fractionated to try to purify the active molecules. The 
fractionation was carried out using automated flash chromatography (puriFlash® 430, 
Interchim, France) on a reversed phase C18 column (puriFlash®, Interchim, France, 30 µ, 
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40 bar). The crude extract was fractionated and monitored at two wavelengths (230 and 
270 nm, the highest absorbance peaks of the extract) with a gradient mobile phase of 0.1 
% trifluoroacetic acid in aqueous acetonitrile and flow rate of 40 ml/min. The 
chromatography was initially run with water 100 % and acetonitrile was then introduced 
and increased gradually. The cartridge was finally flushed with 100% acetonitrile. 
Fractions within peaks and between peaks were all collected separately. The organic 
solvents of each fraction were evaporated at reduced pressure at 30 ˚C using a rotary 
evaporator (BUCHI®, vacuum pump V-710 and water bath B-480) and the water was 
evaporated with freeze drier (MINI LYOTRAP®, LTE Scientific). The fractions were kept 
at -20 ˚C for further analysis and biological testing on viruses.  
2.2.5.3 Analytical analysis of the fractionated RC samples with 
HPLC 
High performance liquid chromatography (Agilent, 1100 series, UK) was used to analyse 
fractions in terms of number of bands contained in each fraction and to optimise the eluent 
system for the further fractionation procedures. The HPLC was run with a reversed phase 
C18 cartridge (Waters, 100x 2.1 mm). The fractions were monitored at 4 wavelengths (230 
and 270, 400 and 520 nm) with both isocratic and gradient mobile phase of 0.1 % 
trifluoroacetic acid in aqueous acetonitrile and flow rate of 0.25 ml/min. After eluent 
system optimisation, the run was initiated with 95 % acetonitrile in the aqueous mobile 
phase and the percentage of water was increased by 20% until 100% and ended with 95% 
of acetonitrile in aqueous solution.       
2.2.5.4 Analytical analysis of the fractionated RC samples with LC-
MS/MS 
A- Reversed-phase high-performance liquid chromatography 
A Micromass Quattro microTM (Waters®) Mass Spectrometer coupled with a Waters 
ACQUITY Ultra Performance LCTM (Manchester, UK) was used for LC-MS/MS 
analytical procedures. A reversed-phase Waters column (150 mmx2.1mm i.d. and particle 
size 4 μm) and mobile phase of A: trifluoroacetic acid (TFA)-water, 0.1% and B: TFA-
acetonitrile, 0.1% were used after optimization for better resolution. Three standards were 
used, quercetin, quercetin 3-glucoside, and keracynin hydrochloride. 5 μl volumes of 
standards solutions (50 μg/l) and RC samples were injected. The chromatograms with 
complete spectral data were monitored and recorded in the range 200-800 nm. The applied 
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elution condition for each cycle was: 95 % of ACN in water for the first 5 minutes and then 
a gradient concentration of ACN, 95% to 70%, for another 5 minutes. After that, the 
gradient concentration of ACN was decreased from 70% to 50 % for 10 minutes and further 
from 50% to 10 % for 10 minutes. The isocratic concentration of 10 % was continued for 
5 minutes and the elution processes were ended by using a 95 % ACN concentration for 5 
minutes to prepare the system for the next elution cycle.     
B- Mass spectrometry 
Spectral mass analysis was obtained on a Micromass (waters/ UK) Quattromicro triple 
quadrupole mass spectrometer coupled at the exit of the diode array detector and equipped 
with a Z-spray ESI source. A flow of 250 μl/min from the DAD eluent was directed to the 
ESI interface using a flow-splitter. The source block temperature was held at 120 ˚C and 
the desolvation gas (nitrogen gas) temperature was 350 ˚C. The flow rate of 650 l/h, and 
cone gas of 82 l/h was used. The capillary potential of 3.2 kV was used. MS spectra 
recorded between m/z range 100-1500, in the positive mode at different cone voltages (CV) 
(15, 30 and 45 V, and 60V). Parent and daughter ions spectra were also recorded using 

















Chapter 3: Antiviral Activity of 



















In addition to development of anti-picornavirus drugs based on inhibition of specific virus 
targets such as 3Cpro or 3Dpol, screens of libraries of drugs developed, approved and widely-
used for treatment of other conditions have identified potentially useful compounds (van 
der Linden et al., 2015; Bauer et al., 2017). The information already available on these 
compounds could shorten the time needed to progress to clinical trials and approval for 
their repurposing as anti-picornavirus drugs, making this an attractive approach (Bauer et 
al., 2017).  
Investigation of the potential usefulness of a group of drugs or compounds that could be 
repurposed in this way is challenging in many ways. For instance, identifying the basis of 
their antiviral activity and finding if it is related to the mechanism of action exploited to 
achieve its original purpose. Secondly, are there common features among this drug group 
that is expected to give them similar antiviral activity? Potential side-effects and how 
quickly the virus can develop resistance against the drugs could finally prevent their 
repurposing.  
The aim of the work included in this chapter is to investigate the antiviral activities of 
several drugs that have been used for a long time in other medical areas. These drugs 
include fluoxetine, a selective serotonin re-uptake inhibitor, and several related drugs 
namely imipramine, a tricyclic antidepressant, promethazine, a neuroleptic and 
antihistamine agent, and dibucaine, a topical anaesthetic. Although all these mentioned 
drugs are from different chemical families, they all share some similar properties. For 
instance, all 4 are considered to be GPCR inhibitors. Dibucaine, imipramine and 
promethazine were found to be effective against Ebola and Marburg viruses in vitro (Cheng 
et al., 2015), while both fluoxetine and dibucaine have been found to inhibit some 
enteroviruses by binding to the 2C protein (Ulferts et al., 2016). The work also includes 
the selection and analysis of drug resistant mutants (DRMs) that could help in determining 
the mechanism of the antiviral activity of active compounds and how rapidly the virus 
develops these mutants. There will also be an attempt to structurally modify some active 




3.2.1 Inhibition of CAV9 infection by fluoxetine 
Antiviral activity of fluoxetine was previously confirmed against CBV types 1, 2 and 3 
(Zuo et al., 2012). In addition, it is found that fluoxetine inhibits members of other EVB 
species members including echovirus 1 (E-1), E-9 and E-11, as well as EVD members 
EV70 and EV68. However, no antivirus activity was detected against EVA, EVC, RVA or 
RVB species (Ulferts et al., 2013). So, there are key differences in the response to 
fluoxetine between enteroviruses. CAV9 is closely related to CBV3 and also belongs to 
EVB, so it is likely also to be inhibited by fluoxetine. To investigate this, a plaque reduction 
assay in the presence of different concentrations of fluoxetine (Figure 3.1) was firstly 
performed. The results showed a dose dependent effect and complete inhibition of virus 
growth at 0.05 mM concentration. The effect of the drug alone on the cell monolayer 
seemed insignificant, as there was no clear difference in the staining of the treated cells in 
comparison to untreated, control cells (data not shown). This was confirmed using an MTT 
cell viability assay (Figure 3.2). This showed some toxicity at lower fluoxetine 
concentrations, but a continuous increase in cell viability above 0.01 mM, reaching 100 % 
at the concentration seen to be 100 % effective for CAV9 inhibition (0.05 mM) and 
exceeding 100 % (i.e. some stimulation of growth) at 0.1 mM. To further confirm the 
effects of fluoxetine (0.05 mM), a flow cytometry approach was used which identifies 
healthy and damaged/apoptotic cells using propidium iodide. Figure 3.3 clearly shows that 
fluoxetine was very active toward CAV9 infection and lacked cell toxicity. The proportion 
of apoptotic cells in the presence (Figure 3.3B) of fluoxetine is at the background level 
seen in the cell-only sample (Figure 3.3A). Virus infection (Figure 3.3C) greatly increases 
the proportion of apoptotic cells, but this is reduced in the presence of fluoxetine (Figure 









Figure 3-1. Inhibition of CAV9 infection by fluoxetine.  
GMK monolayers in a 6 well plate were pre-treated with different concentrations of 
fluoxetine in 0.5 ml of culture medium for 30 minutes. 370 PFU (in 15 µl medium) of 
CAV9 were added and the cells were incubated on a rocking platform for 45 minutes at 
room temperature. 2 ml of a 2:1 mixture of culture medium and 2% CMC were added, and 
the plate were incubated for 3 days in a humidified CO2 incubator at 37 ˚C. The medium 
was discarded, and cells were washed and stained with crystal violet solution. The number 
of plaques were counted and expressed as a % of the number seen in the mock-treated (no 










































Figure 3-2. Cytotoxic effect of different fluoxetine concentrations on A549 cells. 
A549 monolayers were pre-treated with different concentrations of fluoxetine in 0.5 ml of 
culture medium for 30 minutes and the cells were incubated on a rocking platform for 30 
minutes at room temperature. 1 ml of a 2:1 mixture of culture medium and 2% CMC were 
added, and the plate were incubated for 2 days in a humidified CO2 incubator at 37 ˚C. The 
medium was discarded, and cells were washed and 1 mg/ml of MTT in media were applied 
for 2 h, the resulting blue crystals were dissolved in DMSO and absorbance at λ550 was 
























Figure 3-3. Flow cytometry analysis of the effect of fluoxetine on GMK cells and on 
CAV9 infection.  
Cells in wells of a 24 well plate were treated with fluoxetine (50 µM [0.05 mM]) in cell 
medium or only cell medium, and either undiluted CAV9 (100,000 PFU) or just medium 
for 12 hours. Then cells were washed, trypsinized with propidium iodide (PI). They were 
then analysed by flow cytometry. Gating was used to define an apoptotic or damaged cell 
population (H-2) and a normal cell population (H-1). Y-axis: cells count. X-axis: 
fluorescence intensity. A: Control (cells only), B: Cells with virus, C: Cells with fluoxetine, 
D: Cells with fluoxetine and virus. 
A 
Normal cells: 93% 
Apoptotic cells: 7% 
B 
Normal cells: 59% 
Apoptotic cells: 41% 
C 
Normal cells: 92% 
Apoptotic cells: 8%  
D 
Normal cells: 94% 
Apoptotic cells: 6% 
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3.2.2 The effects of imipramine and promethazine on CAV9 
Imipramine and promethazine along with fluoxetine are GPCR inhibitors and it has 
recently been found that several GPCR inhibitors blocked infection by some viruses 
including Ebola virus (Cheng et al., 2015). This means that these could be useful agents 
against CAV9 and other EVs. Beside fluoxetine, two of these GPCR inhibitors namely, 
imipramine (Dempsey et al., 2005) and promethazine (El-Shehabi et al., 2012) were used 
to investigate if they have an effect on CAV9 infection. Plaque reduction experiments were 
performed for imipramine and promethazine at concentrations ranged from 0.03 mM up to 
0.09 mM (Figures 3.4 to 3.7). It can be seen that imipramine did not block infection, at 
these concentrations, in fact the infection seemed to be enhanced by pre-treatment with 
these drugs (Figure 3.4). Visual appearance of the monolayers did not reveal toxicity of 
imipramine. When the concentration of imipramine was increased to 0.2 mM, surprisingly 
inhibition of CAV9 infection (around 85%) was seen (Figure 3.5). A cell viability assay 
for imipramine (Figure 3.6) revealed that it was not toxic even at the higher concentration 
of 0.2 mM, in which the viability was up to 90% of the control. Promethazine also did not 
inhibit, and again stimulated, CAV9 infection at 0.03 mM up to 0.09 mM (Figure 3.7). 
There was no inhibition at a concentration of 0.2 mM (data not shown). 
3.2.3 Inhibition of CAV9 infection by dibucaine 
Like fluoxetine, dibucaine was found to inhibit several enteroviruses, including CBV3, 
EV68 and to a lesser extent EV71 (Zuo et al., 2012). To see the effect on CAV9, a direct 
plaque assay was applied (Figure 3.8) and dibucaine caused a decrease in infectivity above 
0.01 mM, and complete inhibition of virus growth at 0.04 mM. It had no serious effect on 
the cell monolayer judged visually. However, a viability assay (Figure 3.9) showed dose 
dependent toxicity started as low as 0.01 mM and caused cell viability to be reduced to less 




Figure 3-4. The effect of imipramine on CAV9 infection.  
GMK monolayers in a 6 well plate were pre-treated with different concentrations of 
imipramine in 0.5 ml of culture medium for 30 minutes. 370 PFU (in 15 µl medium) of 
CAV9 were added and the cells were incubated on a rocking platform for 45 minutes at 
room temperature. 2 ml of a 2:1 mixture of culture medium and 2% CMC were added, and 
the plate was incubated for 3 days in a humidified CO2 incubator at 37 ˚C. The medium 
was discarded, and cells were washed and stained with crystal violet solution. The number 
of plaques were counted and expressed as a % of the number seen in the mock-treated (no 









































Figure 3-5. The effect of imipramine on CAV9 infection.  
A549 monolayers were pre-treated with imipramine at a concentration of 0.2 mM in 0.5 ml 
of culture medium for 30 minutes or 0.5 ml of culture medium. 370 PFU (in 15 µl medium) 
of CAV9 were added and the cells were incubated on a rocking platform for 45 minutes at 
room temperature. 2 ml of a 2:1 mixture of culture medium and 2% CMC were added, and 
the plate were incubated for 3 days in a humidified CO2 incubator at 37 ˚C. The medium 
was discarded, and cells were washed and stained with crystal violet solution. The number 
of plaques were counted and expressed as a % of the number seen in the mock-treated 





































Figure 3-6. Cytotoxic effect of different imipramine concentrations on A549 cells.  
A549 monolayers were pre-treated with different concentrations of imipramine in 0.5 ml 
of culture medium for 30 minutes and the cells were incubated on a rocking platform for 
30 minutes at room temperature. 1 ml of a 2:1 mixture of culture medium and 2% CMC 
were added, and the plate was incubated for 2 days in a humidified CO2 incubator at 37 ˚C. 
The medium was discarded, and cells were washed and 1 mg/ml of MTT in media were 
applied for 2 h, the resulting blue crystals were dissolved in DMSO and absorbance at λ550 


































Figure 3-7. The effect of promethazine on CAV9 infection.  
GMK monolayers in a 6 well plate were pre-treated with different concentrations of 
promethazine in 0.5 ml of culture medium for 30 minutes. 370 PFU (in 15 µl medium) of 
CAV9 were added and the cells were incubated on a rocking platform for 45 minutes at 
room temperature. 2 ml of a 2:1 mixture of culture medium and 2% CMC were added, and 
the plate was incubated for 3 days in a humidified CO2 incubator at 37 ˚C. The medium 
was discarded, and cells were washed and stained with crystal violet solution. The number 
of plaques were counted and expressed as a % of the number seen in the mock-treated (no 








































Figure 3-8. Inhibition of CAV9 by dibucaine.  
GMK monolayers in a 6 well plate were pre-treated with different concentrations of 
dibucaine in 0.5 ml of culture medium for 30 minutes. 370 PFU (in 15 µl medium) of 
CAV9 were added and the cells were incubated on a rocking platform for 45 minutes at 
room temperature. 2 ml of a 2:1 mixture of culture medium and 2% CMC were added, and 
the plate were incubated for 3 days in a humidified CO2 incubator at 37 ˚C. The medium 
was discarded, and cells were washed and stained with crystal violet solution. The number 
of plaques were counted and expressed as a % of the number seen in the mock-treated (no 
drug) control. Error bars show standard error from 3 independent experiments.   




































Figure 3-9. Cytotoxic effect of different dibucaine concentrations on A549 cells.  
A549 monolayers were pre-treated with different concentrations of dibucaine in 0.5 ml of 
culture medium for 30 minutes and the cells were incubated on a rocking platform for 30 
minutes at room temperature. 1 ml of a 2:1 mixture of culture medium and 2% CMC were 
added, and the plate were incubated for 2 days in a humidified CO2 incubator at 37 ˚C. The 
medium was discarded, and cells were washed and 1 mg/ml of MTT in media were applied 
for 2 h, the resulting blue crystals were dissolved in DMSO and absorbance at λ550 was 
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3.2.4 Drug sensitivity and analysis of the drug resistant mutants  
3.2.4.1 Generation of CAV9 mutants resistant to fluoxetine  
Although fluoxetine anti-CAV9 activity and cell tolerability were clearly confirmed in this 
study, drug resistance is a large problem in the use of antivirus drugs. CBV3 mutations in 
the viral 2C protein were previously reported to give resistance to the drug TBZE-029 (de 
Palma et al., 2006). A CBV3 mutant carrying these mutations, A224V, I227V and A229V 
was also found to be resistant to fluoxetine (Ulferts et al., 2013). To investigate if similar 
or different mutations give resistance of CAV9 to fluoxetine, the virus was propagated in 
the presence of increasing concentration of fluoxetine. The emergence of resistant mutants 
occurred after 9 passages, when the virus was propagated at a fluoxetine concentration of 
0.04 mM. Resistant viruses were picked and propagated. Plaque assays of the original and 
mutant viruses showed a clear difference in the presence and absence of 0.05 mM 
fluoxetine (Figure 3.10). It can be seen that the original virus was almost completely 
inhibited by fluoxetine as only a few tiny plaques were seen compared to the sample 
without fluoxetine. In contrast, the drug resistant mutants showed almost equal numbers of 
plaques in the presence and absence of fluoxetine, although the ones in the presence of 
fluoxetine were smaller than those in its absence, suggesting that resistance was not 
complete.  
3.2.4.2 Cross resistance of fluoxetine with dibucaine  
The presence of cross resistance between compounds means in many cases that they have 
similar mechanism of antiviral activity. In order to predict if other investigated compounds 
used in study have similar antiviral activity as fluoxetine, some of the selected mutants 
from CAV9 against fluoxetine were tested with dibucaine (Figure 3.10). Using a direct 
plaque assay, it can be seen that the original virus was completely inhibited by dibucaine 
as no plaques were seen compared to the sample without dibucaine (Figure 3.10), while the 
drug resistant mutants showed some but otherwise fewer of plaques in the presence of 
dibucaine, indicating partial resistance.  
3.2.4.3 The sequence of the selected CAV9 mutants   
Sequencing of part of the 2C-encoding region of CAV9 of six selected mutants showed 
mutation of the same amino acid isoleucine which was converted to valine at position 227 
(I227V) (Figure 3.11). This mutation seemed to come from a complete conversion of an 
ATA codon to GTA codon as shown in Figure 3.12. In addition, there was another mutation 
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seen in mutant 4 (Figure 3.11), conversion of glycine present in the original virus into serine 
(G258S) in mutant 4. This mutant seemed to show a little more resistance than the others 
to fluoxetine. However, the G258S mutation does not seem to have a major role in the 
mechanism of virus resistance.  





































Figure 3-10. The effect of fluoxetine and dibucaine on two CAV9 fluoxetine-resistant 
mutants and the original CAV9 using a direct plaque assay.  
Cells were pre-treated with (A) fluoxetine 0.05 mM and (B) dibucaine 0.04 mM before 
adding the viruses, then direct plaque assay was applied. The mutated viruses are resistant 
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Figure 3-11. Amino acid sequence alignment of 6 selected CAV9 fluoxetine-resistant 
mutants in comparison to the original virus by partial sequencing of the 2C protein.  
All the mutants showed the same mutation (I>V), while Mutant 4 shows an additional 
mutation of G>S. The I>V mutation is at position 227 in CAV9 2C. CAV9 is the original 











  CAV9    LASTNAGSINAPTVSDSRALARRFHFDMNIEVISMYSQNGKINMPMSVKTCDEECCPVNF 
Mutant1   LASTNAGSVNAPTVSDSRALARRFHFDMNIEVISMYSQNGKINMPMSVKTCDEECCPVNF 
Mutant2   LASTNAGSVNAPTVSDSRALARRFHFDMNIEVISMYSQNGKINMPMSVKTCDEECCPVNF 
Mutant3   LASTNAGSVNAPTVSDSRALARRFHFDMNIEVISMYSQNGKINMPMSVKTCDEECCPVNF 
Mutant4   LASTNAGSVNAPTVSDSRALARRFHFDMNIEVISMYSQNSKINMPMSVKTCDEECCPVNF 
Mutant5   LASTNAGSVNAPTVSDSRALARRFHFDMNIEVISMYSQNGKINMPMSVKTCDEECCPVNF 
Mutant6   LASTNAGSVNAPTVSDSRALARRFHFDMNIEVISMYSQNGKINMPMSVKTCDEECCPVNF 




















Figure 3-12. The nucleotide sequence of the one selected CAV9 mutant (bottom, 
mutant 2) in comparison with the original virus (top) in the region of the I>V 
mutation.  
The program Chromas was used to show the raw output from the sequence analysis. The 
Chromas trace shows that there has been complete conversion of the ATA codon (encoding 





3.2.5 Modification of fluoxetine and dibucaine to generate potential 
new drugs 
Although fluoxetine and dibucaine were active against CAV9, such activity was largely 
absent with the resistant mutants. Therefore, as a first attempt to improve the antiviral 
activity, and possibly overcome the problem of the selection of resistant mutants, 
modifications were made. Fluoxetine was conjugated to the nitrogen mustard drug 
chlorambucil (Figure 3.13). Coupling was through an amide bond and achieved through a 
multi-step process described in section 2.2.4.2. The final fluoxetine-chlorambucil 
conjugate (Fl-Ch) is 3-(3-(2-(bis(2-chloroethyl)amino)ethyl) phenyl1-3-(4 
(trifluoromethyl) phenoxy) propyl)amino) ethyl)propenamide.  
To start to explore how dibucaine could be modified to generate novel anti-virus 
compounds, 2-hydroxyquinolin 2-4-carboxylic acid (the core structure of dibucaine) 
(Figure 3.14) was linked to a butene group, an unsaturated hydrocarbon to give the 
compound (E)-2-(but-2-en-1-yloxy) quinoline-4-carboxlic acid (QHB). 
3.2.6 Antiviral activity of QHB and Flu-Buc  
Both QHB and Fl-Ch activities were measured by direct plaque assay.  In the case of QHB 
(Figure 3.15), there was no inhibition of the virus. In fact, there seemed to be some 
stimulation of virus growth as plaque numbers increased steadily with increasing drug 
higher concentration, up to 60% at 1 mM. The inhibition effect of the fluoxetine-based Fl-
Ch compound (Figure 3.16) was more promising and inhibition was complete at 0.3 mM, 
but this is 10 times the concentration of fluoxetine needed to achieve similar inhibition 
















Figure 3-13. Chemical structure of the original drug (fluoxetine) and fluoxetine 








Figure 3-14. Chemical structure of the original drug (dibucaine) and a quinoline 

























Figure 3-15. Effects of increasing QHB concentrations on CAV9.  
GMK monolayers in a 6 well plate were pre-treated with different concentrations of QHB 
in 0.5 ml of culture medium for 30 minutes. 370 PFU (in 15 µl medium) of CAV9 were 
added and the cells were incubated on a rocking platform for 45 minutes at room 
temperature. 2 ml of a 2:1 mixture of culture medium and 2% CMC were added, and the 
plate was incubated for 3 days in a humidified CO2 incubator at 37 ˚C. The medium was 
discarded, and cells were washed and stained with crystal violet solution. The number of 
plaques were counted and expressed as a % of the number seen in the mock-treated control. 











































Figure 3-16. Effects of increasing Fl-Ch concentrations on CAV9.  
GMK monolayers in a 6 well plate were pre-treated with different concentrations of Fl-Ch 
in 0.5 ml of culture medium for 30 minutes. 370 PFU (in 15 µl medium) of CAV9 were 
added and the cells were incubated on a rocking platform for 45 minutes at room 
temperature. 2 ml of a 2:1 mixture of culture medium and 2% CMC were added, and the 
plate were incubated for 3 days in a humidified CO2 incubator at 37 ˚C. The medium was 
discarded, and cells were washed and stained with crystal violet solution. The number of 
plaques were counted and expressed as a % of the number seen in the mock-treated control. 






































In general, repurposing of already used drugs as antiviral approaches potentially reduces 
by several years the timescale needed to discover general mechanism of action, 
formulations, side effects, interactions, bioavailability, metabolism and excretion 
properties of the investigated compounds. Fluoxetine (Prozac) is the first selective 
serotonin reuptake inhibitor known and has been in medical use since 1986. Fluoxetine is 
FDA approved [and on WHO list of essential medicines (WHO, 2015)] for the treatment 
of wide range of neurological disorders from depression to schizophrenia. The principle 
mechanism of its action is to selectively inhibit serotonin (5-HT) uptake by the membrane 
transporter and is an antagonist at 5HT2C receptors. Uptake studies of fluoxetine in vivo 
indicated a 57% decrease in 5-HT uptake with little or no effect on noradrenaline and 
dopamine transport (Perez-Caballero et al., 2014).  
Dibucaine (cinchocaine) is a quinolone derivative used as a topical anaesthetic for relief of 
haemorrhoid-associated pain. It acts by inhibition of voltage-activated sodium channels 
and it is also an inhibitor of plasma cholinesterase (Neitlich, 1966; Elamin, 2003; Torrens 
& Castellano, 2006; White et al., 2012). 
3.3.2 Fluoxetine as an antiviral drug  
Screening a library of small molecules for antiviral activity towards CBV3 (grown in Hela-
Rw cells) identified fluoxetine (and its metabolite norfluoxetine) (Zuo et al., 2012). 
Fluoxetine showed peak inhibition at a concentration of 6.25µM. Addition of fluoxetine to 
virus stock had no effect on infectious titre, so there is no direct interaction with the capsid, 
instead an early post-entry step of CBV3 infection seemed to be targeted (Zuo et al., 2012). 
As CAV9 was found to have high degree of structural similarity and amino acid sequences 
identity with CBV3 (Chang et al., 1989), it was interesting to find if CAV9 is also inhibited. 
Our results show that CAV9 infection was completely inhibited at a 0.05 mM concentration 
of fluoxetine (Figure 3.1) and there was no toxic effect of the drug on cells in all 
concentrations used (Figures 3.2 and 3.3). In preliminary experiments (data not shown), we 
found no direct effect of fluoxetine on the CAV9 particle and that an early step in infection 
is inhibited, as seen for CBV3 (Zuo et al., 2012).   
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Working independently, a second research group screened a library of bio-active molecules 
and also identified fluoxetine as an inhibitor of CBV3, as well as the other CBVs and also 
echoviruses tested (Ulferts et al., 2013). As CAV9 is a member of the same EV species 
(EVB) as all these viruses, it is not surprising that it is also inhibited by fluoxetine. 
However, our work is useful direct evidence that CAV9 infection could potentially be 
treated with fluoxetine, as CAV9 is one of the most frequently isolated EV types from 
clinical cases. In addition to EVB, fluoxetine inhibited EVD species members, but not the 
other EV species important from the point of view of human health, EVA (including. EV71, 
one of the most important EVs clinically), EVC and RV-A/RV-B, major causes of the 
common cold. RV-C was not tested, presumably because members of this species are 
difficult to propagate. So, fluoxetine use would require accurate identification of the 
infecting virus and it would only be effective against a sub-set of EVs, unless broader-
acting derivatives could be developed. Using a range of techniques, including analysis of 
in vitro translation and using luciferase or GFP-expressing viral replicons to study RNA 
replication, it was found that the basis of fluoxetine antiviral activity was inhibition of RNA 
replication (Ulferts et al., 2013). Use of CBV3 mutants, discussed more thoroughly later, 
indicated that the CBV3 2C protein is key to fluoxetine activity, as mutations giving drug 
resistance map to this protein (Ulferts et al., 2016). These researchers also demonstrated a 
direct binding of dibucaine, which we confirmed to be functionally related to fluoxetine as 
CAV9 mutants resistant to fluoxetine were also resistant to dibucaine (Figure 3.10), to 
purified 2C protein from CBV3.  
In this work, the investigation of fluoxetine activity depended mainly on plaque assay 
which allows viral determination of the actual number of infectious viral particles within 
fluoxetine treated and untreated samples. Direct plaque assay also allows a rough 
estimation of the degree of compound toxicity. The more toxic the compound, the fainter 
the purple colour appears in comparison with the control. It is also easy to work out and it 
is cost efficient. However, it takes a significant time, 3 days for direct plaque assay and an 
even longer for indirect plaque assay. The MTT assay was used to give a more accurate 
estimation of toxicity. In the case of fluoxetine, toxicity and antiviral activity were also 
confirmed independently by using a flow cytometric technique (Figure 3.3), which was 
reliable in terms of giving quantitative results and a quick analysis time (Wlodkowic et al., 
2009). However, the experimental procedure is time-consuming, and this technique was 
not used to study the other drugs.  
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Fluoxetine antivirus activity has been reported to extend beyond picornaviruses, as was 
also found to inhibit HCV (Young et al., 2014). This did not seem to be due to binding a 
virus protein, but to targeting several host factors. It prevents HCV- driven accumulation 
of lipids and synthesis of reactive oxygen species by regulating the c-Jun amino-terminal 
kinase (JNK) and peroxisome proliferator-activated receptor (PPARβ/γ) pathways and also 
inhibited HCV replication through the JNK signals, transcription activator (STAT)-1 
pathways, which enhanced antiviral responses. Likewise, the post-entry stage of dengue 
virus was found to be inhibited by fluoxetine, most probably by interaction with the endo-
lysosomal pathway and autophagy induction (Medigeshi et al., 2016). The anti-
inflammatory activity of fluoxetine has been well documented and may also contribute to 
antivirus effects (Sacre et al., 2010). HCV and dengue virus are both positive sense RNA 
viruses, as are picornaviruses, and are expected to share some features, such as replication 
complex formation. It may therefore be that fluoxetine-induced changes to cellular 
pathways which inhibit HCV and dengue virus replication, could also contribute to the anti-
EV effect, in addition to direct interaction with 2C.  
Fluoxetine has a long half-life of 2 days after a single dose and 4 days following multiple 
doses. Within the liver, cytochrome a P450 (CYP2D6) enzyme demethylates fluoxetine to 
an active metabolite, norfluoxetine which has a very long half-life of up to 7 days and it 
was also found to have antiviral activity against CBV3, and thus, it may increase the 
duration of action of fluoxetine antiviral activity if it is used clinically (Kam & Chang, 
1997). .    
There are several psycho-dependent and independent side effects of fluoxetine. Being 
almost serotonin selective, fluoxetine has much lower side effect than antidepressants from 
other groups, but as there are at least 7 classes of serotonin receptors some side-effects are 
inevitable, and these include weight gain, sexual dysfunction and sleep disturbances. If 
fluoxetine were to be used clinically to treat EV infections and if 2C binding is the basis of 
its inhibitory effect, then presumably modifications to the drug could remove the GPCR 
blocking activity and so the effect on the CNS and side effects. However, recently, in a 
multi-centre cohort study of US patients, treated with fluoxetine for EV68–associated acute 
flaccid myelitis, it was found that fluoxetine was well tolerated by patients, but 
unfortunately did not improve the neurological outcome of the infection (Messacar et al., 
2018). This study is the only reported use of fluoxetine as an anti-EV drug, apart from a 
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case study on an immunocompromised child with chronic enterovirus encephalitis, who 
was treated successfully (Gofshtevn et al., 2016).  
Fluoxetine can also cause side effects by interacting with other drug groups. For instance, 
it supresses cytochrome P450 2D6 (debrisoquine hydroxylase) which hydroxlyses 
debrisoquine and sparteine and thus interacts with drugs that are metabolised by this 
isoenzyme including the tricyclic antidepressants (TCAs) and lipophilic b-blockers. 
Fluoxetine also interferes with the use of diazepam, amitryptyline, omeprazole, warfarin, 
tolbutamide, phenytoin and some nonsteroidal anti-inflammatory agents through inhibition 
of the P450 2C enzyme group. P450 3A4 enzyme substrates such as benzodiazepines, 
calcium blockers, cyclosporin, erythromycin, lignocaine, steroids and carbamazepine are 
also best avoided in fluoxetine-treated patient (Kam & Chang, 1997). Again, modification 
of the drug could overcome these contraindications while retaining antivirus activity. 
3.3.3 Antiviral activity of imipramine and promethazine   
It has been found that imipramine blockage of the spingomyelinase decreases the 
production of ceramide and synthesis of ceramide-rich membrane domains leading to 
complete inhibition of infection by rhinoviruses, RV2, RV14, and RV16. These membrane 
domains contain receptors that are required for RV entry, ICAM-1 for RV14 and RV16 
and the LDLR for RV2 (Grassmé et al., 2005). Niemann-Pick C1 (NPC1) is a cholesterol 
transporter important for several viral families. As a potent NPC1 antagonists, imipramine 
efficiently blocks many viral groups including Ebola virus, Marburg virus, Hepatitis C 
virus, Chikungunya virus, Zika virus, West Nile virus, Dengue virus and Baculovirus 
(Haque et al., 2015; Cheng et al., 2015; Li et al., 2018).  
Along with related drugs, promethazine inhibits Middle East respiratory syndrome 
(MERS) coronavirus infection via blocking of clathrin-mediated endocytosis (Liu et al., 
2015). It also has an effect on HIV-1, herpes simplex virus, bovine herpes virus and 
Newcastle disease virus. (Poste & Reeve, 1972; Cheng et al., 2016).  
These reports of inhibition of different virus infections by imipramine and promethazine 
could mean that they would be useful agents against CAV9 and other EVs. However, these 
two GPCR inhibitors, imipramine (Dempsey et al., 2005) and promethazine (El-Shehabi et 
al., 2012) showed no activity towards CAV9 (Figure 3.4 and 3.7) at concentrations up to 
0.09 mM. At a higher concentration of 0.2 mM imipramine showed significant inhibition 
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of CAV9 but also cell toxicity (Figures 3.5 and 3.6). GPCRs are the largest protein 
superfamily in mammalian genomes and include -more than 800 proteins (Katritch et al., 
2013). Therefore, being a GPCR does not mean that a protein has the same effects, and 
different GPCRs subgroups mediate different physiological and pharmacological 
functions. In addition, there are many drugs known to be GPCR inhibitors and are inactive 
against CBV3. For instance, During the Zuo et al. screening project, up to 1200 GPCR 
inhibitors were assessed for antiviral activity and only 7 compounds showed some antiviral 
activity (Zuo et al., 2012).  
3.3.4 Dibucaine antiviral activity and restrictions of use 
Dibucaine was previously identified to act on the same viruses as fluoxetine, with a more 
potent effect and some suggestion of an effect also on species EVA viruses (Ulferts et al., 
2016). In the current study, both dibucaine (Figure 3.8) and fluoxetine (Figure 3.1) were 
found to inhibit CAV9 in a dose dependent manner and caused complete inhibition of virus 
growth at concentrations of 0.04 mM and 0.05 mM. However, a viability assay (Figure 3.9) 
revealed considerable toxicity at these concentrations. This might mean that some apparent 
antiviral activity of dibucaine might be because of cell toxicity, which makes less cells 
available for virus to replicate.  
The antiviral activity of dibucaine against EVB and EVD was confirmed to be through 
binding to and inhibiting the 2C protein (Ulferts et al., 2016), and not by the principal 
cellular effect of Na-channel blocking action (Torrens & Castellano, 2006; White et al., 
2012). There is some structural similarity (Figure 3.17) between dibucaine, fluoxetine, and 
also TBZE-029, which is another compound found to act on the 2C protein of CBV3 (de 
Palma et al., 2008). Dibucaine is similar to fluoxetine in terms of having a considerable 
inhibitory activity against some EV groups and also viruses from other families, including 
HCV, Ebola virus, Marburg virus and Lassa virus but the mechanism of action is unknown 
in these cases (Madrid et al., 2013; Ekins et al., 2014; Bösl et al., 2019). In another study, 
dibucaine was hypothesized to affect the morphogenesis of Semliki Forest virus (an 
alphavirus), after the stage of reaching plasma membrane (Richardson & Vance, 1978). 
Dibucaine also inhibits envelope/cell fusion during entry of several enveloped viruses, 
including those reported to be inhibited by promethazine listed (Poste & Reeve, 1972). The 
anti-inflammatory properties of dibucaine has been also investigated at a relatively high 
concentration and it may contribute to its antiviral activity (Cassuto et al., 2006).  
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The systemic adverse effects of dibucaine are considered to be serious including cardiac 
arrhythmia, CNS effects and methemoglobinemia (Welch, 2000). Therefore, dibucaine is 
now rarely used systemically and for spinal anaesthesia and confined to topical uses of 
haemorrhoids and other rectal and skin irritations (Yacoubian, 2017). If antiviral activity 
of dibucaine is proved, it will be a new agent for a topical but not for systemic treatment of 
virus infection unless structural modification of dibucaine will otherwise improve its 


























Figure 3-17. Structural similarities between fluoxetine and some studied compounds.  
Fluoxetine features aromatic and aliphatic groups beside secondary amine and three 
fluoride atoms while dibucaine contains aromatic and aliphatic groups beside the tertiary 
amine. Also, TBZE-29 shared some common points with the structure of fluoxetine that 
TBZE-29 contains aromatic, aliphatic groups, and tertiary amine but fluoride atoms are the 
main common feature with fluoxetine. Imipramine and promethazine both contain a tertiary 
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3.3.5 Drug resistant mutants (DRMs) against fluoxetine and dibucaine  
To increase understanding of the mechanism of fluoxetine inhibition of CAV9, DRMs were 
produced (section 3.5.1). Previously, CBV3 DRMs were selected against a novel anti-EV 
drug TBEZ-029 (de Palma et al., 2008). All the DRMs produced had 3 mutations in 
common, clustered in the 2C protein, A224V, I227V, A229V. These were analysed 
individually and in combinations by making specific virus mutants, to find their 
contribution to the DRM phenotype. A complicated pattern was observed. Alone A229V 
gave a drug-dependent mutant that could not replicate in the absence of TBEZ-029, but a 
virus with I222V and A229V was drug resistant not drug dependent. Alone neither A224V 
nor I227V gave a resistant virus, but with both mutations in the same virus drug resistance 
was observed. A mutant with all 3 mutations was used in studies on fluoxetine and 
dibucaine and was resistant to both these drugs (Ulferts et al., 2016), suggesting a common 
mechanism of inhibition, involving 2C, with TBEZ-029. A direct binding of dibucaine to 
purified CBV3 was then observed and presumed to be the inhibitory mechanism (Ulferts 
et al., 2016). The EV71 2C crystal structure has been determined (Guan et al., 2017) and 
the similarity in sequence with CBV3 allowed a model of the CBV3 2C to be derived 
(Bauer et al., 2019). This revealed a pocket in the region of the 2C mutants into which 
fluoxetine was predicted to fit. This modelling now allows a more detailed understanding 
of the interaction of fluoxetine and other drugs and their modification to retain and optimise 
binding, while removing unwanted interactions with other proteins.  
There is no report of an attempt to generate DRMs against fluoxetine itself and so our work 
offers valuable insights. After propagation, selection and purification, the sequence (Figure 
3.11) of the mutated viruses showed that all the mutants had the same mutation (I>V) at 
position 227 in 2C. This mutation found in CAV9 is the same as one of the 3 mutations, 
2C-A224V, I227V, A229V found in TBEZ-029 resistant CBV3 and also known to give 
CBV3 resistance to fluoxetine and dibucaine (Ulferts et al., 2013). The region where the 
mutations are found is highly conserved between CAV9 and CBV3 (both EVB species), 
and also with the EVD virus known to be susceptible to fluoxetine, but not EVA or EVC 
viruses, which are not susceptible to fluoxetine (Figure 3-18). Results from sequencing of 
one CAV9 dibucaine DRM showed an identical mutation to that in the fluoxetine DRM 
(I>V) at the same position of 227 in 2C. The results need to be extended by analysing 
additional independent mutants. One explanation for getting only one mutation, rather than 
the 3 seen in all CBV3 DRMs is that I227 could be the only amino acid that is responsible 
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for the fluoxetine-2C binding in CAV9 and the other two amino acids (A224 and A229) 
are not important, alternatively they are key to the function of CAV9 2C and alteration of 























 CAV9   DPDHFDGYKQQAVVIMDDLCQNPDGKDVSLFCQMVSSVDFVPPMAALEEKGILFTSPFVL  
 CBV3   DPDHFDGYKQQAVVIMDDLCQNPDGKDVSLFCQMVSSVDFVPPMAALEEKGILFTSPFVL  
 EVD    DPKYFDGYKQQTVVLMDDLMQNPDGNDIAMFCQMVSTVDFIPPMASLEEKGTLYTSPFLI  
 EVC    APSHFDGYKQQGYD-MDDLNQNPDGMDMKLFCQMVSTVEFIPPMASLEEKGILFTSDYVL  
 EVA    DPDQFDGYKQQVVTVMDDLCQNPDGKDMSLFCQMVSTVDFIPPMASLEEKGVSFTSKFVI  
         *  *******    **** ***** *   ****** * * **** *****   **     
 
 CAV9   ASTNAGSINAPTVSDSRALARRFHFDMNIEVISMYSQN-GKINMP-----MSVKT-CDEE  
 CBV3   ASTNAGSINAPTVSDSRALARRFHFDMNIEVISMYSQN-GKINMP-----MSVKT-CDDE  
 EVD    ATTNAGSIHAPTVSDSKALARRFKFDMEIESMESYKDG-VRLDMFKAVELCNPEK-CRPT  
 EVC    ASTNSHSIAPPTVAHSDALTRRFAFDVEVYTMSEHSVK-GKLNM------ATATQLCKDC  
 EVA    ASTNASNIIVPTVSDSDAIRRRFYMDCDIEVTDSYKTDLGRLDAG------RAAKLCSEN  
        * **   *  ***  * *  ***  *                              *    
Figure 3-18. ClustalW alignment of part of the amino acid sequences of the 2C 
proteins of CAV9 and CBV3, representing EVB, with a representative of species EVD 
(also susceptible to fluoxetine) and representatives of EVA and EVC (which are not 
susceptible to fluoxetine). 
The region believed to be involved in fluoxetine binding is shown in yellow. The position 
of the CAV9 mutation associated with resistance to fluoxetine and dibucaine is shown in 
red. The position of the 3 mutations seen in CBV3 resistant to TBEZ-029 and giving 
resistance to fluoxetine are shown in blue. The EVD representative has only one difference 
(in grey) from CAV9 and CBV3 in this region, while there is little sequence identity with 













Another thing to mention is that CAV9 resistant mutants were isolated at a fluoxetine 
concentration of 0.05 mM. If the propagation was continued further at concentrations above 
0.05 mM, additional mutations might be required to overcome the effect of the drug. It is 
noticeable that fluoxetine was still having a marked effect on CAV9 at this concentration, 
as plaques were smaller than in the absence of fluoxetine. Finally, the CBV3 mutants were 
generated against4 TBEZ-029, not fluoxetine, and it may be that all three mutations are 
needed for resistance against this molecule (de Palma et al., 2008). Subsequent work with 
fluoxetine was apparently done only using the mutant with all 3 mutations, which was 
resistant to fluoxetine, but this does not prove that all 3 mutations are needed for CBV3 
resistance to fluoxetine.             
The fluoxetine resistant mutants in this work were treated with dibucaine and found to be 
partially resistant to it. This means that fluoxetine and dibucaine may target the same virus 
component. In addition to dibucaine, it has been reported that 2 other compounds, 
pirlindole and zuclopenthixol were effective against some CBVs but they lost their activity 
against TBEZ-029 DRM (Ulferts et al., 2016). It seems that many drugs target this region 
of 2C, but there may be subtle differences between how they bind into the observed pocket 
which could determine the mechanism of DRM selection. This is important clinically as a 
drug such as fluoxetine, which can be overcome by a single mutation, at least by CAV9, 
will be more susceptible to DRM selection than one where multiple mutation is required 
for DRM selection.  
The resistance mutation (I>V) at position 227 in 2C in our work and 3 mutations in the 
previous work (2C-A224V, I227V, A229V) are located C terminal to ATPase motif C, and 
this short stretch is conserved in viruses that are sensitive to fluoxetine,  but there is no 
clear data on whether these compounds affect 2C ATPase activity (Ulferts et al., 2016).  
3.3.6 Synthesis and antiviral activity of the modified drugs  
A fluoxetine chlorambucil conjugate was devised to exploit the 2C binding activity of 
fluoxetine and exploit the ability of chlorambucil to damage nucleic acid. 2C has an RNA 
binding activity (Xia et al., 2015) so binding of the conjugate to 2C should bring virus 
RNA into close proximity. Synthesis of the fluoxetine chlorambucil conjugate was carried 
out by a multi-step procedure (Chapter Two, 2.2.4). A spacer with a suitable functional 
group, bromoethyl amine (with BOC protection group) was used to couple fluoxetine in 
order to reduce steric hindrance around the reaction sites between fluoxetine and 
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chlorambucil moieties. The nucleophilic reaction of the secondary amine took place 
replacing the bromide. The amino group of the spacer was protected first with BOC 
protection group in order to link it to the secondary amine of fluoxetine at end of the spacer. 
BOC was then cleaved with neat TFA to give free amino group at the other end ready for 
conjugation. The final step of the conjugation was coupling of the amino group of the 
spacer that linked to fluoxetine with the chlorambucil carboxyl group to form an amide 
bond. Using the standard coupling reagents DCC, HOBT, and LQ under argon at low 
temperature, the reaction yielded the conjugated compound fluoxetine-chlorambucil (Fl-
Cl) in a reasonable yield. The novel compound was purified with flash chromatography 
and its molecular mass of m/z 651 Daltons was confirmed with GC spectroscopy 
(Appendix 2) 
Quinoline is expected to be the active part of dibucaine structure and preparation of a 
quinoline derivative (QHB) was an attempt to exploit its main core (quinoline unit) in 
derivatization.  The aim was to have an insight into the quinoline unit in the biological 
activity of dibucaine. Therefore, a quinolone-based molecule (QHB) with an unsaturated 
hydrocarbon linker (butenyl group) was prepared by coupling the hydroxy group of the 
quinoline with bromobutene. QHB was expecting to be more hydrophobic than the 
quinoline itself, providing more interaction with cellular lipid compartments including lipid 
droplets that are very important for virus replication and seem to interact with CAV9 and 
parechovirus 2C protein However, QHB (Figure 3.15) did not inhibit the virus. Instead, the 
viral growth seemed to be stimulated at higher concentrations. 
Viral inhibition by Fl-Ch only at high concentration (Figure 3.16) raises the probability that 
the chlorambucil has impaired the ability of fluoxetine to bind to 2C, possibly by masking 
some components needed for the interaction. 
Two other quinoline conjugates were also prepared in an attempt to search for a new 
antiviral candidate based on the main unit of dibucaine (quinoline moiety), but time 
prevented these being tested fully.  
The fluoxetine and dibucaine derivatives were designed without taking into account the 
CAV9 2C structure, which has not been determined. However, the EV71 2C structure 
(Guan et al., 2017) could be used to model a structure for CAV9 2C, using a similar 
approach to Bauer et al., 2019. This should allow detailed molecular simulations which 
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could lead to the rational design of effective drugs, lacking toxicity and with reduced ability 
to select DRMs, and these could be highly useful to combat infections by CAV9 and related 






























Chapter 4: Drugs Affecting Lipid 







For successful intra-host infectious cycle, viruses including positive stranded RNA viruses, 
have multiple interactions with various lipids and lipid based intracellular structures (Wells 
& Coyne, 2019). These interactions are potentially attractive targets for antivirus agents 
(Fernández‐Oliva et al., 2018). It was previously found in our laboratory that CAV9 and 
HPeV1 infection changes lipid droplets (LDs) number and/or size and that EGFP-2C 
fusions co-localise with lipid droplets and cause them to aggregate into large clusters 
(Khrid, unpublished). This manipulation of LDs during infection could suggest that these 
structures are involved in picornavirus replication. This opens up the possibility that drugs 
which target LDs could be useful for anti-picornavirus therapy and may have an effect on 
many different picornaviruses, as CAV9 and HPeV1 belong to genetically diverse 
picornavirus genera but both have some effect on LDs. Several drugs which target LDs 
have been developed, to combat obesity, excessive blood lipid levels etc., and a number of 
other widely used drugs also have an effect on lipid droplets (Daneschvar et al., 2016). 
These could potentially be repurposed for anti-picornavirus therapy. Therefore, the effects 
of various drugs reported to affect LDs/lipid metabolism were analysed. These include 
A922500 and betulinic acid which are diacylglycerol acyltransferase 1 (DGAT1) inhibitors, 
simvastatin which is a 3-hydroxy-3-methylglutaryl (HMG) coenzyme A reductase (HMG-
CoA reductase) inhibitor, C75 a fatty acid synthase (FASN) inhibitor.  Preliminary 
experiments were also performed on aspirin, a nonsteroidal anti-inflammatory drug 
(NSAID) and metformin a biguanide blood glucose lowering agent, both of which have 
been reported to affect LDs. 
4.2 Results 
4.2.1 Inhibition of CAV9 by A922500  
Although the role of DGAT1 (Figure 4.1) in some viral infections, like HCV (Crawford & 
Desselberger, 2017), has been confirmed, it has not been investigated in picornaviruses yet. 
Initially we tested the selective DGAT1 inhibitor A922500 (Han et al., 2003). This 
successfully decreased CAV9 growth in GMK cells (Figure 4.2) in a dose dependent 
manner and caused a significant decrease in viral PFU at 0.075 mM and a complete 
inhibition of virus beyond 0.125 mM in a direct plaque assay.  
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The A922500 effect was compared in two cell lines, GMK and A549 cells. Figure 4.3 
shows the higher antiviral activity started from lower concentrations (0.05 mM) to reach 
near zero percent at 0.075 mM in A549 compared to GMK cells in which complete 
inhibition did not occur until 0.125 mM. However, significant and higher toxicity than 
expected from the intensity of cell staining by crystal violet was revealed by an MTT 
viability assay (Figure 4.4). The reduction in cell viability (of less than 80%) started with 
lower applied concentration of 0.05 mM and became 70% at 0.075 mM (the concentration 
that caused a complete inhibition of virus-related PFU% in A549 cells. The decrease in 
viability percent was clearly evident at 0.125 and 0.15 mM causing serious loss of cell 


























Figure 4-1. Role of DGATs in the biosynthesis of triacylglycerol in the glycerol 
phosphate pathway and inhibition of DGAT1 by A922500.  
DGAT1 and DGAT2 enzymes (A) catalyse the final multi-steps of triacylglycerol synthesis 
by (B) linking fatty CoA to the hydroxy group of diacylglycerol at the surface of the ER. 
GPAT, glycerol-phosphate acyltransferase; AGPAT, acylglycerol-phosphate 
acyltransferase; PAP, phosphatidic acid phosphohydrolase; MGAT, monoacylglycerol 






Figure 4-2. Antiviral activity of A922500 against CAV9 in GMK cells.  
GMK monolayers in a 6 well plate were pre-treated with different concentrations of 
A922500 in 0.5 ml of culture medium for 30 minutes. 370 PFU (in 15 µl medium) of CAV9 
were added and the cells were incubated on a rocking platform for 45 minutes at room 
temperature. 2 ml of a 2:1 mixture of culture medium and 2% CMC were added, and the 
plate was incubated for 3 days in a humidified CO2 incubator at 37 ˚C. The medium was 
discarded, and cells were washed and stained with crystal violet solution. The number of 
plaques were counted and expressed as a % of the number seen in the mock-treated control. 









































Figure 4-3. Antiviral activity of A922500 against CAV9 in A549 cells.  
A549 monolayers in a 6 well plate were pre-treated with different concentrations of 
A922500 in 0.5 ml of culture medium for 30 minutes. 340 PFU (in 20 µl medium) of CAV9 
were added and the cells were incubated on a rocking platform for 45 minutes at room 
temperature. 2 ml of a 2:1 mixture of culture medium and 2% CMC were added, and the 
plate was incubated for 3 days in a humidified CO2 incubator at 37 ˚C. The medium was 
discarded, and cells were washed and stained with crystal violet solution. The number of 
plaques were counted and expressed as a % of the number seen in the mock-treated control. 









































Figure 4-4. Cytotoxic effect of different A922500 concentrations on A549 cells.  
A549 monolayers were pre-treated with different concentrations of A922500 in 0.5 ml of 
culture medium for 30 minutes and the cells were incubated on a rocking platform for 30 
minutes at room temperature. 1 ml of a 2:1 mixture of culture medium and 2% CMC were 
added, and the plate wasre incubated for 2 days in a humidified CO2 incubator at 37 ˚C. 
The medium was discarded, and cells were washed and 1 mg/ml of MTT in media were 
applied for 2 h, the resulting blue crystals were dissolved in DMSO and absorbance at λ550 
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4.2.2 Antiviral activity and toxicity of betulinic acid 
Betulinic acid (BA) inhibits DGAT1 and the sterol regulatory element-binding proteins 
(SREBP) (Quan et al., 2013), and has been shown to have potential against HIV infection 
(Cichewicz & Kouzi, 2004), although it is not clear if this is mediated through its effect on 
LDs.  
When a direct plaque assay was applied, BA visibly showed a strong toxic effect on cells, 
with large patches of detached cells. An indirect plaque assay was therefore used, which 
involves a shorter incubation of the cells (2 days, instead of 3 for direct plaque assay). By 
applying an indirect plaque assay (Figure 4.5), BA showed considerable but not complete 
antiviral activity, with continuous decrease in viral PFU, up to almost 80% inhibition at 
0.15 mM. A viability assay (Figure 4.6), under the same conditions as the first part of the 
indirect plaque assay, showed less than 15% loss of viable cells at concentrations of 0.05 
mM or less and lower than 30% loss at 0.1 mM. This suggests that BA does have inhibitory 
activity against CAV9. 
4.2.3 Anti CAV9 activity of simvastatin 
 Simvastatin (Figure 4.7) is a statin and an inhibitor of 3-hydroxy-3-methylglutaryl (HMG) 
coenzyme A reductase (HMG-CoA reductase). It is one of the widely prescribed anti-
hypercholesterolemic agents (Schachter, 2005). The antiviral activity of simvastatin and 
some other statins against HIV, HBV and HCV has been confirmed (Varma et al., 2011; 
Mehrbod et al., 2014; Del Campo et al., 2018). In our first experiments, simvastatin had no 
activity against CAV9 when tested to up to 0.04 mM. The concentration was therefore 
increased, and the drug was tested in both A549 and GMK cells (Figure 4.8), However, no 
antiviral activity was seen for up to 0.1 mM of simvastatin using GMK. In A549 cells, there 
was actually a dose dependent increase in viral infection after 0.06 mM, achieving a level 
of nearly 200% with a simvastatin concentration of 0.1 mM. Simvastatin therefore did not 
have an inhibitory effect on CAV9 replication. 
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Figure 4-5. Antiviral activity of betulinic acid against CAV9 by indirect plaque assay.  
GMK monolayers in a 6 well plate were pre-treated with different concentrations of 
betulinic acid in 0.5 ml of culture medium for 30 minutes. 370 PFU (in 15 µl medium) of 
CAV9 were added and the cells were incubated on a rocking platform for 45 minutes at 
room temperature. 2 ml of culture medium were added, and the plate was incubated for 48 
hours in a humidified CO2 incubator at 37 ˚C. then the plate was frozen and thawed 3 times 
without discarding the growth media. The amount of virus present in the samples was then 
measured using a normal direct plaque assay using 15 µl medium of 102 dilution of each 
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Figure 4-6. Cytotoxic effect of different betulinic acid concentrations on A549 cells.  
A549 monolayers were pre-treated with different concentrations of betulinic acid in 0.5 ml 
of culture medium for 30 minutes and the cells were incubated on a rocking platform for 
30 minutes at room temperature. 1 ml of a 2:1 mixture of culture medium and 2% CMC 
were added, and the plate was incubated for 2 days in a humidified CO2 incubator at 37 ˚C. 
The medium was discarded, and cells were washed and 1 mg/ml of MTT in media were 
applied for 2 h, the resulting blue crystals were dissolved in DMSO and absorbance at λ550 
























































Figure 4-7. Blocking of the mevalonate pathway in mammalian by statins.  
Statins inhibit HMG-CoA reductase which converts HMG-CoA to mevalonate blocking 










Figure 4-8. Antiviral activity of simvastatin against CAV9 in GMK and A549 cells.  
GMK (A) and A549 (B) monolayers in a 6 well plate were pre-treated with different 
concentrations of simvastatin in 0.5 ml of culture medium for 30 minutes. 370 PFU and 
340 PFU of CAV9 were added to GMK and A549 treated cells respectively and the cells 
were incubated on a rocking platform for 45 minutes at room temperature. 2 ml of a 2:1 
mixture of culture medium and 2% CMC were added, and the plate was incubated for 3 
days in a humidified CO2 incubator at 37 ˚C. The medium was discarded, and cells were 
washed and stained with crystal violet solution. The number of plaques were counted and 
expressed as a % of the number seen in the mock-treated control. Error bars show standard 
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4.2.4 Antiviral activity of C75 
C75 is fatty acid synthase (FAS) inhibitor (Figure 4.9) which has been investigated for 
several viruses including CBVs, rotavirus, West Nile virus and Epstein-Barr virus (Perera 
et al., 2012; Papageorgiou et al., 2015; Boldescu et al., 2017; Fernández-Oliva et al., 2019). 
C75 (Figure 4.10) showed only a slight dose dependent PFU inhibition after 0.05 mM using 
a direct plaque assay in GMK cells and caused up to a maximum of 20% inhibition at a 
higher concentration of 0.2 mM. However, cellular toxicity was revealed by the cell 
viability MTT assay (Figure 4-11), decreasing viability significantly by up to 60 % at 0.2 























Figure 4-9. Role of fatty acid synthase in the early stage synthesis of triacylglycerol.   
Fatty acid synthase catalyses the early stage synthesis of triacylglycerol by stimulating 
production of saturated fatty acids from malonyl CoA which then converted to unsaturated 
fatty acids to be transformed to monoacylglycerol which then becomes di and eventually 
triacylglycerol through SREBP-1c pathway. DHCR, 7-dehydrocholesterol reductase; FPP, 
farnesyl diphosphate; GPP, geranylgeranyl pyrophosphate synthase; CYP51, lanosterol 
14α-demethylase; G6PD, glucose-6-phosphate dehydrogenase; PGDH, 6-
phosphogluconate dehydrogenase; GPAT, glycerol-3-phosphate acyltransferase. Adapted 











Figure 4-10. Antiviral activity of C75 against CAV9 in GMK.  
GMK monolayers in a 6 well plate were pre-treated with different concentrations of C75 in 
0.5 ml of culture medium for 30 minutes. 370 PFU of CAV9 were added to GMK treated 
cells and the cells were incubated on a rocking platform for 45 minutes at room temperature. 
2 ml of a 2:1 mixture of culture medium and 2% CMC were added, and the plate was 
incubated for 3 days in a humidified CO2 incubator at 37 ˚C. The medium was discarded, 
and cells were washed and stained with crystal violet solution. The number of plaques were 
counted and expressed as a % of the number seen in the mock-treated control. Error bars 





































Figure 4-11. Cytotoxic effect of different C75 concentrations on A549 cells.  
A549 monolayers were pre-treated with different concentrations of C75 in 0.5 ml of culture 
medium for 30 minutes and the cells were incubated on a rocking platform for 30 minutes 
at room temperature. 1 ml of a 2:1 mixture of culture medium and 2% CMC were added, 
and the plate was incubated for 2 days in a humidified CO2 incubator at 37 ˚C. The medium 
was discarded, and cells were washed and 1 mg/ml of MTT in media were applied for 2 h, 
the resulting blue crystals were dissolved in DMSO and absorbance at λ550 was recorded. 
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4.2.5 Preliminary results of antiviral activity of aspirin and metformin 
Aspirin and metformin (Figure 4-12) are two of the most commonly used drugs. They have 
been used for long time with strong evidence of their tolerability. As they were investigated 
in the end of time of the current work, the results shown are preliminary and require 
confirmation particularly that of aspirin which was tested with CAV9 only once.  
Aspirin is a nonsteroidal anti-inflammatory drug (NSAID). The mechanism of action of 
aspirin (Figure 4.12) on LDs is yet unclear. However, the preliminary data of aspirin by 
one direct plaque assay on A549 cells (Figure 4.13) showed a significant and dose 
dependent viral PFU inhibition by up to 50%, 60%, 80% and 90% at concentrations of 
4mM, 6mM, 8mM and 10 mM, respectively with no serious toxicity on the same cells type 
when viability assay was set up (Figure 4.14) in which cell viability percent was around 
90% at aspirin concentration of 10 mM and 12 mM.  
Duplicate direct plaque assays of metformin (Figure 4.16) demonstrated a significant 
inhibition of viral PFU by approximately 50% at 5mM and 100% for up to 7 mM. The 










Figure 4-12. Principle mechanism of NSAIDs action.  
NSAIDs act by inhibiting cyclooxygenase (COX-1 and COX-2) enzymes and so decrease 
prostaglandins and thromboxane that are involved in inflammation and blood clotting 
respectively. Decrease in prostaglandin levels is associated with suppression of abnormal 
lipid metabolism in some pathological conditions PG: prostaglandin; TX: thromboxane 
(Peesa et al., 2016). 
146 
 
Figure 4-13. Antiviral activity of aspirin against CAV9 in A549 cells.  
A549 monolayers in a 6 well plate were pre-treated for one time with different 
concentrations of aspirin in 0.5 ml of culture medium for 30 minutes. 340 PFU (in 20 µl 
medium) of CAV9 were added and the cells were incubated on a rocking platform for 45 
minutes at room temperature. 2 ml of a 2:1 mixture of culture medium and 2% CMC were 
added, and the plate was incubated for 3 days in a humidified CO2 incubator at 37 ˚C. The 
medium was discarded, and cells were washed and stained with crystal violet solution. The 
number of plaques were counted and expressed as a % of the number seen in the mock-



































Figure 4-14. Cytotoxic effect of different aspirin concentrations on A549 cells.  
A549 monolayers were pre-treated with different concentrations of aspirin in 0.5 ml of 
culture medium for 30 minutes and the cells were incubated on a rocking platform for 30 
minutes at room temperature. 1 ml of a 2:1 mixture of culture medium and 2% CMC were 
added, and the plate was incubated for 2 days in a humidified CO2 incubator at 37 ˚C. The 
medium was discarded, and cells were washed and 1 mg/ml of MTT in media were applied 
for 2 h, the resulting blue crystals were dissolved in DMSO and absorbance at λ550 was 




























Figure 4-15. Proposed mechanism of action of metformin on glucose production and 
lipid metabolism.  
Metformin stimulates phosphorylation of AMPK which causes directly and by decreasing 
ACC activity inhibition of hepatic production of fatty acids and very low-density 
lipoprotein and increase hepatic fatty acid oxidation. Metformin also principally regulate 
glucose metabolism by decreasing hepatic glucose production and increasing muscle 
glucose transport. AMPK: AMP-activated protein kinase; SREBP-1: sterol regulatory 
element-binding protein 1; ACC: acetyl-CoA carboxylase; FA, fatty acid; FAS: fatty acid 




Figure 4-16. Antiviral activity of metformin against CAV9 in A549 cells.  
A549 monolayers in a 6 well plate were pre-treated with 3 concentrations of metformin in 
0.5 ml of culture medium for 30 minutes. 340 PFU (in 20 µl medium) of CAV9 were added 
and the cells were incubated on a rocking platform for 45 minutes at room temperature. 2 
ml of a 2:1 mixture of culture medium and 2% CMC were added, and the plate was 
incubated for 3 days in a humidified CO2 incubator at 37 ˚C. The medium was discarded, 
and cells were washed and stained with crystal violet solution. The number of plaques were 
counted and expressed as a % of the number seen in the mock-treated control. Error bars 
































Figure 4-17. Cytotoxic effect of different metformin concentrations on A549 cells.  
A549 monolayers were pre-treated with different concentrations of metformin in 0.5 ml of 
culture medium for 30 minutes and the cells were incubated on a rocking platform for 30 
minutes at room temperature. 1 ml of a 2:1 mixture of culture medium and 2% CMC were 
added, and the plate was incubated for 2 days in a humidified CO2 incubator at 37 ˚C. The 
medium was discarded, and cells were washed and 1 mg/ml of MTT in media were applied 
for 2 h, the resulting blue crystals were dissolved in DMSO and absorbance at λ550 was 
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4.2.6 Drug Resistant Mutants of CAV9 against A922500 
The antiviral activity of A922500 (Figure 4.2 and 4.3) was confirmed in the current work 
in 2 cell lines, GMK cells and A549 cells, although toxicity was evident with the cell 
viability assay. In general, the results suggest that A922500 could be a potential agent for 
enterovirus infections.  However, drug resistance is a large problem in the use of antivirus 
drugs. To investigate if mutations give resistance of CAV9 to A922500, the virus was 
propagated in the presence of increasing concentration of A922500. The emergence of 
resistant mutants occurred after 7 passages, when the virus was propagated at an A922500 
concentration of up to 0.1 mM using GMK cells. Mutated viruses were also seen at 
A922500 concentrations of 0.15 mM. Plaque assays of the original and mutant viruses 
showed a clear difference in the presence and absence of 0.125 mM A922500 (Figure 4.18). 
The figure shows that the original virus was completely inhibited by A922500 as no plaques 
were seen compared to the sample without A922500, while the drug resistant mutants 
showed several plaques in the presence and absence of A922500 although the plaques were 
smaller and fewer in number when the drug was added, suggesting that the selected virus 
was not fully resistant. 
To try to identify the basis of drug resistance, which may give information on how 
inhibition of LD formation affects CAV9 replication, we have started to sequence a drug 
resistant mutant. Time has only allowed so far the analysis of the region sequenced in the 
identification of fluoxetine/dibucaine resistant mutants i.e. a 225 amino acid part of the 
polyprotein including the C-terminal 188 amino acids of 2C and 27 amino acids from the 
N-terminus of 3A. This region contains no differences from the original CAV9. 
To study whether the resistant mutants of A922500 confer resistance to fluoxetine, the 
mutants were added to GMK cells pre-treated with 0.05 mM fluoxetine (its details are 
mentioned in chapter three). The results (Figure 4.19) did not show any cross resistant 
between A922500 and fluoxetine. Fluoxetine DRMs were also treated with A922500 
(Figure 4.20) and no viral growth were seen, and this confirms that there is no cross 
resistance between 2 drugs, and they seem to act by different mechanism of action. This is 
consistent with the absence of mutations associated with fluoxetine resistance in the 


















Figure 4-18. Drug resistant mutants of CAV9 against A922500.  
Some cells were treated with 125 µM of A922500. Equal volumes and dilutions of the 
original virus and 2 different mutated viruses were added to A922500 compound treated 
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Figure 4-19. The effect of fluoxetine on the selected A922500 CAV9 mutants. 
Some cells were treated with 125 µM of A922500. Equal volumes and dilutions of the 
original virus and 2 different mutated viruses were added to A922500 compound treated 
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Figure 4-20 The effect of A922500 on the selected fluoxetine CAV9 mutants.  
Some cells were treated with 125 µM of A922500. Equal volumes and dilutions of the 
original virus and 2 different mutated viruses of fluoxetine were added to A922500 
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4.3  Discussion 
4.3.1 Introduction 
Lipid droplets (LDs) are dynamic organelles which take part in many cellular processes 
including lipid homeostasis, signal transduction and membrane trafficking. Alteration of 
LD formation, size and composition can have significant effects on the biology of the cell 
and the development of metabolic and infectious diseases (Crawford & Desselberger, 
2017).  
4.3.2 Antiviral activity of DGAT1 inhibitors; A922500 and betulinic 
acid 
Diacylglycerol acyltransferase 1 (DGAT1) catalyses the final step in the biosynthesis of 
triglycerides (TG) (Figure 4.21) and it is essential for LD formation (Yen et al., 2008). 
DGAT1 has been reported as an important factor for the replication of several viruses such 
as hepatitis C (HCV). It was found that DGAT1 interacts with the HCV nucleocapsid core 
and is required for the trafficking of core to LD, where assembly occurs (Yen et al., 2008). 
Both betulinic acid (BA) (Crawford and Desselberger, 2017) and A922500, which is 
commercially available and more specific than BA (Han et al., 2015), are DGAT1 
inhibitors. A922500 has been widely used in different biological fields to study lipid 
processing through its ability to inhibit the last step of TG esterification (i.e. from DAG to 
TAG) (Han et al., 2015). In the current study, A922500 was investigated as an example of 
a DGAT1 inhibitor to block picornavirus replication. Our studies (Figures 4.2 and 4.3) 
showed dose dependent suppression of CAV9 replication to entirely inhibit growth at 
concentrations beyond 0.065 mM and 0.125 M on A549 and GMK cells, respectively. 
However, it showed significant toxicity by viability assay (using A549 cells) at higher 
concentrations of 0.125 and 0.15 mM (Figure 4.4). The optimal activity-toxicity 
relationship of A922500 should be considered to be 0.065 mM (Figure 4.3), because this 
was the concentration when A922500 caused complete inhibition of virus growth on A549 
cells with low effect in the viability-toxicity assay was carried out on A549 cells (Figure 
4.4). 
The antivirus activity of A922500 has not been previously explored for a picornavirus but 
has been observed in other RNA virus families. A922500 was found to decrease HCV levels 
(Flaviviridae family) by more than 50% intracellularly and a little less extracellularly 
determined from cell lysates or supernatants of infected cells, respectively (Boson et al., 
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2017). Rotavirus (Reoviridae) yields were also reduced in cells treated with A922500 or 
betulinic acid, or with the ACAT (Acyl-CoA:cholesterol acyltransferase) inhibitors CI-976 
or PHB (Crawford & Desselberger, 2017). In another study, replication of SA11 rotavirus 
were significantly reduced with A922500 and betulinic acid, as well as the FASN inhibitors 
cerulenin and C75 (Kim et al., 2012).  
DGAT1 and DGAT2 have the same enzymic action and are both integral ER proteins. They 
take part in the final step in TG biosynthesis by introducing an acyl group to diacylglycerol 
to form triacylglycerol. DGAT1 and DGAT2 are different in many important aspects. 
Firstly, DGAT1, and DGAT2 have no sequence homology and belong to distinct gene 
families. DGAT1 belongs to the DGAT1 gene family which includes also ACAT1 and 
CAT2 genes that encode acyl-CoA: cholesterol acyl transferase enzyme (Turchetto-Zolet 
et al., 2011). DGAT2 gene belongs to DGAT2 gene family which contains also MOGAT1, 
MOGAT2, MOGAT3, and wax alcohol acyltransferases. Both genes are expressed widely 
in adipose tissue, liver (the primary place of DGAT2) and intestine (which hosts most of 
DGAT1). Within the cell and in the ER, DGAT2 has been found to be in close proximity 
to SCDI (stearoyl-coenzyme A desaturase 1), FATP1 (fatty acid transport protein 1) and 
MOGAT2 while DGAT1 is not (Jin et al., 2014).  
The two DGATs might also have diverse roles regarding lipid metabolism. DGAT1 mutant 
mice in one experiment were healthy and unaffected by dietary -induced obesity and more 
sensitive to insulin or leptin activity. However, it was found to be a rare cause of human 
congenital diarrhoea. DGAT2 deficient mice showed very low TAG level which lead to 
death (Tschapalda et al., 2016).  
As DGAT1 and DGAT2 have the same enzymic activity, it is important here to mention 
that there is a significant functional difference between mutational absence of the gene (in 
DGAT1- mutant mice) and pharmacological inhibition of DGAT1. When it is 
pharmacologically inhibited, DGAT1 is still present, though inactive, and acts as a 
dominant negative mutant preventing DGAT2 from fully replacing it (Liu et al., 2013). The 
same may be true of inhibiting DGAT2, but it would be interesting to investigate later 
whether DGAT2 inhibitors have a similar or different antiviral activity from DGAT1. 
Moreover, although the selective DGAT1 inhibitor A922500 was significantly effective 
against CAV9, introduction of DGAT2 inhibitors might synergistically increase the 
antivirus effect. For instance, A922500 was found to inhibit HCV infection by preventing 
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assembly and virus release from cell, without having a significant effect on the earlier steps 
of viral replication. However, only 25% of intracellular triglycerides were inhibited at 20 
µM of A922500 and at the same concentration there was actually a 45% increase in LD 
number with no change in LD size or neutral lipid content. An inhibitor (10j), which acts 
on DGAT1 and DGAT2, caused both TG and LD suppression and also inhibition of early 
HCV replication, as well as assembly and release, probably because an interaction of the 
HCV non-structural protein NS5A and the LD protein TIP47 is needed for virus replication 
(Kim et al., 2018).  
A922500 is a potent orally active compound. It inhibits DGAT1 enzyme of both human 
(with IC50 7 nM) and mouse (with IC50 24 nM). Chronic use of A922500 causes a significant 
reduction of plasma and hepatic triglycerides without affecting DGAT2, ACAT1 or 
ACAT2 (Zhao et al., 2008). 
Inhibition of DGAT1 results in an increased amount of unesterified FAs and acyl-CoAs 
which could cause serious adverse effects on cells, including signalling dysfunction and 
death because of lipotoxicity. However, there is an evidence of increase of DGAT1 
inhibition-induced beta oxidation which is an important pathway of FAs breakdown 
(Villanueva et al., 2009). A922500 may also cause a significant weight reduction in a short 
time without affecting food intake (Zhao et al., 2008). Despite some adverse effects after 
longer term use, it is feasible that A922500 could be safe for the relatively short term of an 
antivirus treatment. 
Betulinic acid (BA) is a pentacyclic triterpene and a DGAT1 inhibitor, extracted different 
plant species. BA antitumor and especially antimelanoma activity have been investigated 
and it has also show analgesic, anti-inflammatory, antibacterial and antimalarial activity 
(Yogeeswari & Sriram, 2005). The inhibitory activity of betulinic acid and derivatives 
against HIV-1 and HIV2 replication in vitro has been reported (Marken & Munro, 2000; 
Kato & Ishiwa, 2015; Chinsembu, 2019). BA was also found to inhibit influenza A virus, 
rotavirus, HSV and more importantly in the context of the present work, echovirus 6 
(Pohjala et al., 2009; Phillips et al., 2018), indicating its wide range of antiviral activity 
including against picornaviruses. Both BA and betulonic acid and its derivatives showed 
better antiviral activity toward Semliki Forest virus (which is another positive-stranded 
RNA virus) compared with the parent compound betulin from which they were derived 
(Pohjala et al., 2009). 
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In the present work we showed that BA has some antiviral activity on CAV9 by indirect 
plaque assay. However, this was not complete even when cell toxicity became substantial 
(Figures 4.5 and 4.6). The toxic effect found could be due to an apoptotic effect that BA 













Figure 4-21. The role of DGAT enzymes in triacylglycerol and lipid droplet synthesis 
in the endoplasmic reticulum (ER).  
DGAT1 forms triacylglycerol which gives rise to lipid droplets, derived from ER, or 











4.3.3 Drug resistant mutants of A922500 
The resistance of viruses to drugs usually involves mutations that mediate modification of 
the target of the drug. As it was found in our lab that the 2C protein of CAV9 and also 
HPeV1 co-localise with lipid droplets, it was interesting to investigate if drug resistant 
mutants are produced against these drugs and if mutations localise to 2C. CAV9 virus was 
propagated in the presence of increasing concentration of A922500. We found some 
evidence for the presence of resistant mutants after 7 passages. The mutants then were 
treated with effective dose of fluoxetine and fluoxetine DRM were also treated with 
A922500 (Figures 4.18-4.20) to see if there is any cross resistance among them. The 
presence of cross resistance would strongly indicate the probability of having same target 
(same mechanism of antiviral activity). However, no virus grew the presence of these 
compounds. This means that A922500 might act in a different way from 
fluoxetine/dibucaine. The sequencing of the region of the A922500 2C protein which 
contains the fluoxetine mutation confirms this result, as no mutation was observed in the 
A922500 DRM. There was also no mutation in the rest of the C-terminal part of 2C or part 
of 3A. The mutation(s) could be in another part of 2C or 3A, but also in another viral 
structural or non-structural protein and this needs to be investigated by complete genome 
sequencing.       
4.3.4 Antiviral activity of C75 
Fatty acid synthase (FASN) is a primary lipogenic enzyme of the long chain fatty acids 
biosynthesis (Figure 4-22). The synthetic drug C75 is used to inhibit FAS. C75 inhibits 
both enoyl reductase domains and partially inhibits thioesterase and beta-ketoacyl synthase 
domains of FASN. Inhibition of these domains cause malonyl-CoA accumulation and 
mediate non-specific inhibition of viral replication (Rendina & Cheng, 2005; Chen et al., 
2014).  
Triglyceride-related biosynthetic intermediates have also been found to be down-regulated 
by C75 and these include mono- and di-acyl glycerol, in addition to phospholipids and 
sphingolipids. All these elements are used to produce LDs, the synthesis of which has been 
found to be inhibited by C75. C75 has been found through its effect on LDs to inhibit 
Dengue virus (Perera et al., 2012) as well as viruses from other diverse families, including  
rotavirus, West Nile virus, Epstein-Barr virus (EBV), Usutu virus  Feline herpesvirus , 
Yellow fever virus (YFV) and Kaposi's sarcoma-associated herpesvirus (KSHV) (Perera et 
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al., 2012; Boldescu et al., 2017; Fernández-Oliva et al., 2019). In the case of CBVs which 
are genetically very close to CAV9, C75 was found to decrease some harmful effects of 
CBV3 on the host cells. However, significant inhibition of the virus was only obtained 
when C75 was used in combination with 25-HC, an SREBP-1c (sterol regulatory element-
binding protein 1c) inhibitor (Papageorgiou et al., 2015). Consistent with this mentioned 
study, in the current study (Figure 4.10), C75 showed some but not significant antiviral 
activity even at higher concentration of 0.2 mM, which was accompanied by considerable 
toxicity on the cells. However, it likely to exhibit significant antiviral activity at lower 
concentration if it is combined with antipicornaviral compounds from other classes as it 
was found in the Papageorgiou et al study mentioned above.  
It is worth here mentioning that the description of C75 as a FASN inhibitor is not absolute. 
For example, although C75 was found to down-regulate several fatty acids such as stearic 
acid palmitic acid, it was also found to up-regulate others such as oleic acid (Perera et al., 
2012) and therefore, it is important to investigate the effects of these specific fatty acids on 









Figure 4-22. Multi-step biosynthesis process of lipid droplets. 
C75 blocks fatty acid synthase (FASN) which catalyses the conversion of acetyl-CoA and 
malonyl-CoA to fatty acids and acting earlier than A922500 and betulinic which act on the 













4.3.5 Inactivity of the HMG-CoA reductase inhibitor, simvastatin  
Simvastatin belongs to the statin family which is considered to be a competitive inhibitor 
of HMG-CoA reductase (hydroxyl methylglutaryl-coenzyme A reductase), a rate limiting 
enzyme in cholesterol biosynthesis (Schachter, 2005). Mechanism of statin action also 
include blockage of downstream mediators, isoprenoids including farnesyl pyrophosphate 
(FPP) and geranylgeranylpyrophosphate (GGPP) which are important for modification of 
some membrane proteins and for replication of some viruses (Blanco-Colio et al., 2003; 
Sun & Whittaker, 2003).  
Statins have been found in vitro to inhibit a variety of viruses including poliovirus, HCV, 
HIV, influenza virus, dengue virus, cytomegalovirus and RSV (Gower & Graham, 2001; 
del Real et al., 2004; Potena et al., 2004; Liu et al., 2006; Martínez-Gutierrez et al., 2011).  
Cholesterol-enriched lipid domains have been shown to be related to enterovirus replication 
and cholesterol inhibition with statins is associated with decreased viral replication 
(Ilnytska et al., 2013). 
Simvastatin could thus have antiviral activity. However, both animal and human studies 
have remained inconclusive about the effectiveness of statins for different virus infections. 
Lovastatin was proposed by a study as an antiviral agent to control RSV replication and the 
results were confirmed by a work involved simvastatin which showed significant protection 
on LPS-induced lung vascular inflammation (Jacobson et al., 2005). Atorvastatin was also 
tested on 6 mice and there were reduced mortality rates and lung virus titers. Some 
protection against influenza-related symptoms and pneumonia, and alleviation of some 
coxsackievirus-related diseases has been reported in patients treated long-term with statins 
(Gamble et al., 1996). However, several studies have concluded there is no benefit of 
simvastatin treatment for influenza or acute respiratory infections (Mehrbod et al., 2014; 
Debing et al., 2015).  
Simvastatin in the current work (Figure 4.8) had no antiviral activity in GMK cells and it 
even stimulated virus growth in A549 cells. Simvastatin is used to decrease cholesterol 
biosynthesis. However, it also modestly increases fatty acid (FA) synthesis. This is because 
as an inhibitor of HMG-CoA reductase, it can block cholesterol synthesis, and this in turn 
increase SREBP production, and thus stimulates FA synthesis (Tang et al., 2011). This in 
turn may stimulate triglyceride synthesis which provides materials needed for LD synthesis, 
which could be the basis of the enhancement of CAV9 replication seen.   
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Statins in general are well tolerated with few adverse effects and have been used for long 
time, in spite of very recently reported side effects including HMG-CoA reductase 
pathway-associated mitochondrial toxicity and calcium signalling and also muscle 
symptoms (Ward et al., 2019). Therefore, simvastatin would have been a good, repurposed 
antiviral candidate had it shown significant antiviral activity. 
4.3.6 Cell specific type 
In terms of cell specific effects, the effects of cell type on the requirements of virus 
replication and effective drug concentration has observed previously. It has been reported 
that lovastatin inhibited dengue virus assembly to a greater extent in HMEC than in Vero 
cells (Martínez-Gutierrez et al., 2011). Both A922500 and simvastatin (Figures 4.2, 4.3, 
and 4.8) showed significantly different effects when the cell line was changed. This could 
be due to differences in the levels of cell structures, proteins or other components needed 
for CAV9 replication.  Cell type-specific effects may strengthen or weaken the case for the 
use of a particular drug, depending on the relevance of a cell type in virus infection. This 
needs to be investigated further using different cell lines, primary cells rather than the 
permanent cell lines used in this study (which may be very different from normal cells), or 
in animals, before the use of a drug is judged feasible or not.   
4.3.7 Preliminary results on aspirin and metformin 
4.3.7.1 Effects of aspirin on CAV9 
Aspirin is a trade name of acetylsalicylic acid and it is a prototype of non-steroidal anti-
inflammatory drugs (NSAIDs). Like other nonselective NSAIDs aspirin through its acetyl 
group irreversibly inactivates cyclooxygenase 1 and 2 (COX-1 and -2), although inhibition 
of COX-2 is much slower than COX-1.  COX-2 is a rate-limiting enzyme in eicosanoids 
formation steps producing prostaglandin (PG) and other downstream eicosanoid products 
from arachidonic acid (AA) (Brock et al., 1999; Mekaj et al., 2015). Aspirin also decreases 
oxidative phosphorylation in mitochondria and stimulates NO radicals that decrease 
inflammation in addition to modulation of transcription and signalling of NF-kB which in 
turn stimulates expression of inflammation-related genes such as interleukin-1 interleukin-
6 and adhesion molecules in cells and in viruses (Somasundaram et al., 2000; Paul-Clark 
et al., 2004; McCarty & Block, 2006). In platelets, aspirin inhibits thromboxane A2 
formation and decreases platelet aggregation. Other main uses of aspirin along with other 
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NSAIDs include mild to moderate pains, fever and various inflammatory reactions (Mekaj 
et al., 2015). NSAIDs are also suggested to have antiproliferative and anticarcinogenic 
properties reported from epidemiological, experimental and clinical findings (but recently 
has been reported that NSAIDs prevent but might trigger cancer formation) (Pannunzio & 
Coluccia, 2018; Wong, 2019).  
Lipid droplets have been found to host COX-2 and PGs. A significant correlation in 
cancerous colonic cells were observed between LDs and levels of PGE2 which was found 
to be synthesized in LDs. COX-2 and PGs have been also observed within LDs in some 
blood cells such as neutrophils, eosinophils and mast cells and in adenocarcinoma cells as 
well. Treatment of cells with aspirin has been reported to significantly block LDs and PGE2 
and these effects were similar to that of C75 on these parameters. However, in COX2-free 
cells, biosynthesis of LDs was found to be normal and significantly inhibited when aspirin 
was applied. Therefore, the inhibitory effects of aspirin on LDs need to be investigated and 
could be independent or only partially dependent on COX-2, rather than absolutely 
dependent (Weinstein, 1980; Triggiani et al., 1995; Accioly et al., 2008; Hartigh et al., 
2010).  
Primary data on aspirin from a single experiment using a direct plaque assay (Figure 4.13) 
and a cell viability assay (Figure 4.14) showed that aspirin significantly inhibited virus 
replication and did not inhibit cell viability significantly, giving encouraging data for future 
work.     
An effect of aspirin on CAV9 replication is not unexpected. Although results regarding 
aspirin are sometimes contradictory for some viruses, in general they often suggest 
considerable antiviral activity. In one study, it had no significant antiviral activity on 
influenza A virus and only a weak effect on rhinoviruses (Crump et al., 2015). CBV3 
(closely related to CAV9) was found to increase in titre and interferon response was 
decreased in infected mice treated with aspirin and also there was an increase in 
pathological changes and deaths (Rezkalla et al., 1986; Zavagno et al., 1987). In contrast, 
the effectiveness of aspirin along other NSAIDs against influenza and also EMCV, Sindbis 
virus and Newcastle disease virus were reported and a high concentration of aspirin also 
inhibited varicella-zoster virus (Inglot, 1969; Primache et al., 1998).  In a study conducted 
at the time of the current work, aspirin in a concentration of 1 mM was reported to cause 
about 71% and 72% inhibition in influenza H1N1 and CAV9 respectively, but no clear 
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activity towards HSV-1 or adenovirus C subtype 5.  Aspirin also showed a variable but 
significant inhibition on several HRV serotypes: HRV-1A and HRV-2 were inhibited by 
48% and 66% respectively while HRV-14 and HRV-39 were inhibited by up to 95% 
(Glatthaar-Saalmüller et al., 2017). Aspirin and indomethacin also found to inhibit 
cytomegalovirus (CMV) and its induced ROS.  Aspirin effects are reported to be due to 
COX-2 inhibition activity, antioxidant and direct ROS scavenging properties, infection-
related NF-kB inhibition and reduction of H2O2 capacity to transactivate ROS mediators 
(Speir et al., 1998). These results, including our own preliminary data, indicate that aspirin 
might have a wide spectrum of activity as it inhibits viruses from different RNA families 
including Picornaviridae, but it also has specific antiviral activity as it was not active 
against some tested DNA viruses such as HSV-1 and adenovirus. The antiviral activities of 
aspirin usually appear at a millimolar rather than micromolar concentration range which 
might be argued to be high (and toxic) to see antiviral effect in human bodies. Although 
effective aspirin concentrations did not show significant toxic effects on cells in the current 
work, there are always differences between controlled tissue culture conditions and 
conditions in vivo. In this regard, it was found that lower effective concentrations were 
required for virus inhibition in infected mice than their equivalent for cell culture when 
aspirin was administered with drinking water (Mazur et al., 2007).  
Viral infection including that of picornavirus is often accompanied by fever headache and 
minor pains. If the antiviral activity of aspirin is confirmed and then clinically applied, 
aspirin would have dual effect as antiviral and as analgesic, antipyretic and anti-
inflammatory. However, antiviral effect is expected to need higher concentration than 
usually used for pain relief. Aspirin like other NSAIDs is widely used and well-tolerated. 
It has also showed a very little tendency to cause viral resistance. One of the most common 
side effects of aspirin is gastric ulcer and the predisposition to peptic ulcer which usually 
occurs in patients with gastrointestinal problems and it is minimised when the drug is 
administered with, or after, meals despite some evidence that taking NSAIDs with or after 
food might result in less pain relief and shorter lasting pain relief, and this reduced effect 
may also be true of its antivirus activity (Moore et al., 2015). 
4.3.7.2 Inhibitory effect of metformin on CAV9 
Metformin is an oral biguanide and a first line treatment for type 2 diabetes. The principle 
of its antidiabetic action includes suppression of hepatic gluconeogenesis and lower of 
167 
 
glucose output. It also improves insulin resistance peripherally by enhancing cellular 
glucose uptake resulting in decrease in circular blood glucose (Rena et al., 2017). These 
effects are mediated mainly through AMP activated protein kinase (AMPK) which 
stimulates the transport of glucose from the blood particularly into muscle cells. One of the 
additional potential advantages of this mechanism is to improve lipid profile and metformin 
has been found to significantly inhibit cholesterol content and decrease different cholesterol 
regulatory genes, as an AMPK is known to be a main controller of ACC activity which 
regulates fatty acid metabolism (Rena et al., 2017). 
Preliminary plaque reduction analysis (Figure 4.16) and viability assay (4.17) revealed a 
significant antiviral activity and an insignificant cellular toxicity of metformin. This drug 
has already been used for many years with strong evidence of being safe. A correlation 
between viral infection and insulin-glucose status have been reported for some viruses. For 
instance, infection with HCV was found to affect glucose metabolism, resulting in insulin 
resistance and predisposing to diabetes. Recovery from HCV infection improved glucose 
control and insulin resistance. Insulin resistance in turn was reported to impair anti-HCV 
response, which was improved when metformin added to peg/interferon and ribavirin. It 
was also found that some HCV proteins induced insulin resistance by damaging insulin-
receptor substrates (Romero-Gómez et al., 2009). In type 2 diabetic-HCV-cirrhosis patients 
who were treated with metformin notable reduction in liver-related carcinoma, 
transplantation and death was seen. These effects were mediated by inhibition of virus cis-
acting elements and down-regulation of viral transcription (Chen et al., 2018). Like HCV, 
HBV chronic infection has been also associated with insulin resistance. Metformin has been 
found to decrease HBV replication and viral antigen (HBsAg) expression and improve 
antiviral activity of interferon Alpha-2b and lamivudine when used in combination (Xun et 
al., 2014). Metformin and other AMPK stimulating drugs have been shown to suppress 
virus infection including HIV and HCMV. In contrast, these viruses have also been shown 
to block AMPK activity (Moser et al., 2012). In dengue virus, re-localisation of both 
AMPK and HMG-CoA was altered along with replication complex when the cells were 
treated with metformin and lovastatin (Soto-Acosta et al., 2017). EVs, particularly CBVs, 
as well as rotavirus, rubella virus and mumps virus are also associated with diabetes (Filippi 
& Von Herrath, 2008). Therefore, metformin could be a potential approach for treating 
infections with these viruses, particularly in the individuals with a genetic-predisposition 
to development of type 1 diabetes.   
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 To the best of our current knowledge, the effect of metformin has not been investigated on 
any of picornavirus members. Therefore, the further investigation of antiviral activity of 
metformin on CAV9 virus would be very novel and it would be very interesting to 
investigate its effects on other picornavirus and mechanism of its action on each one. 
Metformin is well tolerable with only some minor GI side effects that are in general 
transient, making it an excellent repurposed drug (Mccreight et al., 2016; Krishnasamy & 
Abell, 2018). 
Both CAV9 and HPeV1 manipulates LD levels and morphology during infection, we have 
investigated several drugs which interfere with LD formation. The results obtained indicate 
that the DGAT1 inhibitor A922500 could be a useful drug for treating infections by CAV9 
and presumably other related viruses. The commonly used drugs aspirin and metformin 


















































5.1 Introduction  
Natural products and their analogues contributed to about 80% of all drug production by 
1990 and after there was a continuous decline on drug discovery from natural sources (Li 
& Vederas, 2009). Nonetheless, natural products remain a key potential source of new 
therapeutics and the work described in this chapter highlights naturally-occurring 
compounds sources as potential antiviral agents.  
The Ribes genus from the family Grossulariaceae involves several species including 
redcurrant (Ribes rubrum) and black currant (Ribes nigrum) (Schulthes and Donoghue, 
2004, Haasbach et al., 2014, Saleem et al., 2016). According to Haasbach et al, a 
blackcurrant extract caused inhibition of influenza virus replication. It has been reported 
that extracts of some berries such as blackcurrant have significant antiviral activity (Ikuta 
et al., 2013, Tiralongo et al., 2016). Cranberry (Vaccium macrocarpon), an unrelated berry, 
has also been estimated to be effective against influenza virus (Weiss et al., 2005). 
Redcurrant could be good source of therapeutic compounds, as most colourful fruits are 
known to be rich in phenolic compounds including carotenoids, flavonoids and anthocyanin 
(Sass-Kiss et al., 2005), and some phenolic derivatives have been shown to have antiviral 
activity (Wang et al., 2014). 
Microalgae are a rich source of antimicrobial compounds with antiviral, antibacterial and 
antifungal properties. They have a high degree of diversity and the ability to produce 
secondary metabolites in response to different environmental conditions, in addition to a 
rapid rate of growth (they are capable of doubling every few h. during their peak growth 
period) and have a potential antioxidant features (Falaise et al., 2016; Khan et al., 2018). 
In the work described in this chapter, extracts from redcurrant (RC) and various microalgae 
(MA) were investigated in addition to quercetin which could be one consistent of RC 
extracts. As there is great evidence of antioxidant (AO) and fluorescence properties of 
natural products and their usefulness in antiviral approaches, some of investigated extracts 






5.2.1 Comparison of the effects of RC samples from different 
extraction methods on the CAV9 viral infection  
An RC extract was initially made by boiling the fruit with water and filtering and this gave 
promising results. To optimize the extraction methods for antiviral activity, RC was then 
extracted by 3 other procedures. These included extraction in water at room temperature 
(Rt), sonication-based extraction and solid-liquid phase extraction of the solid filtered off 
the room temperature residue, boiled residue and sonication residue. Interestingly, the 
methods of extraction yielded different antiviral efficacy profiles. The results showed that 
the extracted samples of the boiled RC crude materials caused significant inhibition at 4 
mg/ml and almost complete inhibition to the viral growth when higher concentrations were 
used (Figure 5.1). The RC-Rt extract caused complete viral inhibition only at a 
concentration of 16 mg/ml and the sonicated RC extract led to some inhibition of virus at a 
concentration of 16 mg/ml. RC-Rt extract was visibly more toxic on cells than others 
followed by the sonicated sample. The boiled extract showed best antiviral activity and 
least cytotoxicity profiles and therefore was chosen among other extracts for further 
investigations. 
5.2.2 Evaluation of the effects of RC crude extracts on CAV9 and 
HPeV1 viral infection 
The effect of the boiled RC extract on CAV9 infection was then performed more 
quantitatively and in addition, the effect on a diverse picornavirus, HPeV1 (Parechovirus 
genus), was also assessed. The results are shown in figures 5.2 and 5.3. A range of 
concentrations between 2-8 mg/ml and 2-16 mg/ml of the boiled RC samples were 
investigated on CAV9 and HPeV1 in GMK and HT29 cell lines, respectively. The results 
showed dose-dependent inhibition of RC extracts on the infection caused by both CAV9 
and HPeV1viruses. The concentration of RC extract that conferred 50% of CAV9 infection 
inhibition was approximately around 1.8 mg/ml. Also, the total inhibition effect was 
achieved with 8 mg/ml. It required 6 mg/ml of RC extract to cause 50% inhibition of HPeV1 
infection. The complete inhibition of infected cells by HPeV1 was accomplished with 16 
mg/ml, double the concentration acquired for the infection with CAV9 virus. However, the 




5.2.3 The concentration dependent inhibitory effect of the boiled RC 
extract on different strains of Coxsackie virus B3 
CBV3 is closely related to CAV9 but differs in receptor use. To further investigate the 
boiled RC extract, three CVB3 isolates, P55 (2), P6LK12 and P4 (75) were used (Figure 
5.4). The boiled extract sample of RC exhibited a clear positive response with a range of 
concentrations applied. Both P6LK12 and P4 (75) were inhibited by over 95% at the 4 
mg/ml concentration, while P55 (2) virus was completely inhibited at this concentration. 
Surprisingly, when the concentrations of RC sample were increased, P55 (2) virus showed 
some infection. However, the overall results showed that boiled RC extract is significantly 
active against CVB3 strains. 
5.2.4 Effect of RC extract on fluoxetine drug resistant mutants 
To further investigate the basis of the inhibition of CAV9 replication by the RC extract the 
fluoxetine DRMs were used (Figure 5.5). The RC extract caused  a complete inhibition of 
original CAV9 and DRMs,  which means that RC seems to act by a mechanism different 
from that of fluoxetine. This also suggests that combination therapy with the active RC 
component and fluoxetine could be useful to overcome the effects of DRM formation. 
5.2.5 Effect of the RC extract on the CAV9 virus particle  
To establish whether the ability of the RC extract to inhibit CAV9 infection is due to a 
direct effect on the virus particle, the virus was pre-treated for intervals of time between 20 
minutes to 100 minutes in Eppendorf tube before applying to cells (Figure 5.6). The extract 
showed no significant inhibition differences on CAV9 infection after incubation for the 
above periods of time, compared to CAV9 infection without CAV9 treatment. Therefore, 
the antivirus effect of the RC extract does not seem to be due to a direct effect on the particle 
and is probably mediated intracellularly.  
5.2.6 The effects of RC addition on replication during time-course of 
CAV9 pre-infection  
Antiviral agents may interfere with viral replication at early and/or late stages of infection 
of the cell e.g. early during entry/uncoating/translation/RNA replication or later during 
assembly/ maturation/exit. Cells were treated with RC extract (8 mg/ml) at different time 
points, after infecting cells with CAV9. Also, cells were pre-treated with RC extract before 
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the addition of virus for comparison. According to the results shown (Figure 5.7), there was 
no viral growth when cells pre-treated with RC then inoculated with CAV9. The same is 
true when extract was added 2 and 4 hours after infection. From the 6 hours time point, 
however, some virus growth was observed and addition of the extract 10 hours after 
infection gave a result similar to no RC addition. As the infectious cycle of CAV9 is found 
in our laboratory typically to take 12 hours, the results suggest that RC extract might have 
an effect on early stages of viral replication, but not immediately post-entry. Probably, 







































Figure 5-1. Inhibition of CAV9 infection by different crude RC extracts.  
GMK monolayers in a 6 well plate were pre-treated with different concentrations of RC 
extract (4, 8, 12 and 16 mg/ml) in 0.5 ml of culture medium for 30 minutes. 370 PFU/ml of 
CAV9 were added and the cells were incubated on a rocking platform for 45 minutes at 
room temperature. 2 ml of a 2:1 mixture of culture medium and 2% CMC were added, and 
the plate was incubated for 3 days in a humidified CO2 incubator at 37 ˚C. The media was 
discarded, and cells were washed and stained with crystal violet solution C: Cells only, V: 















Figure 5-2. Inhibition of CAV9 infection by RC boiled extract.  
GMK monolayers in 7 25 cm2 (75 ml) flasks were pre-treated with a range of concentrations 
of boiled RC extract (0-8 mg/ml) in half ml of culture medium for 30 minutes. 370 PFU/ml 
of CAV9 were added and the cells were incubated on a rocking platform for 45 minutes at 
room temperature. 4 ml of a 2:1 mixture of culture medium and 2% CMC were added, and 
the flasks were incubated for 3 days in a humidified CO2 incubator at 37 ̊ C. The media was 
discarded, and cells were washed and stained with crystal violet solution and the number 









































Figure 5-3. Inhibition of HPeV1 infection by RC boiled extract. 
HT-29 cells monolayers in 6 well plate were pre-treated with a range of concentrations of 
boiled RC extract (0 - 16 mg/ml) in half ml of culture medium for 30 minutes. 370 PFU/ml 
of HPeV1 were added and the cells were incubated on a rocking platform for 45 minutes at 
room temperature. 2 ml of a 2:1 mixture of culture medium and 2% CMC were added, and 
the plate was incubated for 3 days in a humidified CO2 incubator at 37 ˚C. The media was 
discarded, and cells were washed and stained with crystal violet solution and the number 












































Figure 5-4. Inhibition of 3 different CBV3 isolates by boiled RC extract. 
GMK monolayers in 6 well plate were pre-treated with a range of concentrations of RC 
extract (0 - 12 mg/ml) in 0.5 ml of culture medium for 30 minutes. 370 PFU/ml of three 
types of virus (P55 (2), P6LK12 and P4 (75) were added and the cells were incubated on a 
rocking platform for 45 minutes at room temperature. 2 ml of a 2:1 mixture of culture 
medium and 2% CMC were added, and the plate was incubated for 3 days in a humidified 
CO2 incubator at 37 ˚C. The media was discarded, and cells were washed and stained with 
crystal violet solution and the number of plaques were counted. CTRL 0: Cells only without 
























































Figure 5-5. The effect of RC on CAV9 fluoxetine-resistant mutants in GMK cells. 
Some of cells were pre-treated with RC 2 mg/ml, 4 mg/ml and 6 mg/l (top row) and others 
with fluoxetine 0.05 mM (bottom row) before adding the virus, then direct plaque assay 









Mutated virus+RC 4, 6 and 8 mg/ml 
 








 Figure 5-6. Analysis of the effect on infection of pre-treating CAV9 particles with 
boiled RC extract. 
 Each column represents a duplicate of the cells GMK monolayers in 24 well plate. CAV9 
(370 PFU/ml) was pre-treated with RC boiled extract for the specific time (20 minutes to 
100 minutes, shown in yellow) in a tube before addition to the cells. The cells were 
incubated on a rocking platform for 45 minutes at room temperature. 2 ml of a 2:1 mixture 
of culture medium and 2% CMC were added, and the plate were incubated for 3 days in a 
humidified CO2 incubator at 37 ˚C. The media was discarded, and cells were washed and 
stained with crystal violet solution and the number of plaques were counted. CTRL: Cells 



























Figure 5-7. Comparison of the effects on infection of RC pre-treatment and addition 
of RC extract at different times after infection.  
Some cells (Bef) were pre-treated with RC extract for 30 minutes. All the cells were then 
infected with 370 PFU/ml of CAV9 before treatment with 8 mg/ml of RC at the times 
shown. The cells were incubated on a rocking platform for 45 minutes at room temperature. 
2.0 ml of a 2:1 mixture of culture medium and 2% CMC were added, and the plate incubated 
for 3 days in a humidified CO2 incubator at 37 ˚C, media was discarded, and cells were 
washed, and stained with crystal violet solution. C in top row, cells [GMK] only, bottom 
row cells plus CAV9); V, Virus; h; hour. Bef; pre-treated with RC extract for 30 minutes 






































5.2.7 Evaluation of the effects for the fractionated boiled RC on CAV9 
viral infection/ plaque assay 
To start to identify the active component(s) present in the boiled RC extract, fractionation 
was performed using automated flash chromatography as described in methods. Various 
fractions showed different effects on CAV9 using plaque assays (Figure 5.8 and Figure 
5.9). The F3 fraction (Figure 5.8) had the most activity as no virus growth was seen even 
at lowest concentration of 0.25 mg/ml.  F2 and F5 also had potent antiviral effects. F1 
showed more moderate dose-dependent activity. Both F4 and F6 had no inhibitory effect 
on CAV9, in fact virus growth seemed to be enhanced slightly by F4 reaching up to 105% 
and substantially by F6 being 140% at 0.5 mg/ml, although there was a reduction of 
stimulation at higher concentrations. The antiviral activity of RC fractions in Figure 5.8 
was estimated for once due to fractions deficiency.   
To investigate the dose dependence of the highly active fractions, F2, F3 and F5 more fully, 
lower concentrations were used (Figure 5.9). This showed dose dependence and effective 
inhibition for each one, although none reached complete inhibition. F1 was used at the same 
concentration range as in Figure 5.8 and showed the same results. Increasing the 
concentration of F4 above that used previously achieved total inhibition of the infection. 
Increasing the concentration of the fractions F6 up to 2.0 mg/ml did not reduce viral growth 
further. The results suggest that there may be more than one active component present in 
the RC extract, as several fractions have an antivirus effect, or it may be that the imperfect 










Figure 5-8. Effects of RC fractions on CAV9 infection.  
Applying the direct plaque assay, GMK cells were infected with 370 PFU of CAV9 after 
pre-treatment with 4 concentrations of each RC fraction. Cells were incubated for 3 days 
in a humidified CO2 incubator at 37 ˚C, the media was discarded and cells were washed, 
and stained with crystal violet solution. Plaques were counted and the number plotted as a 





































Figure 5-9. Effects of higher or lower concentrations of RC fractions against CAV9.  
Applying a direct plaque assay, GMK cells were infected with 370 PFU of CAV9 after pre-
treatment with higher or lower concentrations of boiled RC extracts (from F1 to F6) than 
those used in Figure 5.8. Cells then incubated for 3 days in a humidified CO2 incubator at 
37 ˚C, the media was discarded and cells were washed, and stained with crystal violet 
solution. Plaques were counted and the number plotted as a % of the number seen in the 

































































































































































5.2.8 Investigation of the effect of light on the activity of photosensitive 
constituents of RC extracts 
The extracts of RC samples contain constituents that absorb light at different wavelengths 
and are activated to emit fluorescence at 310 nm and in the visible range at 615 nm (data 
not shown). They absorb at visible wavelength 620, 520, and 450 nm, and at 220, 280 nm 
in the uv range. Some fractions contain entities with no photosensitivity properties. It is 
known that fruit in general have many chemicals which act as antioxidant agents, 
nevertheless the absorbance properties suggest that some photosensitive constituents could 
be present and these may produce reactive oxygen species (ROS) or damage cells/viruses 
in other ways. Therefore, RC photosensitive constituents were exploited to assess the 
inhibition of viral growth. RC toxicity was examined first using a cell viability assay in 24-
well plates (Figure 5.10) and the associated cell viability ranged between 80%-90% at all 
concentrations used.     
5.2.9 The effect of different RC extracts on infection measured using 
MTT assays 
The effect of RC extracts on cell viability and the inhibition of the viral activity in the dark 
were evaluated further using MTT assay. The experiment was carried out to compare the 
toxicity and the antiviral activity of different crude RC extracts without using plaque assays 
(Figure 5.11). All the extracts showed some toxicity, but the sample of boiled RC extract 
was the least toxic (Figure 5.11, A). Although, it showed 30% toxicity on the cells alone, 
nevertheless, the RC boiled extract increased the viability of the infected cells to nearly 
100% compared to the control (cells without viruses) at the given concentration of 4 mg/ml. 
Both samples of the room temperature extraction (RC-Rt) and RC sonicated extraction 
samples (RC-SS) did not show any clear inhibition to the viral growth compared to the 
control with the virus only. Also, the solid-liquid phase extracted samples (RC-SBo2) 
showed only a slight inhibition of the viral infection of around 10%. The sample RC-Rt had 
the highest toxicity effect on the cells alone with approximately 75% in comparison to the 
control, while RC-SS extract and RC-Boi2) samples caused approximately 42% and 58% 
toxicity to the cells. Also, six fractions of RC sonicated extracts were tested and evaluated 
with the same method as the crude extracts (Figure 5.11B). The fraction RC1 was the only 
fraction that showed an improvement in cell viability in infected cells.  
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5.2.10 Effect of light exposure and RC extracts on the viral infection 
and cell viability  
To determine the phototoxic effects of the crude extracts (the fluorescent constituents) on 
the virus activities indirectly, the confluent cells (GMK) in 96-well plate were exposed to 
either blue light (BL) or red light (RL) for 20 minutes after they were pre-treated with 
different RC extracts and then infected with CAV9 virus. This light exposure experiment 
was carried out on the same day and under the same conditions as the dark experiment. It 
was clearly seen that the antiviral inactivation effect of boiled RC sample was increased 
remarkably with BL, exceeding 130% of control (Figure 5.12 A). In addition, no cell 
toxicity was recorded upon incubation with the sonicated RC samples alone and exposure 
to BL, as compared to the control. However, there was no noticeable improvement with BL 
regarding other extracts in terms of toxicity or antiviral activity. The effect of the fractions 
of sonicated RC fractions (RC1– RC6) and the blue light were also investigated, (Figure 
5.12 B). They impacted no remarkable viability improvement and the maximum viability 
increase was not more than 16% with RC5.  
The infected cells pre-treated with the crude RC-Bo1 extract and exposed to RL had 
approximately 50 % increase in viability compared to the viability of infected cells alone. 
The other crude extracts and fractions gave little benefit (Figure 5.13).  
In summary, there was some potential benefit of light treatment on cell viability in non-










Figure 5-10. Cytotoxic effect of different boiled RC concentrations on A549 cells.  
A549 monolayers in 24-well plate were pre-treated with different concentrations of RC in 
0.5 ml of culture medium for 30 minutes and the cells were incubated on a rocking platform 
for 30 minutes at room temperature. 1 ml of a 2:1 mixture of culture medium and 2% CMC 
were added, and the plate was incubated for 2 days in a humidified CO2 incubator at 37 ˚C. 
The medium was discarded, and cells were washed and 1 mg/ml of MTT in media were 
applied for 2 h, the resulting blue crystals were dissolved in DMSO and absorbance at λ550 

























Figure 5-11. The effect of RC extracts and sonicated fraction samples on GMK cells 
with/ without CAV9 in the dark.  
A: RC crude extracts (conc. 4 mg/ml). Cells were incubated with crude RC extracts 
produced by different extraction methods (blue bars), or CAV9 (C+V), or with RC extracts 
plus CAV9 and incubated for 3 days at 37 ˚C after a plate was wrapped with aluminium 
foil. CTRL, control with cells only, B: The fractionated samples of sonicated RC extract 
(RC1 to RC6, conc. 0.25 mg/ml). In both cases media were discarded and MTT in media 
were applied for 2 h, the resulting blue crystals were dissolved in DMSO and absorbance 
at λ550 was recorded. The cell’s viabilities were calculated as percentages of the control of 
cells alone (green bar). RC-Bo1: Boiled extract. RC-Rt: Room temperature extract. RC SS: 













































Figure 5-12. The effect of RC extracts and sonicated fraction samples on GMK cells 
with/ without CAV9 after exposure to blue light (BL) for 20 minutes. RC crude 
extracts (conc. 4 mg/ml). 
A: Cells were incubated with crude RC extracts (conc. 4 mg/ml) produced by different 
extraction methods (blue bars), with CAV9, or with RC and virus, then exposed to blue 
light for 20 min. and incubated for 3 days at 37 ˚C after the plate was wrapped with 
aluminium foil. CTRL Control with cells only. B: Fractionated samples of sonicated RC 
extracts (conc. 0.25 mg/ml). In both cases media were discarded and MTT in media were 
applied for 2 h, the resulting blue crystals were dissolved in DMSO and absorbance at λ550 
was recorded. The cell’s viabilities were calculated as percentages of the control of cells 


















































Figure 5-13. The effect of RC extracts and sonicated RC fraction samples on GMK 
cells with/ without CAV9 after exposure to red light (RL) for 20 minutes.  
A: Crude RC extracts. Cells were incubated with crude RC extracts (conc. 4 mg/ml) 
produced by different extraction methods (blue bars), with CAV9, or with RC and virus, 
then exposed to red light for 10 min and incubated for 3 days at 37 ˚C after the plate was 
wrapped with aluminium foil. CTRL: Control with cells only (green bar), B: Fractionated 
samples of sonicated RC extracts (conc. 0.25 mg/ml). In both cases media were discarded 
and MTT in media were applied for 2 h, the resulting blue crystals were dissolved in DMSO 
and absorbance at λ550 was recorded. The cell’s viabilities were calculated as percentages 




















































5.2.11 The effect of microalgae extracts on CAV9 infectivity and cell 
viability in the absence and presence of light.  
It has been found that microalgae (MA) contain several compounds with antiviral activities 
(Ahmadi et al., 2015). Recent research has also found further applications of MA 
metabolites as fluorescent diagnostic tool (Chu, 2012). To establish if microalgae extracts 
could have a direct effect on the CAV9 particle, leading to inhibition of infection and 
whether light exposure would enhance antiviral activity, two series of MA were 
investigated for their antiviral activities against CAV9. Firstly, the virus was treated with 
several MA samples in the dark (Figure 5.14) then used to infect cells. Although MA 
extracts showed variable antiviral activity, they mostly had little toxicity to the cells. In 
fact, most of them increased the viability of cells in the absence of the virus. Most of the 
samples also had an antivirus effect in the dark. The sample MA-19 had a particularly 
efficient effect on CAV9.   
 The samples of MA (MA9, MA11, MA15, MA17 and MA19) were exposed to blue light 
(Figure 5.15A) which unexpectedly seemed to cause a general decrease in the antiviral 
activity in comparison to the dark experiment. The MA-19 that showed inhibition of more 
than 98% on the virus activity in the dark had negligible effect with the blue light (Figure 
3.15 A). Also, all MA samples that were exposed to BL had no effect on cell viability. The 
sample of MA-F3 that was exposed to RL (Figure 3.15 B), also demonstrated moderate 
antiviral effects of around 55% viability compared to control but had no toxicity effect on 
cell’s viability (control cells without virus). While MA1-F4 was ineffective (less than 5% 
viability) and had high cell toxicity.  
Thus, although MA extratcs showed some effect on CAV9, this was not enhanced by light 





Figure 5-14. The effect of MA extracts on the viability of GMK cells and on CAV9 
infectivity in the dark.  
Control cells (CTRL) were incubated with the media only (green bar). Some cells were 
incubated with MA extracts with a concentration of 2.5 mg/ml (blue bars). Some cells were 
incubated with pre-incubated viruses with (red bars) or without MA extracts (purple bar). 
The plate was wrapped with aluminium foil. The cells were incubated for 3 days at 37 ˚C 
and the media was discarded, MTT in media were applied then for 2 h. The resulting blue 
crystals were dissolved in DMSO and absorbance at λ550 was recorded. The cell’s viabilities 


























Figure 5-15. The effect of MA extracts on GMK cells with/ without CAV9 with 
exposure to A: Blue light (BL); B: Red light.  
Control cells (CTRL) were incubated with the media only (green bar). Some cells were 
incubated with MA extracts with a concentration of 2.5 mg/ml (blue bars). Cells were 
incubated with CAV9 with or without pre-treatment with MA extracts, then exposed to the 
light for 30 min. The plate was wrapped with aluminium foil. The cells were incubated for 
3 days at 37 ˚C and the media was discarded, MTT in media were applied then for 2 h. The 
resulting blue crystals were dissolved in DMSO and absorbance at λ550 was recorded. The 























































5.2.12 Quercetin antiviral activity in different cell lines 
Quercetin is a naturally occurring compound present in several berries. It has been found 
to have an antiviral effect and could be an active component in the RC extract. Purified 
quercetin was therefore tested for activity against CAV9. In GMK cells quercetin caused a 
dose dependent decrease in CAV9 plaque formation when the concentrations increased 
from 0.10 to 0.75 mg/ml (Figure 5.16). The viral infection dropped sharply from 80% to 
approximately 7% of the value in the absence of the drug. However, total inhibition of the 
plaques was achieved with quercetin concentration of 2.0 mg/ml. A comparison of 
quercetin efficacy to inhibit the viral infection of CAV9 was made in two cell lines, A549 
and GMK (Figure 5.17). In A549 cells, quercetin showed markable antiviral activity. This 
started at a concentration as low as 0.10 mg/ml to reach approximately 100% at only 0.50 
mg/ml. As seen in Figure 5.16, the inhibition effect of quercetin was much lower in GMK 
cells. A concentration of 0.5 mg/ml caused only around 50% inhibition of GMK infected 
cells.  Increasing quercetin further from 0.75 mg/ml to 2.0 mg/ml, resulted in much high 
inhibition of the infected cells from  92% to 98%. It was concluded that the percentage of 
viral inhibition was significantly higher in A549 than GMK cells at low to moderate 
concentrations (0.10-0.50 mg/ml). Some of the apparent antiviral effect may be due to cell 









Figure 5-16. Effects of quercetin on CAV9 infection.  
GMK cells were infected with 370 PFU of virus after pre-treatment with increasing 
concentrations of quercetin. The cells were incubated at 37 ˚C for 24 hours then lysed by 
freeze thawing three times. The amount of virus present was measured by plaque assay 
and expressed as a percentage of the value measured from virus-infected cells in the 










































Figure 5-17. Comparison between CAV9 inhibition by quercetin in A549 and GMK 
cell lines. 
A549 cells or GMK cells were infected with 370 PFU of CAV9 after pre-treatment with a 
range of concentrations of quercetin. The cells were incubated at 37 ˚C for 48 hours then 
lysed by freeze thawing three times. The amount of virus present was measured by plaque 
assay and expressed as a percentage of the value measured from virus-infected cells in the 














































Figure 5-18. Cytotoxic effect of different quercetin concentrations on A549 cells.  
A549 monolayers in 24-well plate were pre-treated with different concentrations of 
quercetin in 0.5 ml of culture medium for 30 minutes and the cells were incubated on a 
rocking platform for 30 minutes at room temperature. 1 ml of a 2:1 mixture of culture 
medium and 2% CMC were added, and the plate was incubated for 2 days in a humidified 
CO2 incubator at 37 ˚C. The medium was discarded, and cells were washed and 1 mg/ml 
of MTT in media were applied for 2 h, the resulting blue crystals were dissolved in DMSO 
and absorbance at λ550 was recorded. The cell’s viabilities were calculated as percentages 






























5.2.13 Evaluation of antioxidant activities of the crude RC extracts and 
related fractions in cell free media 
It has been reported that viral infection-induced free radical production reduces cellular AO 
levels and adversely affects cell function. On the other hand, various AO species were 
found to inhibit viral infection (Venkata et al., 2013). To investigate if the antivirus effect 
of the RC extracts could be due to AO activity, we evaluated the AO activity of boiled RC 
extract using a myoglobin-based assay (Figure 5.19) and demonstrated reduction of 
myoglobin absorbance from 1.8 to 1.2. The end product of the reactions with RC samples 
showed significant antioxidant capabilities for all the extracts after nearly one hour from 
the start. Using myoglobin protective ratio percent (MPR) (Figure 5.20), the sample of 
liquid-solid extract (RC-SBo2) displayed the most powerful AO activity with its MPR 
above 110%. The MPR of RC boiled extract (RC-Bo1) was about 90% while that extracted 
at room temperature (RC-Rt) extract was just above 80%. 
Using the myoglobin assay and gallic acid (GA) as a standard (Figure 5.21A), GA showed 
comparable AO activity with a concentration of only 7.5 μg/ml to that concentration of RC-
Bo1 extract with 250 μg/ml. The samples of the crude RC-Bo1 reactions at lower 
concentrations from (10 μg/ml to 150 μg/ml) were much slower and didn’t reach to a 
plateau within 50 min. The Rate of the AO (RC-Bo1) reaction with ferryl myoglobin (Rate 
(1/s) was calculated at the range of concentrations from 10 μg/ml to 250 μg/ml (Figure 
5.21B). The calculated data demonstrated that the rate of the reactions for RC-Bo1 as AO 
is concentration dependant reaction at the initial period of the reaction time. RC-
Bo1exhibited remarkable AO activity with much faster rate to those figures of the other 
crude extracts. The reactions of RC-Bo1 fractions (Figure 5.22) with ferryl myoglobin were 
very fast and completed within few seconds. Therefore, it was difficult to record the kinetics 
of those fractions with this spectroscopic method.  









Figure 5-19. Antioxidant activity AO of boiled RC extract.  
Myoglobin (Mb) alone (13.5 μM) was added to 2 ml of PBS at pH7.2 in cuvette and the 
absorbance was recorded at wavelength of 409 nm. Hydrogen peroxide (H202, 140 μM) was 
added at room temperature. The reaction was terminated after 10 min by adding 2 μl of 
catalase enzyme and the absorbance was recorded again after 2 min. The absorbance was 
also recorded at wavelength λ409 nm. RC samples with concentration of (250 μg/ml) were 






































Figure 5-20. The myoglobin protective ratio (MPR) for AO activity of RC extract 
samples.  
Myoglobin (Mb) alone (13.5 μM) was added to 2 ml of PBS at pH7.2 in cuvette and the 
absorbance was recorded at wavelength of 409. Hydrogen peroxide (H202, 140 μM) was 
added at room temperature. The reaction was terminated after 10 min by adding 2 μl of 
catalase enzyme and the absorbance was recorded again after 2 min. The absorbance was 
also recorded at wavelength λ409 nm. RC samples with concentration of (250 μg/ml) or 
Gallic Acid (GA, 7.5 μg/ml) were added and the absorbance was recorded again at λ409 for 
the antioxidants. RC-Rt: Room temperature extract. RC-Bo1: Boiled extract. RC-SBo2: 





































Figure 5-21. Kinetics and rate of reaction of antioxidant activity of boiled RC extract. 
 A: Kinetics of AO activity for crude RC boiled extract (RC-Bo1) samples against 
time. Myoglobin (Mb) alone (10 μM) was added to 2 ml of PBS at pH7.2 in cuvette and 
the absorbance was recorded at wavelength of 409. Hydrogen peroxide (H202, 100 μM) was 
added at room temperature. The reaction was terminated after 10 min by adding 1 μl of 
catalase enzyme. A range of concentrations of RC-Bo1 were added to each cell and the 
kinetics was recorded for 50 min (3000 s). B: The calculated rate of reaction of AO with 


































































Figure 5-22. Kinetics of AO activity for crude RC fractionated of boiled extract (RC-
F1-F6) samples against time. 
 Myoglobin (Mb) alone (13.5 μM) was added to 2 ml of PBS at pH7.2 in cuvette and the 
absorbance was recorded at wavelenµth of 409. Hydrogen peroxide (H202, 140 μM) was 
added at room temperature. The reaction was terminated after 10 min by adding 2 μl of 
catalase enzyme. A concentration of 100 μg/ml from each RC fractions was added to each 










































5.2.14 LC-MS\MS analysis of RC fractions  
To attempt to purify and identify active components from the boiled RC extract, it was 
fractionated by flash chromatography and the fractions were analysed with LC-MS/MS 
spectroscopy.  
5.2.15 Methods of LC-MS/MS analysis 
A mixture of gradient and isocratic program was employed after eluent’s optimization. The 
diode array traces of each fraction (5 μg/ml) was recorded over 30 minutes and monitored 
at wavelengths between 200-800. The C18 reversed column based chromatographic 
separation along with trifluoroacetic acid (TFA) added to mobile phase was used in this 
work. The applied chromatographic technique is characterised by its good performance, 
high sensitivity and good selectivity (Chen et al., 2014). TFA as ion-pairing agent was 
added to mobile phase to improve peak sharp and resolution. TFA was used at 0.1%. It has 
been reported that increased TFA concentration causes an improvement in peaks resolution 
and TFA of 1%, 5% and 10% were used with better separation and shorter elution time in 
some previous published works (Chen et al., 2014). Therefore, higher TFA concentration 
may be suggested for future work. Positive ion mode was applied which has strong evidence 
of increasing response and sensitivity of tested compounds (Chen et al., 2014).        
The fractionation resulted in separation of the constituents into several bands containing 
mixtures of chemicals with similar polarities. The data obtained from LC-MS/MS, the UV 
spectra and MS confirmed the presence of two main types of compounds, the 
anthocyanins/anthocyanidins and flavonoids, alongside many other small molecules such 
as sugar, ascorbic acid, coumaric, cinnamic, etc. Several compounds in the separated 
fractions have molecular masses (ES/CI) of well-known compounds and documented 
extensively in the literature, but there were also unknown entities (Silva., 2007; 
Nakabayashi., 2009; Sasaki., 2014). Selected examples of analytical characterisation by a 
liquid chromatography system coupled to electrospray mass spectrometer LC-MS/MS for 
three fractions are presented in this section. The investigated fractions (F1 and F2) have 
similar elution pattern within a 60 min run (Figure 5.23 and 5.24, a-c). The first eluted peak 
was at retention time (tR) of 0.89 min, the second peak eluted at tR at 9.28 min with 
absorbance wavelengths of (230, 270 and 500 nm) with diode array. The peak at 16 min 
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was more pronounced in F2 than F1 fractions. The traces in figure 5.23 (d) and 5.24 (d) 
represent the total ion counting of the fractions after passing through MS spectrometer. It 
showed the peaks of ions that correspond to the constituents eluted and fractionated by LC 
system at small delay of about 0.5 min.  The majority of constituent were between 1.47-9.8 
min, then another major band between 45-50 min.    
The elution of fraction F3 was optimised to run within 14 min (Figure 5.26, a-g). The 
Fraction F3 revealed most of its constituents with absorbance wavelength of 620 nm 
(Figure 5.25, a). It has peaks at tR of 0.6-1.25 min, then major peaks at 5.12-5.40 min where 
it was also predominant in the other range of UV diode array traces at 220, 260, 360, 450, 
520 nm (Figure 5.25, b-f). Those close peaks revealed a mixture of unresolved constituents 
eluted together. There were small peaks at 9.8 min but the largest peak it appeared at 
wavelength of 620 nm at tR between 13.13-13.32 min. The trace in (Figure 5.25, g) 
displayed the total ion counting for the constituents of F3 passing through MS system, it 
seemed to be also a mixture of constituents. The absorbance spectra of couple of 
constituents in F3 fraction were recorded at tR of 5.64 and 5.27 min, confirmed the 
differences of the constituent’s spectra eluted at the time (Figure 5.26, a & b). The spectra 
in Figure 5.26a, showed aliphatic and aromatic types compounds around the visible range 
between wavelength 200-350 nm, while b trace displayed an extra peak appeared around 
518 nm, which can indicate to the existence of poly-cyclic aromatic compounds, such as 




Figure 5-23. LC-MS elution of fraction F1. 
a, b, and c are LC traces for 60 min elution time of F1 band at wavelength absorbance 270, 

































































































Figure 5-24. LC-MS elution of Fraction F2.  
a, b, and c are LC traces for 60 min elution time of F1 band at wavelength absorbance 270, 




























































































Figure 5-25. LC-MS elution of Fraction F3. 
a, b, c, e, and f are LC traces for 14 min elution time of F3 band with diode array at 
wavelength absorbance 220, 260, 360,450, 520, and 620 nm. g: MS trace for total ion 
counting (TIC) in 14 min for F3 elution. LC-MS was optimised with the sample’s flow of 
250 μl/min from the DAD eluent was directed to the ESI interface using a flow-splitter. 
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The source block temperature was held at 120 ˚C and the desolvation gas (nitrogen gas) 
temperature was 350 ˚C.  The flow rate of 650 l/h, and cone gas of 82 l/h was used. The 
capillary potential of 3.2 kV was used. MS spectra recorded between m/z range 100-950, 
















Figure 5-26. The diode array UV spectra of RC F3 constituent recorded from the 
wavelength 200-800 nm.  
This was recorded for F3 during elution through LC-MS/MS; (a) at tR of 5.638 min and (b) 
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5.2.16 Analysis of MS and MS/MS spectroscopy 
Selected MS spectra from F1, F2, and F3 at certain Retention times (tR) were obtained and 
presented in this section according to their masses against charges (m/z). It was found from 
several LC-MS/MS analysis, the existence of anthocyanins/anthocyanidins and flavonoids 
moieties, Figure 5.27. Example of MS spectra gave dominant peaks with m/z 142-147, 610-
612, 684 Daltons (D), they demonstrated the masses of m/z and their isotopes at 1.4 min tR, 
Figure 5.28.  The peak at 142-147 D could be a fragment of the compound belong to 610 
D. The predicted proposed structures for the 610 D identified as cyanidin-3,5-di-O-
glucoside = 611 or, also called (cyanidin sophoroside) according to other literatures 
(Cavaliere et al., 2005; Abad-García et al., 2009). Quercetin-3-O-digalactoside featured 
flavonoid moiety coupled to two glucoside groups either at the hydroxy group of ring B at 
hydroxy group of the ring B gave also m/z 610. The predominating detected peaks (Figure 
5.29) for the constituents of F2 with 595 (cyanidin 3-galactoside) and 727 D, cyanidin 3-
sambubioside-5-rhamnose (Kovinich, 2014) at around 9.8 min also predicted to contain 
anthocyanidin with glucosyl and galactosyl groups while an xylose group was added to the 
peak of 727 D. The MS spectra for F2 at tR of 45.8 min (Figure 5.30) gave a peak with m/z 
of 885 D. Several proposed structures were displayed in Figure 5.30 based on the main unit 
for the predicted structure which was cyanidin or flavonoid group attached to galactosyl, 
malonyl, cinnamyl, coumaroyl, and feruloyl groups. The masses for the selected fractions 
and their constituents were suggested by two other techniques through MS/MS 
compartment. Utilizing MS/MS fragmentation pattern of the whole molecules (parent ions) 
to daughter ions (Figure 5.31), several parent ions were recorded for the daughter ion (m/z 
287 D) in F1 at tR around 1.4 min. There were fragmentation pattern of the parent ions with 
several fragments/daughter ions (m/z 370, 375, 427, 443, 461, 527, 596, 611, 731, 813, and 
892). The recorded parents in F2 for m/z of 827 D detected at tR 27 in Figure 5.32 could be 
corresponding to cyanidin molecule acylated with glucosyl and malonic. It gave parent ion 
of m/z 915 D (literature identification as prodelphinidin trimer = 915 (Liu et al., 2009) 
while the peaks at tR 22.2 and 23.1 with further coupling molecules to appear at m/z 1083 
and 1108 D, respectively. The parent ions of one of F3 constituent (Figure 5.33) with tR 9.3 
was m/z 303 D which revealed parent ions at 415, 450, 466, 613, and 745. The obtained 
parent ions of m/z 145 (Figure 5.34) showed parent ions of m/z 186, 229, 307, and 804 D. 
Another analytic technique was applied called multiple reaction monitoring (MRM) which 
focus of the whole molecule and one fraction of the interest. An example of MRM 
210 
 
technique to provide more information about certain mass more information was displayed 



























         Anthocyanin type               Flavonoid typ 
Figure 5-27. Basic structures of anthocyanin and flavonoid.  
 
 
Figure 5-28. Mass spectra of F1 fraction and the predicted structure of some 
predominant peaks.  
Each peak in the mass spectra of F1 (A) was listed with its ion intensities and m/z ratio. 
The data were recorded at exact tR of 1.415 min. The chemical structure for the predicted 
peaks at m/z 610 D.  LC-MS sat up with the sample’s flow of 250 μl/min from the DAD 
eluent was directed to the ESI interface using a flow-splitter. The source block temperature 
was held at 120 ˚C and the desolvation gas (nitrogen gas) temperature was 350 ˚C.  The 
flow rate of 650 l/h, and cone gas of 82 l/h was used. The capillary potential of 3.2 kV was 
used. MS spectra recorded between m/z range 100-1500, in the positive mode with cone 
voltages (CV) 30 V.   
 
        m/z  610.15 
 
             m/z  611.16 
F1 tR 1.4 min 
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Figure 5-29. Mass spectra of F2 fraction and the predicted structure of some 
predominant peaks.  
Each peak in the mass spectra of F2 (Cur 15) was listed with its ion intensities and m/z ratio 
595 and 727 D. The data were recorded at the exact tR of 9.8 min. LC-MS prepared with 
the sample’s flow (250 μl/min) from the DAD eluent was directed to the ESI interface using 
a flow-splitter. The source block temperature was held at 120 ˚C and the desolvation gas 
(nitrogen gas) temperature was 350 ˚C.  The flow rate of 650 l/h, and cone gas of 82 l/h 
was used. The capillary potential of 3.5 kV was used. MS spectra recorded between m/z 


































































Figure 5-30. Mass spectra of F2 fraction and the predicted structure of some 
predominant peaks. 
 Each peak in the mass spectra of F2 (Cur 10) was listed with its ion intensities and m/z 
ratio 595 and 727 D. The data were recorded at the exact tR of 45.8 min. LC-MS optimised 
the sample’s flow (250 μl/min) from the DAD eluent was directed to the ESI interface using 
a flow-splitter. The source block temperature was held at 120 ˚C and the desolvation gas 
(nitrogen gas) temperature was 350 ˚C.  The flow rate of 650 l/h, and cone gas of 82 l/h 
was used. The capillary potential of 3.5 kV was used. MS spectra recorded between m/z 
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Figure 5-31. MS/MS parent ions of m/z 287 spectra from F1 constituent at tR of 13 
min.  
LC-MS/MS was optimised with the sample’s flow of 250 μl/min from the DAD eluent was 
directed to the ESI interface using a flow-splitter. The source block temperature was held 
at 120 ˚C and the desolvation gas (nitrogen gas) temperature was 350 ˚C. The flow rate of 
650 l/h, and cone gas of 82 l/h was used. The capillary potential of 3.2 kV was used. MS 
spectra recorded between m/z range 100-950, in the positive mode cone voltages (CV) (45 
V). Parent and daughter ions spectra were also recorded in positive mode using argon as 
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Figure 5-32. MS/MS Parent ions of m/z 827 spectra from F2 constituent at tR of 22.2, 
23.1, and 27.9 min.  
LC-MS/MS was optimised with the sample’s flow of 250 μl/min from the DAD eluent was 
directed to the ESI interface using a flow-splitter. The source block temperature was held 
at 120 ˚C and the desolvation gas (nitrogen gas) temperature was 350 ˚C.  The flow rate 
of 650 l/h, and cone gas of 82 l/h was used. The capillary potential of 3.2 kV was used. MS 
spectra recorded between m/z range 100-950, in the positive mode cone voltages (CV) (35 
V). Parent and daughter ions spectra were also recorded in positive mode using argon as 
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Figure 5-33. MS/MS parent ions of m/z 303 spectra from F3 constituent at tR of 9.3 
min.  
LC-MS/MS with the sample’s flow of 250 μl/min from the DAD eluent was directed to the 
ESI interface using a flow-splitter. The source block temperature was held at 120 ˚C and 
the desolvation gas (nitrogen gas) temperature was 350 ˚C.  The flow rate of 650 l/h, and 
cone gas of 82 l/h was used. The capillary potential of 3.2 kV was used. MS spectra 
recorded between m/z range 100-950, in the positive mode cone voltages (CV) (35 V). 
Parent and daughter ions spectra were also recorded in positive mode using argon as 
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Figure 5-34. MS/MS parent ions of m/z 145 spectra from F3 constituent at tR of 12.3 
min.  
LC-MS/MS was optimised with the sample’s flow of 250 μl/min from the DAD eluent was 
directed to the ESI interface using a flow-splitter. The source block temperature was held 
at 120 ˚C and the desolvation gas (nitrogen gas) temperature was 350 ˚C.  The flow rate 
of 650 l/h, and cone gas of 82 l/h was used. The capillary potential of 3.2 kV was used. MS 
spectra recorded between m/z range 100-950, in the positive mode cone voltages (CV) (25 
V). Parent and daughter ions spectra were also recorded in positive mode using argon as 
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Figure 5-35. Multiple reaction monitoring (MRM) parent and daughter ions of a) m/z 
728 > 245; b) 728 > 455; c) 804 > 414; d) 827 > 610 spectra for F3 constituents.  
LC-MS/MS was optimised with the sample’s flow of 250 μl/min from the DAD eluent was 
directed to the ESI interface using a flow-splitter. The source block temperature was held 
at 120 ˚C and the desolvation gas (nitrogen gas) temperature was 350 ˚C.  The flow rate 
of 650 l/h, and cone gas of 82 l/h was used. The capillary potential of 3.2 kV was used. MS 
spectra recorded between m/z range 100-950, in the positive mode cone voltages (CV) (40 
V). Parent and daughter ions spectra were also recorded in positive mode using argon as 
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5.3.1 Redcurrant Extracts 
5.3.1.1 Introduction    
The work described in this chapter mainly describes an analysis of the possible antivirus 
effect of compounds contained within redcurrants. These were chosen as related berries 
have been shown to contain biologically active materials, including potential antivirus 
agents, but redcurrants have not been extensively studied.  
5.3.1.2 Antiviral activity of RC extracts  
Different RC extracts produced using different methods of extraction showed differences 
in cell toxicity profiles and variable antiviral activity. It was anticipated to find the extracts 
of redcurrant filtrates produced at room temperature (RC-Rt and RC-SS sonication) would 
be more potent than the filtrate of boiled extract, as there should be less degradation of 
labile compounds. However, the boiled extract showed in several experiments using plaque 
assays or cell viability measured by the MTT assay (Figures 5.1, 5.11-5.13), more 
significant antiviral activity and less toxicity to the cells than other tested extracts. In fact, 
it has been found that boiling of some plant material increases the biological activity and/or 
the levels of one or more of their components. For example, boiling of broccoli and green 
beans increases their phenolic levels (Turkmen et al., 2005) and boiling of tomatoes raises 
free flavonol content (Stewart et al., 2000). Therefore, boiling of RC might have increased 
the phenolic or other more potent compounds leading to an increase in the antiviral activity 
of the boiled RC extract. Another possible explanation is that during boiling, some of 
chemical properties of heated compounds may change for example destroying chemical 
bonds, breaking down the complex compounds into their simple components, or it may 
even produce completely new chemical entities compounds with more or less activity than 
the original ones. Noteworthy, RCs have small solid seeds inside the berry. An increase in 
temperature during the boiling step might have extracted some active ingredients from 
seeds that were not released when the extraction was carried out at Rt (filtration at Rt and 
sonication).  
The antivirus effect was mainly tested using CAV9, but the extract was also active against 
several isolates of CBV3, a closely related virus to CAV9, which nonetheless has 
differences in cell entry mechanisms, which could impact on antivirus therapy. However, 
the extract was equally effective against the CBV3 isolates. It was also effective against 
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HPeV1, which is quite different from CAV9, genetically. It is belonging to another 
Picornaviridae genus, Parechovirus, while CAV9 belongs to Enterovirus. There are many 
similarities between the HPeV1 genome and those of other picornaviruses, but there are 
several differences in molecular and biological properties. Unlike several other 
picornaviruses, HPeVs are partially resistant to guanidine hydrochloride and resistant to 
brefeldin A (Krogerus et al., 2003). The membrane changes seen in HPeV-infected cells are 
not as extensive as those seen in EV-infected cells. HPeVs also do not appear to cause host-
cell protein synthesis shut-off (Stanway et al., 1994). There are unique features in terms of 
the biochemical properties of the HPeV proteins, for instance the maturation cleavage of 
VP0 to VP2 and VP4 does not occur (Stanway et al., 1994) and 2A belongs to a distinctive 
protein class (Stanway & Hyypiä, 1999). Unlike the poliovirus (PV) 2C protein, for 
example, the 2C protein of HPeVs is not present in the replication complex (Krogerus et al., 
2003, 2007). The 2BC precursor is also not seen in infected cells (Krogerus et al., 2003). 
As for other picornaviruses, HPeVs inhibit cellular secretion but this does not seem to be 
caused by 3A as in EVs, or 2BC or 3A/2BC as seen in other picornaviruses (Krogerus et 
al., 2007). The antiviral spectrum seen suggest that phytochemicals present in RC can have 
broad activity against enteroviruses, or even picornaviruses as a whole and overcome the 
problems of the large number of virus types. 
The direct contacts of the viruses with the RC extracts revealed no effect of the extract on 
the virus particle itself (Figure 5.6), indicating that RC extracts do not work, for instance, 
in the manner of pleconaril in binding to a pocket under the virus surface and inhibiting 
uncoating (Rossmann et al., 2002) and so the effect is intracellular. The observed lack of a 
complete inhibitory effect when cells are treated with RC extract after 6 hours of infection 
indicates that a relatively early step in infection, but probably beyond the very early stages 
of attachment and uncoating, is the target (Figure 5.7).  
5.3.2 The effect of microalgae extracts on the viruses and cells viability 
All microalgae samples demonstrated variable inhibition patterns of viral growth. Some of 
them demonstrated the ability to enhance cell viability without the viruses at low 
concentration and probably stimulated cell growth. The majority of the samples of RC and 
MA are rich source of antioxidant and this may have a role in increasing cells viability. 
Additionally, another set of the investigated species of MA showed extreme toxicity on 
cells. These obtained diverse MA results (being active, inactive, stimulating cells’ viability 
or being very toxic) reflect diversity between different MA species. Some of these samples 
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are from different species and even those of the same species are likely to contain different 
chemical and biomedical constituents. In addition, being toxic at certain concentration does 
not mean that the extract is toxic at all concentrations and all of its components are toxic, 
because in general each of MA species contains many ingredients and metabolites. Some 
of these ingredients may have beneficial effects, some may be independently harmful and 
other may be useless. By doing fractionation, useful fractions can be separated from those 
which caused adverse effects to probably obtain a pure antiviral agent or agents without 
harmful effects. For the investigated active compounds, it might be worth to be further 
purified and identified. However, owing to the cells were subjected to a length of time to 
the experimental conditions during the viability assays, the results might be deficient of 
constructive assessment.   
The investigated MA samples belong to distinct MA members. Chlorella which contains 
MA17 and MA-30 is one of MA genus which has high nutritional content and is known to 
produce a wide range of carotenoids and contains phenolics that have been used for 
cardioprotective antioxidant, anticancer and anti-microbial disorders. Species from the 
Chlorella genus were reported to have antiviral activity. For example, Chlorellaceae was 
investigated to inhibit influenza A and B replication from not only strains that considered 
to be sensitive to oseltamivir but also resistant strains (Sathasivam & Ki, 2018; Silva et al., 
2018; Barkia et al., 2019). Chlamydomonas is a green alga with unique flagellated single 
cell properties which has been used as a model organism and investigated for several 
biological and antimicrobial activities (Couso et al., 2018; Sasso et al., 2018).  
MA are very primal plants (with size of approximately 3-20 µm). However, they are the 
most genetically varied, complex and polyphyletic organisms worldwide (Mustopa et al., 
2015; Barkia et al., 2019). Therefore, the antiviral or other biological activities of certain 
MA may be not be very representative for all species within the family. Side effects have 
been reported for some MA specials. Chlorella for example may cause gastro intestine 
problems such as nausea and vomiting and some reported allergic reaction and more 
seriously renal failure due to acute tubulointerstitial nephritis.  
Despite showing some promise in the antivirus assays, MA samples were available in very 




5.3.3 Photodynamic inactivation activity of RC and MA 
The natural extracts of RC and MA contain entities with photosensitive chemicals when 
some of the extracts were fractionated. Although, it is known that fruit in general have 
many chemicals that act as antioxidants the ability of some RC photosensitive constituents 
to elevate and produce Reactive Oxygen Species (ROS), which can cause immediate 
damage to biological systems was assessed in terms of the inhibition of the viral growth.     
The idea of using blue and red light sources with the RC and MA samples came from the 
previous use of several photosensitizer (PS) that occur naturally in many plants, such as 
psoralens, perylenequinonoid and hypericin pigments. These PS have been shown to have 
photo-destruction activity against HIV and several other viruses. (Wainwright, 1998). 
Pigments in colourful fruits like redcurrant may be photo-active and in recent research some 
microalgae metabolites were introduced as a fluorescent agent that could be used in PDI 
(Chu, 2012).  
 In this study, the preliminary fluorescence imaging from confocal microscope was carried 
out and confirmed the presence of highly photosensitive substituents within the RC samples 
(data not included). Although RL had no beneficial effects on RC or MA samples, the 
effects of BL vary between RC and MA. In the case of RC extracts, the antiviral activity 
and cells viability were almost equal to the healthy control cells, but the boiled RC extract 
showed unique antiviral activity and enhanced cell viability with BL. Surprisingly, the use 
of BL with MA-19 caused significant decrease in its antiviral activity comparing to its 
inhibition to the viral activity in the dark. It is worth mentioning there are many reports that 
documented the presence of several different constituents some of them photosensitisers, 
producing high quantum yield of reactive oxygen species (ROS) and in the same time 
contain quenchers as antioxidants. The types, numbers, quantum yield of ROS, quantities 
of the photosensitive and the quencher’s constituents in RC and MA species, probably 
attributed to their variation responses to the BL light and RL exposure and their PDI 
efficacy. These different effects would only be resolved by purification of potential 
antivirus compounds. 
Currently, PDI of viruses has some use in the medical field including disinfection and 
purification of blood products and treatment of local virus infection such as papilloma virus 
warts and herpes virus. Whether systemic application of PDI could be feasible is not clear. 
Noteworthy, PDI can affect all virus vital structure including nucleic acids, lipids and 
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proteins and inhibition of viral replication by PS has been shown. PDI has documented 
activity against many viruses such as poliovirus, influenza virus, HSV, arbovirus, 
encephalitis virus, phage and SV40 (Wiehe et al., 2019). 
 Investigation of RC as a potential source of PS against one of picornavirus infection is 
novel and has a great probability to be involved to the library of effective PS. However, it 
needs first to be purified from other components and identified and preferably investigated 
against other types of virus.  
5.3.4 Quercetin antiviral activity 
In addition to strong evidence of antiviral activity of quercetin against EVs and other 
viruses (as is discussed below), our data from LC-MS/MS and HPLC indicated the 
availability of flavanol in the boiled RC extract and in some of its fractions that showed 
significant activity against infection. In the current work, quercetin has showed a significant 
anti-CAV9 activity although there was a considerable differences of quercetin potency 
between the 2 cell lines used, A549 and GMK.  
Quercetin was shown to inhibit rhinovirus (RV) (which belongs to the Enterovirus species) 
infection in vitro and in vivo by multiple mechanisms. It was found to inhibit RV 
endocytosis and to decrease PI3-Kinase by competing for ATP binding and Akt 
phosphorylation and therefore decrease RV-induced chemokines and cytokines, including 
IFN and IL-8. Quercetin is also thought to decrease PI-4 kinase which is found to be very 
important for virus growth in lipid organelles (Ganesan et al., 2013). Quercetin has anti-
inflammatory and antioxidant properties and it is found to induce mitochondria antiviral 
signally response to increase rhinovirus clearance (Farazuddin et al., 2018). 
Interestingly, LY 294002, a potent PI-3 kinase inhibitor was designed accordingly to the 
quercetin structure (Vlahos et al., 1994). In PV (another EV species within picornavirus), 
quercetin was found to inhibit viral 3Dpol (RNA polymerase) and so RNA synthesis 
(Castrillo & Carrasco, 1987).  
In addition, quercetin has been found to decrease TAG synthesis and LD size in HCV (an 
RNA virus) and disorganise core protein localization around LDs and this was thought to 
be due to an inhibitory effect on DGAT activity. It has also been reported that 50 µM 
quercetin can oppose an elevation of fatty acid synthase, diglyceride acyltransferase, low-
density lipoprotein, acetyl-CoA carboxylase and microsomal triglyceride transfer protein 
224 
 
(Rojas et al., 2016). Other quercetin-HCV findings suggested additional quercetin-related 
mechanisms of action including, inhibition of IRES and NS5A mediated-IRES translation, 
NS3 protease and HSP (Bachmetov et al., 2012). Influenza virus another RNA virus has 
also been found to be inhibited by quercetin via interfering with attachment, endocytosis 
and viral cell fusion (Wu et al., 2016).  
Quercetin also inhibits viral replication of many other viruses including adenovirus, 
parainfluenza virus, respiratory syncytial virus, mouse hepatitis virus DENV-2, herpes 
simplex virus, human T-lymphotropic virus, Japanese encephalitis virus, porcine epidemic 
diarrhoea virus, pseudorabies virus, Sindbis virus and HBV (Ganesan et al., 2013; Maalik 
et al., 2014; Chiow et al., 2016; Parvez et al., 2019).  
Many of the mentioned quercetin mechanisms are potentially applicable to CAV9 and the 
majority of picornaviruses. In addition, quercetin may inhibit viral infection by more than 
one mechanism, which means that there is little chance for viruses to develop resistance 
and it may target host factors and viral particles simultaneously. As quercetin has showed 
significant inhibition activity against several enteroviruses including rhinovirus, poliovirus 
and CAV9 (in the current work), in addition to non-picornaviruses such as HCV and 
influenza virus, there is a great probability that quercetin could be active against most or 
all picornavirus members.  
Quercetin is cheap and abundantly available. Although antiviral activity of quercetin is 
usually achieved in the micromolar ranges in vitro, it has been reported that nanomolar 
plasma concentration is probably enough to prevent in vivo viral replication. In terms of 
reported side effects, quercetin has shown a high safety profile of up to 5g a day. Quercetin 
was reported to harm kidney at doses greater than 1g/day. However, human studies have 
showed quercetin usage for several months in doses of up to 1g/day without reported 
serious affects (Chiow et al., 2016; Lu et al., 2017; Andres et al., 2018). Therefore, 
quercetin could have a wide range of antiviral activity and might not cause serious side 
effects. 
5.3.5 Antioxidant activity of RC extracts and fractions 
 It is known that natural sources including fruits contain hundreds of antioxidants (Choe 
and Min, 2009). Antioxidants have been found to inhibit some enterovirus species like 
EV71 (Ho et al., 2009). There are several antioxidant assays reported in the literatures 
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among them the myoglobin protection ratio (Terashima et al., 2007, 2010, 2012, 2013; An 
et al., 2014; Morikawa et al., 2015). The reaction of myoglobin (Mb) in the II or met III 
form (i.e., in the heme) with H2O2 leads to oxidation of the hem to the (oxo) ferryl state 
FeIV = O (ferrylmyoglobin) (Gibson et al, 1958). Measuring antioxidant activity of RC 
samples was carried out based on UV-spectroscopic absorbance of myoglobin structural 
changes after reaction with hydrogen peroxide (H2O2) following the literature method 
(Terashima et al, 2013). It is found that all RC extracts tested had high antioxidant activity 
(AO). The sample solid-liquid phase extract demonstrated the highest myoglobin protection 
MPR percentage and faster kinetics followed by boiled RC extract and then RC extract at 
room temperature. The fractionated samples were difficult to monitor due to the fast 
reactions of the ferryl ions with those fractions containing AO moieties (Figure 5.22).  
The method of extraction may affect AO properties of each extract. For instance, during 
the solid-liquid phase extraction of the boiled RC it was refluxing with 60% of 
dichloromethane and 40% methanol. Organic compounds that are extracted with such 
solvents might have high antioxidant activity. Also, it has been found that boiling of natural 
compounds increase their polyphenol contents (Hes et al., 2014), polyphenols are known 
naturally occurring AOs. Antioxidant capacity of the RC samples might have positive 
impact and contributed in their antiviral activity. For instance, the sample of boiled extract 
had higher percent of MPR and AO activity than the sample RC-Rt and also the former had 
higher antiviral (AV) activity than the latter sample.  
Most fractions from the boiled RC sample also had good AO activity (Figure 5.22). 
However, the preliminary data showed; the antioxidant (AO)-antiviral activity of boiled RC 
fraction is related in some fractions and less relevant to other fractions. F1 showed the 
highest AO activity and considerable antiviral activity. The AO and antiviral activities were 
both significant for F1, F4 and F5. However, F6 had strong AO but weak antiviral activity. 
The antiviral activity of F2 and F3 was high despite less significant AO activity. The 
fraction F6 which has strong antioxidant activity but lacks antiviral activity may contain 
certain types of AO different from those contained in another active fraction. Accordingly, 
it is still early to decide if antivirus activity is directly related to the AO properties.  
5.3.6 Analytical analysis of RC fractions 
On the basis of flash chromatography and HPLC, retention time, choice of mobile phase, 
and gradient, the conditions for fractionation and purifications of phenolic compounds 
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could be optimized. There is extensive literature reporting the importance of these factors 
alongside the pH of the media that will provide adequate charges for accurate separations 
of the large numbers of the natural components with different polarities (Werner et al., 
2008). 
Although, the prediction of the structures for the masses obtained at certain tR should be 
alongside of other analysis such as NMR and elemental analysis. Nevertheless, the 
methodology of the current work was based on liquid chromatography with diode array 
detection (HPLC/DAD) coupled to electrospray ionization (ESI) and triple quadrupole 
mass spectrometry can provide preliminary prediction for the type of constituents and 
identify the structural characterization of phenolic compounds present in RC extracts.  Also, 
comparing masses with published literatures can provide an insight to many of the 
polycyclic phenolic compound (Silva et al., 2007; Vagiri et al., 2012; Sasaki et al., 2014). 
Recently, HPLC and LC-MS has been widely used in separation and identification of 
anthocyanins, and sometimes in partial quantification. Both HPLC with both diode array 
detector (DAD) and MS detectors are sensitive and efficient for the separation and detection 
of multiple components based on UV absorbance and MS fragmentation behavior 
(Kovinich et al., 2014; Skrovankova et al., 2015). In general, the investigated RC fractions 
showed certain peaks at similar tR and other peaks at various tR. They were mostly feature 
different components with predominant few major masses recorded by electrospray mass 
spectra (ES+, m/z) for the total ion counting (TIC) which of different fractions have many 
similar chemical constituents for various masses of well documented and also unknown 
chemical entities. The analysis of LC-MS/MS indicated the existence of polycyclic 
compound within the RC extracts. According to enormous published articles for many 
fruits and berries extracts, the polycyclic constituents identified anthocyanins, 
anthocyanidins, flavonoids, and coumarins as the main chemical units. A diverse type of 
modifications for the ring A, B, and C within the units of anthocyanin/anthocyanidin and 
flavonoids were found by attaching sugar or organic molecules, or combination of those 
variable groups. Further LC-MS/MS analysis by parents/daughters and Multi Reactions 
Monitoring (MRM) techniques identified pattern of variable modifications with organic 
groups. Among those groups were arabinoside, galactoside, glucoside, coumaroyl, feruloyl 
and/or malonyl groups. The major RC constituents of the investigated fractions were 
complying with the literature reported constituents from fruits, flowers, and some 
vegetable’s extracts. The fragments of parents / daughter ions and neutral loss scanning 
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mode to observe the loss of dehydrated sugar moieties. By comparing the characteristic 
fragmentation patterns to those available in literature database, some of the flavonoids and 
anthocyanins were identified (Werner et al., 2008). The glycol-conjugated and free 
polyphenols from diverse families (hydroxybenzoic acids, hydroxycinnamic acids, flavan-
3-oles, procyanidins, coumarins, flavanones, flavones, dihydrochalcones, flavonols and 
anthocyanins) were detected in many fractionated samples after fragmentation patterns 
according to aglycone family, glycan sequence, interglycosidic linkages and attachment 
point of the substituents to the aglycone, allowing to interpret the mass spectra of no 
available phenolic compounds (Abad-García et al., 2009). Methodological rules to make 
easier the identification of unknown polyphenols by LC-MS/MS and isotopic ionization of 
compounds in black currants and other fruits or natural plants extracts were established and 
reported before. Several anthocyanins in the extracts of skin from Syrah grapes were 
identified by HPLC with diode array detection, including 3-monoglucosides of delphinidin, 
cyanidin, petunidin, peonidin, and malvidin, and the acetylglucosides and p coumaryl 
glucosides of malvidin and peonidin. The elucidation of anthocyanins by MS/MS 
investigated the aglycon moiety and number and types of sugars even without standards 
(Abad-García et al., 2009). 
Flavonoids belong to polyphenols with various modified species and a basic structure of 
C6-C3-C6. They have multiple applications in nutrition and cosmetic fields but also in 
pharmaceutical and medicinal arena (Panche et al., 2016). In terms of viruses, many of 
flavonoid subgroups have been investigated against viruses from different families such as 
enteroviruses, poliovirus, respiratory syncytial virus, influenza and parainfluenza viruses, 
immune deficiency viruses type 1 and type 2, herpesvirus and rabies virus (Kumar & 
Pandey, 2013; Dai et al., 2019). Anthocyanins are glycosidic anthocyanidin and classified 
under phenolic compounds which are abundant in vegetables and fruits including berries 
and responsible for their red, blue and purple colours. Commercial standards of many 
anthocyanins are not sufficiently available, and this complicates their measurement by 
HPLC (Chen et al., 2014). Therefore, structural prediction is sometimes indicated to be 
then subjected to other identifying methods. Cyanidin derivatives which are rich pigments 
belonging to anthocyanidins are also proposed as structures for some masses detected in 
MS spectra during this work including cyanin chloride and cyanidin-3-glucoside. 
Cyanidins like cyanidin-3-glucoside were reported previously as major analytes in several 
studies of natural extracts (Gouvêa et al., 2012). Naturally occurring cyanidin derivatives 
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can be sources of antiviral compounds and/or photosensitizers which could be used for their 
photodynamic antiviral activities. Rich pigments especially from berries have been reported 
for their strong antioxidant activities (Khoo et al., 2017). Therefore, the proposed detected 
cyanidin in the current work may contribute or be the origin of the antioxidant activities 
seen in RC extracts and their fractions. Groups such as cinnamyl, coumaroyl, feruloyl and 
malonyl are known for their antioxidant and anti-inflammatory properties and some of them 
like cinnamyl and coumaryl containing compounds have evidence for significant antiviral 
activity (Galabov et al., 1998; de Oliveira Silva & Batista, 2017). Based on the current LC-
MS/MS spectra and by comparing literatures, masses corresponded to cyanidin -3- glucose 
and keracyanine which is an analytical standard of cyanidin-3-rutinoside with antioxidant, 
anti-inflammatory activity and has been found to reduce absorption of carbohydrates and 
could be a potential agent for the treatment of diabetes mellitus. Interestingly, 595 was 
detected in previous published work with blackcurrant and 449 was found to be one of its 
major fragment ions and it was corresponded to the dissociation of a glucoside group with 
loss m/z of 146 (da Silva et al., 2007). Parent ion scan not only reveals but also confirms 
masses of interested peaks. It gives explicit spectra at low concentrations and separate 
interfering MS/MS spectra and increases the sensitivity and accuracy of analysis (Liu et al., 
2014). 
 In practise, identification of a finally purified but otherwise unknown compound is difficult 
to achieve by one analytical system and usually combines LC-MS/MS with various ion 
sources, mass analysers and standard metabolite references with known molecular masses, 
and NMR. Other possible complementary methods include elemental analysis, 
crystallography, spectroscopic methods such as UV and IR detection with possible use of 
several recently introduced techniques such as computer-assisted structure elucidation 
(Abad-García et al., 2009; Buevich & Elyashberg, 2016). 
The final identification of active compounds will allow them to be made on a larger scale 
and so tested thoroughly in terms of antivirus effect and toxicity. Thus, the initial work 





































6.1 Discussion and suggestions 
Picornaviruses are the largest and most diverse virus family that includes human pathogens 
in terms of the number of virus types, of which over 300 infect humans (ICTV, 2019). This 
makes vaccination against most picornaviruses impossible and so other interventions are 
required. Virus inhibition strategies are usually based on targeting viral conserved features 
(proteins or RNA structures in the picornavirus genome) or targeting host factors and 
organelles that viruses manipulate and exploit to favour their replication. As a virus in 
general and RNA virus in particular easily generate mutations, combination or 
incorporation of two suggested antivirals might greatly improve activity and decrease 
resistance at the expense of increasing side effects.   
Currently, no an individual anti-picornaviral drug has been approved to treat or prevent 
diseases caused by these viruses at present, in picornaviral life-threatening infections there 
is only the option of supportive treatment that does not impact on the infection itself. These 
include treatment of respiratory failure, haemorrhage and seizures (Zou et al., 2012). 
Finding effective anti-picornavirus drugs can prevent such infections and their serious 
consequences. Similarly, to limit virus replication in some cases, infected patients are 
provided with infusions of intravenous immunoglobulin from pooled donors (Zou et al., 
2012), and drug treatment if found would avoid the huge cost, danger and difficulties of 
such complex treatment. Therefore, there is a necessity for the development of new 
therapies and drugs against the wide range of infections and to overcome their high 
mutation rate. In this work, a number of new possible sources of natural extracts and 
repurposing of drugs of known uses have been explored and evaluated against virus 
replication and cell survival. These have been investigated against CAV9, a clinically 
important virus of the Enterovirus genus within Picornaviridae. Although repurposed 
drugs and natural extracts look distinct in terms of their origins, they share a very important 
common feature of being consumed (e.g. in berries) or used therapeutically for many years 
(e.g. fluoxetine) and having strong evidence of safety and tolerability profile.  
Since the National Center for Advancing Translational Sciences (NCATS) initiative for 
drug repurposing, “Discovering new therapeutic uses for existing molecules”, major 
companies like Pfizer, AstraZeneca, Sanofi, Eli Lilly, Abbott, GlaxoSmithKline, Bristol-
Myers Squibb and Janssen Pharmaceuticals have been active in this area (Allarakhia, 2013). 
The project is very appealing as brand-new drug development requires a long time and huge 
efforts and money. Only 0.01% of investigated new compounds succeeded to the market 
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with a rejection rate of 45% due to toxicity or inactivity (Ashburn & Thor, 2004). Drug 
repurposing has much in its favour in terms of these parameters, due to the presence of 
previous inclusive pharmacological information e.g. including principle mechanism of 
action, kinetic profile, toxicity and interaction with other drugs, in addition to structural and 
physicochemical properties. This knowledge potentially leads to rapid progress to phase I 
and phase II clinical trials, early FDA approval and a short route to the clinic, although 
there is still the hurdle of demonstrating a new mechanism, target, dosing and route of 
administration for the new purpose. Drug repurposing is quite a profitable approach. For 
instance, the repurposed antidepressant duloxetine (Ashburn & Thor, 2004), now used for 
urinary incontinence, made a sale profit of approximately US$ 800 million within 4 years 
of its relaunch and Thalomid®, which is reprofiled thalidomide, and its derivative 
Revlimid® (Lenalidomide), made a profit of more than $2.8 billion for Celgene (Cha et al., 
2018). In the USA, repurposed drugs made up approximately 30-40% of the drug market 
after 2007 (Agrawal, 2015).  
One aim of the current study was to test the anti-picornaviral activity of a number of 
existing drugs which may target virus proteins (e.g. fluoxetine), or against host factors 
(specifically lipid droplets) which have been shown to be involved in picornavirus 
replication. Each strategy has its advantages and disadvantages. Targeting viral proteins is 
more frequently overcome by emergence of resistant viruses and host factors approaches 
may cause more side effects than blocking viral components.  
Several antidepressant drugs such as fluoxetine, imipramine and promethazine, in addition 
to dibucaine, which is used as a topical anaesthetic have been investigated for their 
repurposing antiviral properties. Fluoxetine and dibucaine showed a significant inhibitory 
effect on CAV9. Imipramine also showed a significant antiviral activity but only when its 
concentration was much higher than needed for fluoxetine and dibucaine. Sequencing of 
selected fluoxetine mutants revealed a single consistent mutation in the 2C protein (I227V). 
Preliminary results from sequencing one dibucaine mutated virus revealed a mutation at the 
same position. If this is confirmed in future work by sequencing other mutants, this is 
consistent with the current proposed mechanism of action of fluoxetine, binding to a pocket 
in the 2C protein (Bauer et al., 2019). These results are consistent with the previous findings 
using CBV3 DRMs originally selected against the drug TBEZ-029, which were also 
resistant to fluoxetine and dibucaine (de Palma et al., 2008; Ulferts et al., 2016). One 
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difference is that the TBEZ-029 DRMs had two nearby mutations (A224V) and A229V) in 
addition to 1227V. I227V, is a key mutation in resistance to TBEZ-029, but none of the 3 
mutations alone was sufficient to give drug resistance, in contrast to CAV9 resistance to 
fluoxetine and dibucaine. CBV3 studies on fluoxetine and dibucaine used the three 
mutation DRM and no attempt was made to select new DRMs, so this difference could be 
due to the different features of TBEZ-029 compared to fluoxetine/dibucaine, rather than 
differences between CAV9 and CBV3. This question may be answered using the modelled 
CBV3 2C structure (Bauer et al., 2019) docked to TBEZ-029 and to fluoxetine. Similar 
modelling of the CAV9 2C structure would also be useful, particularly in designing new 
compounds that fit into the pocket and which may require more than one mutation to give 
resistance, as clinical use of fluoxetine may not be feasible if a single mutation is enough 
to give resistance.   
In an attempt to improve fluoxetine and dibucaine antiviral activity to also inhibit the DRM, 
they were chemically combined to selected groups or compounds. Quinoline a core 
structure of dibucaine and a proposed source of its activity was linked to a butene group. 
The resultant compound QHB showed the opposite of the expectation and virus growth 
seemed to be stimulated by the compound. A fluoxetine-chlorambucil conjugate (F1-Ch) 
showed significant antiviral activity although was only seen at high concentration. This is 
possibly because there were still some impurities, shown by gas chromatography in spite 
of a purification procedure that was carried out by flash chromatography (Appendix II). 
Therefore, the first suggestion for F1-Ch is to purify it again by chromatography and test 
again against the virus. F1-Ch should also be investigated against fluoxetine and dibucaine 
DRMs. The quinoline core of dibucaine was also conjugate to chlorambucil and to a long 
chain linolenic acid in two separate chemical reaction procedures and these 2 novel 
compounds have not been examined with CAV9 nor with its resistant mutants. So, it would 
be very interesting to explore their antiviral activity. As discussed above, future drug 
modifications should be designed in the light of a modelled 2C structure. However, the 
accuracy of the CBV3 model (or a new CAV9 model), based on the EV71 (a different 
species of enterovirus) 2C structure, may not allow such detailed analysis, especially as the 
proposed fluoxetine binding site is in a region of 2C where CBV3 and EV71 sequences are 
relatively different and also EV71 is not itself inhibited by fluoxetine.  
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Anti-CAV9 activity of several existing drugs against a host factor, LDs which have been 
shown to be involved in picornavirus replication has also been investigated. Among 
investigated LD-interacting members, DGAT inhibitors including A922500 seemed to be 
the most acting compounds although toxicity accompanied its activity is a considerable 
issue that would need to be addressed. Simvastatin which is a 3-hydroxy-3-methylglutaryl 
(HMG) coenzyme A reductase (HMG-CoA reductase) inhibitor did not show activity and 
C75, a fatty acid synthase (FASN) inhibitor showed slight effect at a high concentration. 
Preliminary data on aspirin, a nonsteroidal anti-inflammatory drug (NSAID) and metformin 
a biguanide blood glucose lowering agent exhibited interesting, but not yet clear-cut 
antiviral activity and these primary results require further confirmation. In this regards it is 
worth mentioning that data investigated for one compound are not necessarily representing 
for the whole drug family members, and individual drug variation must always be 
considered. If the primary results of aspirin and metformin are confirmed, then propagation 
of DRM viruses against them could be very useful to determine the basis of their anti-CAV9 
activity. LDs targeting compounds by definition are supposed to target LDs, the host 
factors. However, emergence of DRMs against A922500 means that actually a CAV9 
protein may be targeted, rather than LDs themselves, in the same way that fluoxetine is a 
GPCR inhibitor, but anti-CAV9 activity may be due to binding to 2C, rather than to 
inhibition of a GPCR. On the other hand, the anti-enterovirus drug enviroxime inhibits virus 
replication by decreasing Golgi complex PI4P levels by directly inhibiting the enzyme 
PI4KIIIβ (van der Schaar et al., 2012). Despite having a cellular target, CBV3 DRMs can 
be obtained and these have single mutations in the CBV3 3A protein, suggesting that these 
DRMs now use alternative pathways for replication.  The CAV9 2C protein seems to 
interact with LDs but preliminary results from partially sequencing one A922500 DRM did 
not show a mutation in the part of 2C sequenced. This is not surprising as the region of 2C 
sequenced so far does not interact with LDs (Khrid, unpublished). The rest of 2C and the 
other viral proteins should be sequenced in the DRM to find the mutation responsible for 
resistance. It would be useful to have a clearer idea of which step in CAV9 replication 
involves LDs. Different reporter systems will be created for CAV9, to use EGFP or 
luciferin as reporter proteins to separately analyse steps such as translation and RNA 
replication, as done for CBV3 (Ulferts et al., 2016). 
Lipid droplets have been reported to fuel replication of some viruses (Zhang et al., 2017). 
However, some reports have suggested indirect rather than direct involvement of LDs in 
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viral replication which might be equally important. In PV, the infection-related 
membranous structures are showed to be important for hiding the propagated viruses from 
the cellular immune system and host anti-virus response but was not very important for 
RNA replication. PV infection induces accumulation of lipases to LDs, increases neutral 
lipid lipolysis and phosphorylation of lipid and thus sustains infection-related 
phosphatidylcholine production which in turn supports expansion of the PV replication 
complex. As picornaviruses have the ability to quickly inhibit host transcription and 
translation processes, there would be a relatively short chance for a cell to avoid viral 
infection. Drug targeting of lipids may contribute to increase the time exposure and 
sensitivity of picornavirus to cellular immune system and improve the anti-virus response. 
As part of host organelles, targeting of LDs might adversely affect cell’s homeostasis. 
However, interestingly and in some situations, cells can overcome pharmacological 
inhibition of lipids and perhaps other essential elements in favour of their survival by 
properly redistributing of these lipids in some ways that do not support virus life cycle 
(Perera et al., 2012).  
Plants and other natural sources are rich in bioactive compound and there is strong evidence 
of antivirus compounds, along with antibiotics and other useful chemicals. Boiled extracts 
from redcurrent showed a significant inhibitory effect on CAV9, closely related CBV3 and 
genetically distinct HPeV1. This means that RC could be active against other picornavirus 
groups. It also means that RC components may target certain proteins, domains or motifs 
which are common or conserved in many virus species, or it could target one or more of 
host factors that are essential for these viruses, or it might have multiple targets. 
Investigation of action modes requires purification of a single component/s which can then 
be identified and analysed by LC-MS/MS, NMR and elemental analysis. In this regard, 
partial fractionation has been done so far. Fractions obtained had different colours, 
suggesting different constituents, and various antiviral activities ranging from significant 
activity at relatively low concentrations to significantly active at moderate to high 
concertation or not active at all.  
Differences in antioxidant activity were also observed through different RC extracts and 
various RC fractions. All RC extracts seemed to have significant although variant AO 
activity and fractions from boiled RC also showed some significant and some moderate AO 
activity. RC-related AO activity is promising not only for antiviral activity but also in other 
AO-associated diseases such as diabetes, cardiovascular diseases, kidney injuries and 
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cancer. RC extracts also seem to have noticeable photosensitive properties. All RC-
investigated properties are very interesting, promising and novel, however, each component 
(antiviral compounds, AO components and PS) needs to be isolated, purified and analysed 
to be useful for application.  
There were several fractions that were observed to inhibit CAV9 and therefore, RC could 
be a source for more than one active compound for treatment of picornavirus and these 
compounds could be used solely or in combination to decrease the occurrence of virus 
resistance.  A boiled extract of RC was also active against fluoxetine resistant mutant 
virus (and A922500) and so its purified compounds are potential candidates to combine 
with other drugs to overcome the possibility of drug resistance.  
Quercetin and/or its derivatives could be contained within the RC extract, based on 
preliminary characterisation of the components. When it was investigated against CAV9, 
pure quercetin was significantly active. It has also been reported to be active on other RNA 
and DNA viruses. In addition, quercetin has been demonstrated to inhibit viruses by variant 
modes of action from entry to release. These include attachment, endocytosis, translation, 
RNA replication, anti-inflammatory effects, LD inhibition and heat shock protein 
interactions. Accordingly, quercetin has the potential to have a multi-virus, multi-
mechanisms action. The antioxidant activity of quercetin has been previously documented, 
and it is interesting in the future to investigate its PDI activity.  
Microalgae are very diverse, just like the results obtained in this work. Some MA extracts 
were very active, and others were not. Some caused stimulation of cell viability. The MA 
results indicate that this source could be significantly rich in anti-picornavirus compounds 
and more work is required on this field. Unexpectedly, using light on MA extracts had a 
negative effect on at least M19. The reasons for this MA activity loss need to be explored. 
It could be due to loss of AO activity or structural changes. 
Since the first compound was successfully purified form opium 200 years ago, the number 
of naturally produced or derived (analogues) drugs has been significantly increased to reach 
approximately 80% around 1990. However, during 1990 and thereafter there has been a big 
expansion of chemistry-related synthetic drugs, and this has been at the expense of the 
investment in natural sources. This may be due to laborious procedures and technical 
limitations in purifying and identification of new natural compounds including supply 
reliability, seasonal change, source loss and extinction and structure complexity. It is also 
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because of the general attitudes of large pharmaceutical companies to invest in libraries of 
synthetic compounds. 
However, plants and other natural remain a very rich resources of not only antibiotics such 
as penicillin, erythromycin and tetracycline, anti-malarials like quinine and anti-parasitics 
e.g. ivermectin, but also medicines of different family groups including lipids lowering 
agents (by astatine) analgesics (aspirin), cardiovascular agents (digitoxin) and even 
immunosuppressed (cyclosporine) and anticancer agents (doxorubicin). Therefore, 
underestimation of these rich resources means missing a huge number of biologically active 
molecules. In any case, it has been reported that only 15% or even less of natural sources 
are explored and these have given all the approved known naturally derived medicines. The 
remaining 85% could contain huge numbers of antiviral and other bioactive molecules.  The 
conclusion is not that naturals are more important than chemistry-based products, but it 
rather means that both ways are very important in novel antiviral approaches and one 
general aim of this study is to highlight their equally important approaches.  
One drawback of the current work is that the GMK cell line was used to investigate the 
antiviral activity of many of the compounds and extracts and A549 cells were used to 
measure the toxicity of the investigated agents. In principle, the same cells should always 
be used for both toxicity and antiviral activity of compounds. However, due to the 
unforeseen situation of losing GMK cells at the end of the study, there was no option except 
to finish the work with the available A549 cells. Data from viability assay with A549 gave 
some unexpected results, as with A922500 and dibucaine, which did not show visible 
toxicity with GMK cells in plaque assay but then showed significant toxicity with A549 on 
viability assay. However, in general and for the majority of tested compounds, it was useful, 
and the results were with expectation with that of GMK cells-plaque assay in most cases. 
For future work, viability assay or other toxicity sensitive assay would be recommended to 
be carried out on GMK cells for the investigated compounds. Given that there were some 
cell type differences in antiviral effect of some compounds, for instance quercetin, it would 
also be interesting to test all compounds on multiple cell lines. This might reveal activity 
missed on one cell line where differences in cell biochemistry or structure may mean that 
a drug has no effect. 
In general, all the included work of this study has been done by myself, except the GS work 
which was totally done by Dr Sinan Battah, and the LC-MS/MS analysis which was a 
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shared work between Dr Sinan Battah and myself. The chemical syntheses were devised 
by Dr Sinan Battah and the practical work was carried out by myself.  
6.2 Conclusion 
In this study, many chemically-derived compounds were studied for potential repurposing 
as antivirus agents and natural materials were explored for their potential as sources of 
compounds for the development of antiviral agents. Several assays were used to evaluate 
toxicity and antiviral activity of these agents and all the employed methods provided 
valuable data about the natural compounds and chemicals under investigation. Some 
repurposed active compounds seem to have a similar within CAV9 target (2C protein). 
However, they might be used in different ways. i.e. fluoxetine systemically and dibucaine 
locally. Both imipramine and the novel structurally modified F1-Ch showed significant 
antiviral activity at high doses, but their proposed mechanisms are yet to be known. Finding 
that fluoxetine and dibucaine have antiviral activity against CAV9 just like their activity on 
CBV3 and that they are acting on the same region the 2C protein support the well-known 
close relationship between CAV9 and CBV3.  
Variant pathways involved in lipid and LDs production and metabolism have been 
investigated, using distinct agents in order to screen different LD biosynthetic pathways 
and find which are involved in viral replication, and so could be useful antiviral targets. 
The DGAT1 inhibitor A922500 looks to be more active than all other agents, although it 
showed cellular toxicity, and this might give false antiviral activity and therefore its 
antiviral activity needs further investigation. As some of investigated lipid-interacting 
compounds have different mechanism of action than other such as A922500 and fluoxetine, 
they are possible candidates for combination therapy which is sometimes suggested for 
virus infection.  Naturals are rich sources of anti-picornavirus activity, RC extract and 
quercetin showed significant antiviral activity against CAV9 and in the case of RC, against 
CBV3 and HPeV1 as well. Several microalgae species were significantly active as well. 
Natural products could also be very useful for combination therapy. For example, RC 
extracts inhibited fluoxetine drug resistant mutant at an even lower concentration required 
to inhibit the parent virus. In addition, natural products, as shown with RC, are also a 
substantial source of antioxidant compounds that could be exploited clinically and 
industrially. RC is also a source of photosensitizers which have started to enter the medical 
application world. As through this study both repurposed chemicals and naturals have 
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exhibited a significant antiviral activity, it is recommended that there should be a balance 
between two sources in terms of research and investment. 
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Appendix 1 Materials used in this work and the sources 
A. Materials for cell culture   
• Accutase solution (Sigma-Aldrich).   
• Trypsin-EDTA (0.25 %) (Gibco, by Life Technologies).   
• Dimethyl sulfoxide minimum (DMSO) ≥99.5 % (Sigma-Aldrich).  
• Dulbecco's Modified Eagle's Medium high glucose (DMEM) (Sigma-Aldrich).  
• McCoy's 5A Medium (Life Technologies). 
• Fetal bovine serum (FBS) (Sigma-Aldrich).   
• MEM non-essential amino acid 100x Solution (Sigma-Aldrich). 
• Penicillin-streptomycin with 10,000 units penicillin and 10 mg streptomycin per ml 
(Sigma-Aldrich).   
• HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) (Sigma-Aldrich).   
B. Materials for virology  
• Carboxymethylcellulose sodium (CMC) (Sigma-Aldrich).   
• Crystal violet, pure, indicator (ACROS Organics).  
• Triton X-100 (Sigma-Aldrich).   
• Formaldehyde, 37 % by weight (Fisher Chemical).  
• Ethanol, absolute (Fisher BioReagents).   
C. Drugs 
• Fluoxetine HCl (LKT laboratories, Inc.).  
• Imipramine (Sigma-Aldrich).   
• Promethazine (Sigma-Aldrich).   
• Quercetin ≥ 95 % (HPLC) (Sigma-Aldrich). 
• C75 (Cayman Chemical). 
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• Simvastatin ≥ 97 % (HPLC) (Sigma-Aldrich). 
• Betulinic acid ≥ 98 % (HPLC) (Sigma-Aldrich).   
• A922500 (Sigma-Aldrich). 
• Metformin (Sigma-Aldrich). 
• Acetylsalicylic acid (Sigma-Aldrich). 
D. Biological materials 
• Redcurrants (RCs, Ribes rubrum) were grown in Wivenhoe, Essex, UK and harvested 
when ripe; 2 kg of red currant fruit was obtained and used after storing at -20 °C.   
• Microalgae (MA): Samples of microalgae (MA) extracts (labelled MA9, MA11, 
MA15, MA17, M19, MA-S1, MA-S2, MA-S3, MA-S4, CO2, Ceb, CO6 and NO8) 
were provided by the School of Chemical Engineering (United Arab Emirates 
University) after extraction by the method previously described (Al-Zuhair et al., 
2006). 
E. Materials for molecular biology  
• Agarose (Electrophoresis Grade) (Fisher BioReagents).     
• Isopropanol (Fisher BioReagents).   
• QIAamp Viral RNA Mini Kit (Qiagen).   
• QIAquick gel extraction kit (Qiagen). 
• SafeView nucleic acid stain (NBS biologicals).   
• Tris base (Fisher BioReagents).   
• Water, nuclease-free (Thermo Scientific). 
Primers (Sigma-Aldrich); 
➢ CAV92C5d (AGCCCTCATCGGTTGCACCTCGT).  
 
➢ CAV92Cmf (TGCTCCTACATGGGAGTCCAGGT). 
 




➢ CAV92Cmr (TCCATCAGGGTTCTGGCATAGGTC). 
 
F. Materials for extraction and fractionation of RC and for chemical 
modification 
• 1-Hydroxybenzotriazole hydrate (HOBT) ≥97 % (Aldrich Chemistry). 
• 2-Hydroxyquinoline-4-carboxylic acid 97 % (Sigma-Aldrich). 
• 2-Bromoethylamine hydrobromide 99 % (Alfa Aesar). 
• 1-Butyl-3-methylimidazolium bromide >97.0 % (Fluka). 
• N,N′-Dicyclohexylcarbodiimide (DCC) ≥99 % (Fluka).  
• 1-Butyl-3-methylimidazolium bromide >97 % (Sigma-Aldrich). 
• N,N-Dimethylformamide (DMF) anhydrous, 99.8 %. (Sigma-Aldrich). 
• Dichloromethane (DCM) ≥99.8 % (VWR Chemicals). 
• N,N-Diisopropylethylamine (DIPEA) ≥99 % (Sigma-Aldrich).  
• Phthalimide, potassium derivative 99 % (Acros Organics). 
• Hydrazine acetate 97 % (Sigma-Aldrich). 
• Tetrahydrofuran ≥99.9 % (Sigma-Aldrich). 
• Chlorambucil (Sigma-Aldrich). 
• 4-Bromo-1-butene, 97 % (Aldrich Chemistry). 
• Di-tert-butyl dicarbonate 99 % (Acros Organics).  
• Acetonitrile (Fisher Chemical).   
• Fluoxetine HCl (LKT laboratories, Inc).  
• tert-Butyl (2-bromoethyl) carbamate ≥98 % (Sigma-Aldrich).  
• H2CO3 (Sigma-Aldrich). 
• Trifluoroacetic acid ≥99 % (Sigma-Aldrich). 
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• Ethyl acetate ≥99.5 % (VWR Chemicals). 
• Mono (1-butyl-3-methyl-1h-imidazol-1-3-diium) monobromide (PubChem).  
• Acetone ≥99 % (VWR Chemicals).  
• Ethanol, absolute (Fisher Chemical).  
• Methanol (Fisher Chemical).  
• Toluene (Fisher Chemicals).   
G. Solutions and buffers 
• Phosphate buffered saline buffer:  
Seven tablets of PBS were added to 700 ml of deionized water to prepare 1X PBS buffer. 
The solution then was autoclaved. 
• HEPES buffer:  
To prepare a HEPES solution of 250 mM, 12 g of HEPES was dissolved in 100 ml of de-
ionized distilled water and then adjusted to pH 7.4 with 10 M NaOH, and then autoclaved.    
• Carboxy methyl cellulose 2 % (CMC): 
CMC (2 g) was dissolved in 100 ml of distilled water and then autoclaved. 
• Crystal violet solution 0.5 % (CV): 
Crystal violet (0.5 g) was added to 495 ml of distilled water and 5 ml of ethanol.  
• Fixing solution: 
For a fixing solution of 4 % formaldehyde, 5 ml of 37% formaldehyde was added to 50 ml 
of 1X PBS buffer.  
• Permeabilization solution: 
Triton X-100 (125 µl) was added to 50 ml of 1X PBS buffer and 65 µl of Tween 20 to give 
a final concentration of Triton of 0.25%.  
• DNA electrophoresis buffer (Tris-EDTA or ELFO)  
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First, 50X Tris-EDTA stock was prepared by adding 242 g of Tris and 100 ml of 0.5 M 
EDTA (pH 8.0) to 600 ml of deionized water. The pH was adjusted to 7.7 with glacial acetic 
acid then the solution was made up to 1 l. Then, the dilution of 1X Tris-EDTA was used to 
make agarose gels and running buffer.  
• Clear loading dye for agarose gels 
Glycerol (50 ml) was added to 200 µl of 0.5 M EDTA (pH 8.0) and 49.8 ml deionized 
water.  
• Gene Ruler 1kb ladder (ThermoFisher Scientific) 
This was used as a size-marker for DNA electrophoresis and was prepared for use by 
mixing the marker (5 µl) with deionized water (20 µl) and the provided 6x loading buffer 
(5 µl). Usually, 5 µl of the mixture was loaded per well. 
H. Cell lines  
• African Green Monkey Kidney epithelial (GMK) cell line, originally provided by 
Dr Merja Roivainen. 
• The Lung Carcinoma cell line (A549), provided by Dr Muslim Idan Mohsin.  
• The Human Colon Adenocarcinoma (HT29) cell line, provided by Dr Andrea Mohr. 
I. Viruses 
• Coxsackievirus A9 (CAV-9), Griggs strain, was recovered from the cDNA clone 
pCAV9 (Hughes et al., 1995).  
• Human parechovirus (HPeV1), Harris strain, was recovered from the cDNA clone 
pHPeV1 (Nateri et al., 2000).  
• Coxsackie B viruses (CBV): Three CBV3 isolates, P55 (2), P6LK12 and P4 (75) 
were provided by Professor Heikki Hyöty.  
Fresh stocks of these viruses were produced by adding 10 μl of the original virus stock to 
cell monolayers (GMK for CAV9 and CBV3; HT29 for HPeV1) in 25 cm2 flasks and 
incubating in a 5% CO2 incubator at 37 °C
 until all cells were detached. Flasks were freeze-
thawed three times and the liquid was centrifuged (12,000 rpm in a microcentrifuge, 2 min) 
and the supernatant was divided into aliquots and stored at -80 °C. 
315 
 










Figure II-1. Fluoxetine chlorambucil conjugate (Fl-Ch) GC spectra. 
A is the total ion counting (TIC) peaks at elution time 49.5 min. B: (Fl-Ch) m/z 
(M+-3, 647.6 D), (M+-2, 648.5 D),  (M+-1, 649.5 D) , (M+-3 + CH3, 662.6 D), (M+-










Figure II-2. Elution spectra revealing impurities accompany fluoxetine 
chlorambucil conjugate (Fl-Ch).   
A1: Total ion counting (TIC) peaks at elution time 49.5 min. B1: The peak with 316 
D is impurity (excess of chlorambucil). 
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